In Memoriam to Our Fallen Ranger Medic Comrades…

SFC Marcus V. Muralles

KIA – 28 June 2005 – Afghanistan
Operation: Enduring Freedom

Special Operations Flight Medic 2003-2005
HHC, 3/160th Special Operations Aviation Regiment

Company Senior Medic and Platoon Medic 1999-2003
B Co, 3rd Battalion, 75th Ranger Regiment

Company Senior Medic and Platoon Medic 1990-1993
C Co, 3rd Battalion, 75th Ranger Regiment

PFC James M. Markwell

KIA – 20 December 1989 – Panama
Operation: Just Cause

Platoon Medic 1989
C Co, 1st Battalion, 75th Ranger Regiment

…and one for the Airborne Ranger in the Sky.
Historically in warfare, the majority of all combat deaths have occurred prior to a casualty ever receiving advanced trauma management. The execution of the Ranger mission profile in the Global War on Terrorism and our legacy tasks undoubtedly will increase the number of lethal wounds.

Ranger leaders can significantly reduce the number of Rangers who die of wounds sustained in combat by simply targeting optimal medical capability in close proximity to the point of wounding. Survivability of the traumatized Ranger who sustains a wound in combat is in the hands of the first responding Ranger who puts a pressure dressing or tourniquet and controls the bleeding of his fallen comrade. Directing casualty response management and evacuation is a Ranger leader task; ensuring technical medical competence is a Ranger Medic task.

A solid foundation has been built for Ranger leaders and medics to be successful in managing casualties in a combat environment. An integrated team response from non-medical personnel and medical providers must be in place to care for the wounded Ranger. The Ranger First Responder, Squad EMT, Ranger Medic Advanced Tactical Practitioner, and Ranger leaders, in essence all Rangers must unite to provide medical care collectively, as a team, without sacrificing the flow and violence of the battle at hand.

An integrated team approach to casualty response and care will directly translate to the reduction of the died of wounds rate of combat casualties and minimize the turbulence associated with these events in times of crisis. The true success of the Ranger Medical Team will be defined by its ability to complete the mission and greatly reduce preventable combat death. Rangers value honor and reputation more than their lives, and as such will attempt to lay down their own lives in defense of their comrades. The Ranger Medic will do no less.

I will never leave a fallen comrade...

Harold R. Montgomery
MSG, USA
Regimental Senior Medic
1997-Present
RHHC Senior Medic
1995-1997
1/75 Plt, Co, BAS NCOIC
1990-1995

Russ S. Kotwal, MD
LTC, MC
Regimental Surgeon
2005-Present
3/75 Battalion Surgeon
1999-2003
# Table of Contents

<table>
<thead>
<tr>
<th>Subject</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>SECTION ONE</td>
<td></td>
</tr>
<tr>
<td>RMED Mission Statement</td>
<td>1-1</td>
</tr>
<tr>
<td>RMED Charter</td>
<td>1-2</td>
</tr>
<tr>
<td>Review Committees</td>
<td>1-3</td>
</tr>
<tr>
<td>Editorial Consultants &amp; Contributors</td>
<td>1-4</td>
</tr>
<tr>
<td>Key References</td>
<td>1-5</td>
</tr>
<tr>
<td>RMED Scope of Practice</td>
<td>1-6</td>
</tr>
<tr>
<td>RMED Standing Orders &amp; Protocol Guidelines</td>
<td>1-8</td>
</tr>
<tr>
<td>Casualty Assessment &amp; Management</td>
<td>1-10</td>
</tr>
<tr>
<td>Tactical Combat Casualty Care (TCCC)</td>
<td>1-17</td>
</tr>
<tr>
<td>SECTION TWO</td>
<td></td>
</tr>
<tr>
<td>Tactical Trauma Assessment Protocol</td>
<td>2-1</td>
</tr>
<tr>
<td>Medical Patient Assessment Protocol</td>
<td>2-2</td>
</tr>
<tr>
<td>Airway Management Protocol</td>
<td>2-3</td>
</tr>
<tr>
<td>Surgical Cricothyroidotomy Procedure</td>
<td>2-4</td>
</tr>
<tr>
<td>King-LT D Supralaryngeal Airway Insertion Procedure</td>
<td>2-5</td>
</tr>
<tr>
<td>Orotracheal Intubation Procedure</td>
<td>2-6</td>
</tr>
<tr>
<td>Hemorrhage Management Procedure</td>
<td>2-7</td>
</tr>
<tr>
<td>Tourniquet Application Procedure</td>
<td>2-8</td>
</tr>
<tr>
<td>Hemostatic Agent Application Protocol</td>
<td>2-9</td>
</tr>
<tr>
<td>Tourniquet Conversion Procedure</td>
<td>2-10</td>
</tr>
<tr>
<td>Thoracic Trauma Management Procedure</td>
<td>2-11</td>
</tr>
<tr>
<td>Needle Chest Decompression Procedure</td>
<td>2-12</td>
</tr>
<tr>
<td>Chest Tube Insertion Procedure</td>
<td>2-13</td>
</tr>
<tr>
<td>Hypovolemic Shock Management Protocol</td>
<td>2-14</td>
</tr>
<tr>
<td>Saline Lock &amp; Intravenous Access Procedure</td>
<td>2-15</td>
</tr>
<tr>
<td>External Jugular Intravenous Cannulation Procedure</td>
<td>2-16</td>
</tr>
<tr>
<td>Sternal Intraosseous Infusion Procedure</td>
<td>2-17</td>
</tr>
<tr>
<td>Hypothermia Prevention &amp; Management Kit Procedure</td>
<td>2-18</td>
</tr>
<tr>
<td>Head Injury Management Protocol</td>
<td>2-19</td>
</tr>
<tr>
<td>Mild Traumatic Brain Injury (Concussion) Management Protocol</td>
<td>2-20</td>
</tr>
<tr>
<td>Seizure Management Protocol</td>
<td>2-21</td>
</tr>
<tr>
<td>Spinal Cord Injury Management Protocol</td>
<td>2-22</td>
</tr>
<tr>
<td>Orthopedic Trauma Management Protocol</td>
<td>2-23</td>
</tr>
<tr>
<td>Burn Management Protocol</td>
<td>2-24</td>
</tr>
<tr>
<td>Foley Catheterization Procedure</td>
<td>2-25</td>
</tr>
<tr>
<td>Pain Management Protocol</td>
<td>2-26</td>
</tr>
<tr>
<td>Anaphylactic Shock Management Protocol</td>
<td>2-27</td>
</tr>
</tbody>
</table>
### SECTION TWO Continued

<table>
<thead>
<tr>
<th>Subject</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hyperthermia (Heat) Management Protocol</td>
<td>2-28</td>
</tr>
<tr>
<td>Hypothermia Prevention &amp; Management Protocol</td>
<td>2-29</td>
</tr>
<tr>
<td>Behavioral Emergency Management Protocol</td>
<td>2-30</td>
</tr>
<tr>
<td>Altitude Medical Emergency Management Protocol</td>
<td>2-31</td>
</tr>
<tr>
<td>Acute (Surgical) Abdomen</td>
<td>2-33</td>
</tr>
<tr>
<td>Acute Dental Pain</td>
<td>2-33</td>
</tr>
<tr>
<td>Acute Musculoskeletal Back Pain</td>
<td>2-33</td>
</tr>
<tr>
<td>Allergic Rhinitis</td>
<td>2-34</td>
</tr>
<tr>
<td>Asthma (Reactive Airway Disease)</td>
<td>2-34</td>
</tr>
<tr>
<td>Bronchitis</td>
<td>2-34</td>
</tr>
<tr>
<td>Cellulitis</td>
<td>2-35</td>
</tr>
<tr>
<td>Chest Pain (Cardiac Origin Suspected)</td>
<td>2-35</td>
</tr>
<tr>
<td>Common Cold</td>
<td>2-35</td>
</tr>
<tr>
<td>Conjunctivitis</td>
<td>2-36</td>
</tr>
<tr>
<td>Constipation</td>
<td>2-36</td>
</tr>
<tr>
<td>Contact Dermatitis</td>
<td>2-36</td>
</tr>
<tr>
<td>Corneal Abrasion &amp; Corneal Ulcer</td>
<td>2-37</td>
</tr>
<tr>
<td>Cough</td>
<td>2-37</td>
</tr>
<tr>
<td>Cutaneous Abscess</td>
<td>2-37</td>
</tr>
<tr>
<td>Deep Venous Thrombosis (DVT)</td>
<td>2-38</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>2-38</td>
</tr>
<tr>
<td>Epiglottitis</td>
<td>2-38</td>
</tr>
<tr>
<td>Epistaxis</td>
<td>2-39</td>
</tr>
<tr>
<td>Fungal Skin Infection</td>
<td>2-39</td>
</tr>
<tr>
<td>Gastroenteritis</td>
<td>2-39</td>
</tr>
<tr>
<td>Gastroesophageal Reflux Disease (GERD)</td>
<td>2-40</td>
</tr>
<tr>
<td>Headache</td>
<td>2-40</td>
</tr>
<tr>
<td>Ingrown Toenail</td>
<td>2-40</td>
</tr>
<tr>
<td>Joint Infection</td>
<td>2-41</td>
</tr>
<tr>
<td>Laceration</td>
<td>2-41</td>
</tr>
<tr>
<td>Malaria</td>
<td>2-41</td>
</tr>
<tr>
<td>Otitis Externa</td>
<td>2-42</td>
</tr>
<tr>
<td>Otitis Media</td>
<td>2-42</td>
</tr>
<tr>
<td>Peritonsillar Abscess</td>
<td>2-42</td>
</tr>
<tr>
<td>Pneumonia</td>
<td>2-43</td>
</tr>
<tr>
<td>Pulmonary Embolus (PE)</td>
<td>2-43</td>
</tr>
<tr>
<td>Renal Colic</td>
<td>2-43</td>
</tr>
<tr>
<td>Sepsis / Septic Shock</td>
<td>2-44</td>
</tr>
<tr>
<td>Smoke Inhalation</td>
<td>2-44</td>
</tr>
<tr>
<td>Sprains &amp; Strains</td>
<td>2-44</td>
</tr>
<tr>
<td>Subungual Hematoma</td>
<td>2-45</td>
</tr>
<tr>
<td>Syncope</td>
<td>2-45</td>
</tr>
<tr>
<td>Testicular Pain</td>
<td>2-45</td>
</tr>
<tr>
<td>Tonsillopharyngitis</td>
<td>2-46</td>
</tr>
<tr>
<td>Urinary Tract Infection (UTI)</td>
<td>2-46</td>
</tr>
<tr>
<td>Subject</td>
<td>Page</td>
</tr>
<tr>
<td>----------------------------------------------</td>
<td>------</td>
</tr>
<tr>
<td><strong>SECTION THREE</strong></td>
<td></td>
</tr>
<tr>
<td>Pharmacology Section I: &quot;Proficient and Always Carried&quot;</td>
<td>3-1</td>
</tr>
<tr>
<td>Pharmacology Section II: &quot;Proficient&quot;</td>
<td>3-11</td>
</tr>
<tr>
<td>Pharmacology Section III: &quot;Familiar&quot;</td>
<td>3-26</td>
</tr>
<tr>
<td><strong>SECTION FOUR</strong></td>
<td></td>
</tr>
<tr>
<td>RMED Duties &amp; Responsibilities</td>
<td>4-1</td>
</tr>
<tr>
<td>Medical &amp; Casualty Response Planning</td>
<td>4-2</td>
</tr>
<tr>
<td>Initial Planning / WARNORD</td>
<td>4-2</td>
</tr>
<tr>
<td>Tactical Operation Development</td>
<td>4-3</td>
</tr>
<tr>
<td>Coordination &amp; Synchronization</td>
<td>4-6</td>
</tr>
<tr>
<td>Briefs, Rehearsals, and Inspections</td>
<td>4-6</td>
</tr>
<tr>
<td>After Action Review in Training or Combat</td>
<td>4-7</td>
</tr>
<tr>
<td>Casualty Collection Point (CCP) Operations</td>
<td>4-8</td>
</tr>
<tr>
<td>CCP Duties &amp; Responsibilities</td>
<td>4-8</td>
</tr>
<tr>
<td>Casualty Response Rehearsals</td>
<td>4-9</td>
</tr>
<tr>
<td>CCP Site Selection</td>
<td>4-9</td>
</tr>
<tr>
<td>CCP Operational Guidelines</td>
<td>4-10</td>
</tr>
<tr>
<td>CCP Building Guidelines</td>
<td>4-10</td>
</tr>
<tr>
<td>Evacuation Guidelines</td>
<td>4-11</td>
</tr>
<tr>
<td>CCP Layout Templates</td>
<td>4-11</td>
</tr>
<tr>
<td>General Guidelines for CCP Personnel</td>
<td>4-14</td>
</tr>
<tr>
<td>Casualty Marking &amp; Tagging</td>
<td>4-14</td>
</tr>
<tr>
<td>MEDEVAC Request Format</td>
<td>4-16</td>
</tr>
<tr>
<td>Hazardous Training Medical Coverage</td>
<td>4-17</td>
</tr>
<tr>
<td>Pre-Deployment &amp; RRF-1 Assumption Procedures</td>
<td>4-22</td>
</tr>
<tr>
<td>Post-Deployment &amp; Recovery Procedures</td>
<td>4-24</td>
</tr>
<tr>
<td><strong>SECTION FIVE</strong></td>
<td></td>
</tr>
<tr>
<td>RMED Packing Lists</td>
<td>5-1</td>
</tr>
<tr>
<td>RMED RBA/RLCS Minimum Packing List</td>
<td>5-1</td>
</tr>
<tr>
<td>RMED Assault Aid-Bag Minimum Packing List</td>
<td>5-2</td>
</tr>
<tr>
<td>RMED Medications Kit Minimum Packing List</td>
<td>5-3</td>
</tr>
<tr>
<td>Combat Wound Pill Pack (CWPP) Stockage List</td>
<td>5-3</td>
</tr>
<tr>
<td>Saline Lock Kit Stockage List</td>
<td>5-4</td>
</tr>
<tr>
<td>Chest Tube Kit Stockage List</td>
<td>5-4</td>
</tr>
<tr>
<td>Cricothyroidotomy Kit Stockage List</td>
<td>5-4</td>
</tr>
<tr>
<td>IV Kit Stockage List</td>
<td>5-4</td>
</tr>
<tr>
<td>Minor Wound Care Kit Stockage List</td>
<td>5-5</td>
</tr>
<tr>
<td>Abbreviation List</td>
<td>5-6</td>
</tr>
<tr>
<td>Conversion Charts</td>
<td>5-10</td>
</tr>
<tr>
<td>The Ranger Medic Code</td>
<td>5-11</td>
</tr>
<tr>
<td>The Ranger Creed</td>
<td>5-12</td>
</tr>
</tbody>
</table>
SECTION ONE

GENERAL OVERVIEW
MISSION STATEMENT

The mission of the 75th Ranger Regiment Trauma Management Team (Tactical) is to provide medical care and training in accordance with the tenets of Tactical Combat Casualty Care, Tactical Medical Emergency Protocols, and Pre-Hospital Trauma Life Support; in order to provide optimal health care to a Joint Special Operations Task Force conducting missions in support of U.S. policies and objectives.
RANGER MEDIC CHARTER

“SOCM ATP”
(Special Operations Combat Medic
Advanced Tactical Practitioner)

S - Shoot and engage targets to defend casualties and self.

O - Operate relatively independently with highly-dispersed highly-mobile combat formations in an austere environment.

C - Communicate via secure and non-secure means.

M - Move tactically through unsecured areas.

A - Absolute master of the basics through pre-hospital trauma life support and tactical combat casualty care.

T - Timely, consistent, and competent provider of advanced trauma management within scope of practice.

P - Practitioner who assists licensed medical providers with medical emergencies and routine care encountered while in garrison, training, and during deployments.
REVIEW COMMITTEES

2001
MAJ Kotwal (3/75 Battalion Surgeon)
MAJ Meyer (3/75 Battalion PT)
CPT Detro (3/75 Battalion PA)
SFC Miller (3/75 Battalion Senior Medic)
SFC Montgomery (Regimental Senior Medic)
SSG Flores (3/75 Company Senior Medic)
SSG Gentry (3/75 Company Senior Medic)
SSG Muralles (3/75 Company Senior Medic)
SSG Odom (3/75 Company Senior Medic)
SSG Rothwell (3/75 Company Senior Medic)

2003
MAJ Wenzel (Regimental Surgeon)
MAJ Cain (1/75 Battalion Surgeon)
MAJ Kotwal (3/75 Battalion Surgeon)
MAJ Sassano (Regt Med Ops Officer)
SFC Montgomery (Regimental Senior Medic)
SFC Miller (Regt Med Plans & Trng NCO)
SFC Swain (2/75 Battalion Senior Medic)
SFC Flores (3/75 Battalion Senior Medic)
SSG Odom (3/75 Senior Medic)
SSG Williamson (2/75 Company Sr Medic)

2004
MAJ Wenzel (Regimental Surgeon)
CPT Pairmore (1/75 Battalion PA)
CPT Nieman (2/75 Battalion PA)
CPT Kelsey (Regt Med Ops Officer)
MSG Montgomery (Regt Senior Medic)
SFC Crays (2/75 Battalion Senior Medic)
SFC Flores (3/75 Battalion Senior Medic)
SSG Odom (3/75 Battalion Senior Medic)
SSG Williamson (Regt Med Training NCO)
SSG Medaris (1/75 Company Senior Medic)
SSG Garcia (2/75 Company Senior Medic)
SSG Severtson (2/75 Company Sr Medic)

2005
LTC Kotwal (Regimental Surgeon)
MAJ Matthews (1/75 Battalion Surgeon)
MAJ McCarver (2/75 Battalion Surgeon)
CPT Sterling (Regimental PA)
CPT Detro (3/75 Battalion PA)
CPT Reedy (1/75 Battalion PA)
CPT Slevin (2/75 Battalion PA)
CPT Grenier (2/75 Battalion PT)
CPT Soliz (3/160 Battalion PA)
MSG Montgomery (Regimental Senior Medic)
SFC Crays (2/75 Battalion Senior Medic)
SFC Warren (1/75 Battalion Senior Medic)
SSG Williamson (Regt Med Plans & Trng NCO)
SSG Gillaspie (2/75 Company Senior Medic)
SGT Kindig (2/75 Company Senior Medic)
SGT Robbins (3/75 Company Senior Medic)
SGT Slavens (3/75 Company Senior Medic)
SGT Morissette (3/75 Platoon Medic)
SPC Kacroski (2/75 Platoon Medic)
SPC Ball (2/75 Platoon Medic)
SPC Lewis (3/75 Platoon Medic)
SPC Guadagnino (3/75 Platoon Medic)
SPC Drapeau (3/75 Platoon Medic)

2006
LTC Kotwal (Regimental Surgeon)
CPT Redman (1/75 Battalion Surgeon)
CPT Cunningham (2/75 Battalion Surgeon)
CPT Miles (3/75 Battalion Surgeon)
CPT Sterling (Regimental PA)
CPT Detro (Regimental PA)
CPT Fox (3/75 Battalion PA)
CPT Speer (Regt Med Ops Officer)
CPT Pollman (3/75 Battalion PT)
MSG Montgomery (Regimental Senior Medic)
SFC Odom (Regimental Medical Training NCO)
SSG Veliz (ROC Senior Medic)
SSG Garcia (2/75 Battalion Senior Medic)
SSG Williamson (3/75 Battalion Senior Medic)
SSG Gillaspie (2/75 Company Senior Medic)
SSG Bernas (2/75 Company Senior Medic)
SSG Chavaree (3/75 Company Senior Medic)
SSG Henigsmith (3/75 Company Senior Medic)
SGT Maitha (3/75 Company Senior Medic)
EDITORIAL CONSULTANTS

Executive Standing Members:
CAPT (Ret) Frank Butler, MD
CW4 (Ret) William Donovan, PA-C
COL John Holcomb, MD
LTC Russ Kotwal, MD, MPH
SFC (Ret) Robert Miller, NREMT
MSG Harold Montgomery, NREMT
Jeffrey Salomone, MD

Consulting & Contributing Members:
LTC Bret Ackermann, DO
MSG Perry Black, NREMT
CPT (Ret) Gregory Bromund, PA-C
LTC Brian Burlingame, MD
MAJ Jeffrey Cain, MD
CPT John Detro, PA-C
MAJ Arthur Finch, PhD
J.F. Rick Hammesfahr, MD
MAJ Shawn Kane, MD
MSG(Ret) Cory Lamoreaux, NREMT
LTC Robert Lutz, MD
MAJ Clinton Murray, MD
CPT (Ret) David Nieman, PA-C
LTC Kevin O’Connor, DO
CPT James Pairmore, PA-C
MAJ John Rayfield, MD
CPT Raymond Sterling, PA-C

Representative Organizations:
Committee on Tactical Combat Casualty Care
Defense and Veterans Brain Injury Center
Emory University Department of Surgery, Atlanta, GA
Grady Memorial Hospital, Atlanta, GA
Joint Special Operations Medical Training Center
PHTLS Committee of the NAEMT
US Army Institute of Surgical Research
US Special Operations Command State Department of EMS and Public Health

2007 Edition Chief Editors:
LTC Russ Kotwal, MD, MPH
MSG Harold Montgomery, NREMT, SOF-ATP
KEY REFERENCES

Texts:

Articles:
SCOPE OF PRACTICE

RANGER FIRST RESPONDER (RFR) – A Ranger who has successfully completed the Ranger First Responder Course. RFRs conduct their scope of practice under the license of a medical director. Every Ranger is to be RFR qualified.

### THE 8 “CRITICAL” RFR TASKS:

<table>
<thead>
<tr>
<th>1</th>
<th><strong>C</strong></th>
<th>Contain Scene and Assess Casualties</th>
</tr>
</thead>
<tbody>
<tr>
<td>o</td>
<td><strong>R</strong></td>
<td>Return Fire and Secure Scene</td>
</tr>
<tr>
<td>o</td>
<td><strong>D</strong></td>
<td>Direct Casualties to Cover</td>
</tr>
<tr>
<td>o</td>
<td><strong>E</strong></td>
<td>Evaluate for Life Threatening Injuries</td>
</tr>
<tr>
<td>o</td>
<td><strong>T</strong></td>
<td>Triage – Immediate, Delayed, Minimal, Expectant</td>
</tr>
<tr>
<td>o</td>
<td><strong>M</strong></td>
<td>Call Medical Personnel for Assistance as Required</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>2</th>
<th><strong>R</strong></th>
<th>Rapidly Identify and Control Massive Hemorrhage</th>
</tr>
</thead>
<tbody>
<tr>
<td>o</td>
<td><strong>D</strong></td>
<td>Direct &amp; Indirect Pressure</td>
</tr>
<tr>
<td>o</td>
<td><strong>I</strong></td>
<td>Tourniquet</td>
</tr>
<tr>
<td>o</td>
<td><strong>E</strong></td>
<td>Emergency Trauma Dressing</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>3</th>
<th><strong>I</strong></th>
<th>Inspect and Ensure Patent Airway</th>
</tr>
</thead>
<tbody>
<tr>
<td>o</td>
<td><strong>O</strong></td>
<td>Open and Clear Airway</td>
</tr>
<tr>
<td>o</td>
<td><strong>N</strong></td>
<td>Nasopharyngeal Airway</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>4</th>
<th><strong>T</strong></th>
<th>Treat Life Threatening Torso Injuries</th>
</tr>
</thead>
<tbody>
<tr>
<td>o</td>
<td><strong>O</strong></td>
<td>Occlusive Seal Dressing</td>
</tr>
<tr>
<td>o</td>
<td><strong>N</strong></td>
<td>Needle Decompression</td>
</tr>
<tr>
<td>o</td>
<td><strong>A</strong></td>
<td>Abdominal wound management</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>5</th>
<th><strong>I</strong></th>
<th>Inspect for Bleeding, Gain IV Access, Manage Shock</th>
</tr>
</thead>
<tbody>
<tr>
<td>o</td>
<td><strong>H</strong></td>
<td>Head to Toe Blood Sweeps</td>
</tr>
<tr>
<td>o</td>
<td><strong>18</strong></td>
<td>18 Gauge Saline Lock</td>
</tr>
<tr>
<td>o</td>
<td><strong>I</strong></td>
<td>IV Fluids when dictated by Shock</td>
</tr>
<tr>
<td>o</td>
<td><strong>P</strong></td>
<td>Prevent Hypothermia</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>6</th>
<th><strong>C</strong></th>
<th>Control Pain and Prevent Infection</th>
</tr>
</thead>
<tbody>
<tr>
<td>o</td>
<td><strong>C</strong></td>
<td>Combat Wound Pill Pack</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>7</th>
<th><strong>A</strong></th>
<th>Aid and Litter Team</th>
</tr>
</thead>
<tbody>
<tr>
<td>o</td>
<td><strong>P</strong></td>
<td>Package and Prepare for Transfer</td>
</tr>
<tr>
<td>o</td>
<td><strong>S</strong></td>
<td>SKEDCO, Litters, Manual Carries</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>8</th>
<th><strong>L</strong></th>
<th>Leader Coordinated Evacuation</th>
</tr>
</thead>
<tbody>
<tr>
<td>o</td>
<td><strong>C</strong></td>
<td>Casualty Precedence – Critical (Urgent), Priority, Routine</td>
</tr>
<tr>
<td>o</td>
<td><strong>E</strong></td>
<td>CASEVAC or MEDEVAC Coordination</td>
</tr>
</tbody>
</table>
SQUAD EMT – A non-medical MOS Ranger currently registered as an EMT-Basic/Intermediate by the Department of Transportation (DOT) and designated by the command to operate in this capacity. This individual functions as a bridge between the RFR and the Ranger Medic in respect to tactical and administrative trauma management. Squad EMTs conduct their scope of practice under the licensure of a medical director.

SPECIAL OPERATIONS COMBAT MEDIC ADVANCED TACTICAL PRACTITIONER (SOCM-ATP) – A Ranger Medic currently registered as an NREMT-Paramedic by the DOT and/or USSOCOM State-Paramedic (Advanced Tactical Practitioner) who has been awarded the identifier W1 (Special Operations Combat Medic) and has been approved by the unit Medical Director to function at this advanced level of care. A Ranger Medic can train and direct routine and emergency medical care, establish combat casualty collection points, conduct initial surgical and medical patient assessment and management, triage and provide advanced trauma management, and prepare patients for evacuation.

Routine garrison care includes assisting unit medical officers with daily sick call and requires advanced knowledge in common orthopedic problems, respiratory illnesses, gastrointestinal disorders, dermatological conditions, and environmental hazard illnesses. Ranger Medics train non-medical personnel on first responder skills and preventive medicine. Ranger Medics conduct their scope of practice under the licensure of a medical director and are not independent health care providers. Ranger Medics should always obtain medical director advice and supervision for all care provided. However, on rare occasions Ranger Medics may be required to operate relatively independently with only indirect supervision in remote, austere, or clandestine locations. In these cases, it is still extremely rare that a Ranger Medic will be unable to communicate by radio, phone, or computer.

STANDING ORDERS – Advanced life support interventions, which may be undertaken before contacting on-line medical control.

PROTOCOLS – Guidelines for out of hospital patient care. Only the portions of the guidelines, which are designated as “standing orders”, may be undertaken before contacting an on-line medical director.

MEDICAL CONTROL / MEDICAL DIRECTOR / MEDICAL OFFICER – A licensed and credentialed medical provider, physician or physician assistant, who verbally, or in writing, states assumption of responsibility and liability and is available on-site or can be contacted through established communications. Medical care, procedures, and advanced life-saving activities will be routed through medical control in order to provide optimal care to all sick or injured Rangers. Medical Control will always be established, regardless of whether the scenario is a combat mission, a training exercise, or routine medical care. Note that, ultimately, all medical care is conducted under the licensure of an assigned, attached, augmenting, or collocated physician.
STANDING ORDERS AND PROTOCOLS

These standing orders and protocols are only to be used by Ranger Medics assigned to the 75th Ranger Regiment.

PURPOSE

The primary purpose of these protocols is to serve as a guideline for tactical and non-tactical pre-hospital trauma and medical care. Quality out-of-hospital care is the direct result of comprehensive education, accurate patient assessment, good judgment, and continuous quality improvement. All Ranger medical personnel are expected to know the Trauma Management Team Protocols and understand the reasoning behind their employment. Ranger Medics should not perform any step in a standing order or protocol if they have not been trained to perform the procedure or treatment in question. Emergency, trauma, and tactical medicine continues to evolve at a rapid pace. Accordingly, this document is subject to change as new information and guidelines become available and are accepted by the medical community.

STANDING ORDERS AND PROTOCOLS

These standing orders and protocols are ONLY for use by Ranger Medics while providing BLS, ACLS, PHTLS, TCCC, and TMEPs. Ranger Medics who are authorized to operate under the Trauma Management Team guidelines may not utilize these standing orders outside of their military employment. All Ranger Medics must adhere to the standards defined in these protocols. Revocation of privileges will be considered by the granting authority if these standards are violated.

COMMUNICATIONS

In a case where the Ranger Medic cannot contact Medical Control due to an acute time-sensitive injury or illness, a mass casualty scenario, or communication difficulties, all protocols become standing orders. Likewise, in the event that Medical Control cannot respond to the radio or telephone in a timely fashion required to provide optimal care to a patient, all protocols are considered standing orders. In the event that Medical Control was not contacted, and treatment protocols were carried out as standing orders, Medical Control will be contacted as soon as feasible following the incident and the medical record (SF 600 or Trauma SF 600) will be reviewed and countersigned by Medical Control. Retroactive approval for appropriate care will be provided through this process.

When communicating with medical control, a medical officer or a receiving facility, a verbal report will include the following essential elements:

1. **Provider** – name, unit, and call back phone number
2. **Patient** – name, unit, age, and gender
3. **Subjective** – findings to include chief complaint and brief history of event
4. **Objective** – findings to include mental status, vital signs, and physical exam
5. **Assessment** – to include differential diagnosis and level of urgency
6. **Plan** – to include treatment provided, patient response to treatment, and ETA

Provide patient status updates as dictated by patient status changes en route.
PATIENT CARE DOCUMENTATION

Patient care documentation is of paramount importance and should be performed for every patient encounter using a JTF Combat Casualty Card, a Trauma SF 600 Medical Record, or a SF 600 Medical Record.

RESUSCITATION CONSIDERATIONS

Resuscitation is not warranted in patients who have sustained obvious life-ending trauma, or patients with rigor mortis, decapitation, or decomposition. However, when reasonable, consider performing resuscitation efforts when this is your only patient. The perception of fellow Rangers and family members in this instance should be that every effort was made to sustain life. When possible, place “quick look” paddles or EKG leads to confirm asystole or an agonal rhythm in two leads and attach a copy of this strip to the medical record. Also note that, technically, only a medical officer can pronounce a patient as deceased.

GENERAL GUIDELINES FOR PROTOCOL USAGE

1. The patient history should not be obtained at the expense of the patient. Life-threatening problems detected during the primary assessment must be treated first.

2. Cardiac arrest due to trauma is not treated by medical cardiac arrest protocols. Trauma patients should be transported promptly to the previously coordinated Medical Treatment Facility with CPR, control of external hemorrhage, cervical spine immobilization, and other indicated procedures attempted en route.

3. In patients who require a saline lock or intravenous fluids, only two attempts at IV access should be attempted in the field. Intraosseous infusion should be considered for life-threatening emergencies. However, patient transport to definitive care must not be delayed for multiple attempts at IV access or advanced medical procedures.

4. Medics will verbally repeat all orders received and given prior to their initiation. It is preferable that medical personnel work as two-man Trauma Teams whenever practical.

NEVER HESITATE TO CONTACT A MEDICAL DIRECTOR AT ANY TIME FOR ASSISTANCE, QUESTIONS, CLARIFICATION, OR GUIDANCE.
CASUALTY ASSESSMENT AND MANAGEMENT

I. OVERVIEW:

ESTABLISH PRIORITIES
1. Obtain situational awareness...then ensure scene security.
2. Control yourself...then take control of the situation. The senior medical person on the scene needs to control the resuscitation effort. All orders to team members need to come from one person, the senior medical person in charge.
3. Just remember, there are three groups of casualties that you may encounter. With the first group, no matter what you do, they will live. With the second group, no matter what you do, they may die. With the third group, if you do the right thing, at the right time, your treatment will be the difference between life and death. Focus your efforts on this third group.

TRIAGE CATEGORIES
- Immediate – casualties with high chances of survival who require life-saving surgical procedures or medical care
- Delayed – casualties who require surgery or medical care, but whose general condition permits a delay in treatment without unduly endangering the casualty
- Minimal – casualties who have relatively minor injuries or illnesses and can effectively care for themselves or be helped by non-medical personnel
- Expectant – casualties who have wounds that are so extensive that even if they were the sole casualty and had the benefit of optimal medical resource application, their survival would be unlikely

EVACUATION PRECEDENCES (“CPR”)
- Critical (Urgent) – evacuate within 2 HOURS in order to save life, limb, or eyesight
- Priority – evacuate within 4 HOURS as critical and time sensitive medical care is not available locally, the patient’s medical condition could deteriorate, and/or the patient cannot wait for routine evacuation.
- Routine – evacuate within 24 HOURS, as the patient’s medical condition is not expected to deteriorate significantly while awaiting flight

PRIMARY SURVEY
During the primary survey, life-threatening conditions are identified and simultaneously managed. The primary survey consists of:
- A - Airway Maintenance and C-spine Stabilization (situation dependent)
- B - Breathing
- C - Circulation with Control of Massive Hemorrhage (conducted first in combat setting)
- D - Disability [mental status]
- E - Exposure/Environmental Control [prevent hypothermia]
RESUSCITATION
Aggressive initial resuscitation should include hemorrhage control, airway establishment and protection, ventilation and oxygenation, IV fluid administration as needed, and hypothermia prevention. As resuscitative interventions are performed, the provider should reassess the patient for changes in status.

SECONDARY SURVEY
The secondary survey should consist of obtaining a brief history and conducting a complete head-to-toe evaluation of the trauma patient. This in-depth examination utilizes inspection, palpation, percussion, and auscultation, to evaluate the body in sections. Each section is examined individually.

TREATMENT PLAN
Initially, provide critical resuscitative efforts to resolve potential life-threatening injuries detected in the primary and secondary survey. Secondly, determine the patient disposition. Is the patient stable or unstable? What further diagnostic evaluation, operative intervention, or treatment is required? What level of medical care is needed? When does the patient need to be evacuated? All of these questions must be answered in a logical fashion in order to prioritize and mobilize the resources available.

II. THE PRIMARY SURVEY
The primary survey is broken down into five major areas: Airway and C-Spine Control, Breathing, Circulation, Disability, Exposure/Environment Control.

- During combat operations, while operating under the auspices of Tactical Combat Casualty Care (TCCC), the primary survey is conducted as C-A-B-D-E instead of A-B-C-D-E.
- Hemorrhage control is the most common cause of preventable death in combat and thus takes priority over airway management in this environment.

A. AIRWAY AND C-SPINE
The upper airway should be assessed to ascertain patency. Chin lift, jaw thrust, or suction may be helpful in reestablishing an airway. Specific attention should be directed toward the possibility of a cervical spine fracture. The patient’s head and neck should never be hyper-extended or hyper-flexed to establish or maintain an airway. One should assume a c-spine fracture in any patient with an injury above the clavicle. Approximately fifteen percent of patients who have this type of injury will also have a c-spine injury. Quick assessment of Airway & Breathing can be observed by the patient’s ability to communicate and mentate.

B. BREATHING
The patient’s chest should be exposed and you should look for symmetrical movement of the chest wall. Conditions that often compromise ventilation include: MASSIVE HEMOTHORAX, TENSION PNEUMOTHORAX, OPEN PNEUMOTHORAX, and FLAIL CHEST.
C. CIRCULATION
Circulation is divided into two parts: Hemodynamic Status and Hemorrhage Control.

1. Hemodynamic Status
A formal blood pressure measurement SHOULD NOT be performed at this point in the primary survey. Important information can be rapidly obtained regarding perfusion and oxygenation from the level of consciousness, pulse, skin color, and capillary refill time. Decreased cerebral perfusion may result in an altered mental status. The patient's pulse is easily accessible, and if palpable, the systolic blood pressure in millimeters of mercury (mm Hg) can be roughly determined as follows:

- **RADIAL PULSE:** PRESSURE ≥ 80 mm Hg
- **FEMORAL PULSE:** PRESSURE ≥ 70 mm Hg
- **CAROTID PULSE:** PRESSURE ≥ 60 mm Hg

Skin color and capillary refill will provide a rapid initial assessment of peripheral perfusion. Pink skin is a good sign versus the ominous sign of white or ashen, gray skin depicting hypovolemia. Pressure to the thumb nail or hypothenar eminence will cause the underlying tissue to blanch. In a normovolemic patient, the color returns to normal within two seconds. In the hypovolemic, poorly oxygenated patient and/or hypothermic patient this time period is extended or absent.

2. Hemorrhage Control (Conducted first in Combat Setting)

- **EXTERNAL HEMORRHAGE.** Exsanguinating external hemorrhage should be identified and controlled in the primary survey. Direct pressure, indirect pressure, elevation, tourniquets, hemostatic agents, and pressure dressings should be utilized to control bleeding. Note that tourniquets should be used as a primary adjunct for massive or arterial bleeding until controlled by dressings or hemostatic agents.

- **INTERNAL HEMORRHAGE.** Occult hemorrhage into the thoracic, abdominal, or pelvic region, or into the thigh surrounding a femur fracture, can account for significant blood loss. If an operating room is not immediately available, abdominal or lower extremity hemorrhage can be reduced by hemostatic agents, wound packing, ligation, and clamping.

### Estimate of Fluid and Blood Requirements in Shock:

<table>
<thead>
<tr>
<th></th>
<th>Class I</th>
<th>Class II</th>
<th>Class III</th>
<th>Class IV</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Blood Loss (ml)</strong></td>
<td>Up to 750</td>
<td>750-1500</td>
<td>1500-2000</td>
<td>&gt; 2000</td>
</tr>
<tr>
<td><strong>Blood Loss (%BV)</strong></td>
<td>Up to 15%</td>
<td>15-30%</td>
<td>30-40%</td>
<td>&gt; 40%</td>
</tr>
<tr>
<td><strong>Pulse Rate</strong></td>
<td>&lt; 100</td>
<td>&gt; 100</td>
<td>&gt; 120</td>
<td>&gt; 140</td>
</tr>
<tr>
<td><strong>Blood Pressure</strong></td>
<td>WNL</td>
<td>WNL</td>
<td>Decreased</td>
<td>Decreased</td>
</tr>
<tr>
<td><strong>Pulse Pressure (mmHg)</strong></td>
<td>WNL/increased</td>
<td>Decreased</td>
<td>Decreased</td>
<td>Decreased</td>
</tr>
<tr>
<td><strong>Capillary Blanch Test</strong></td>
<td>Normal</td>
<td>Positive</td>
<td>Positive</td>
<td>Positive</td>
</tr>
<tr>
<td><strong>Respiratory Rate</strong></td>
<td>14-20</td>
<td>20-30</td>
<td>30-40</td>
<td>&gt; 35</td>
</tr>
<tr>
<td><strong>Urine Output (mL/hr)</strong></td>
<td>&gt; 30</td>
<td>20-30</td>
<td>5-15</td>
<td>Negligible</td>
</tr>
<tr>
<td><strong>CNS-Mental Status</strong></td>
<td>Slightly anxious</td>
<td>Mildly anxious</td>
<td>Anxious/confused</td>
<td>Confused/lethargic</td>
</tr>
<tr>
<td><strong>Fluid Replacement</strong></td>
<td>Saline Lock</td>
<td>Saline Lock</td>
<td>Colloid / Blood</td>
<td>Colloid / Blood</td>
</tr>
</tbody>
</table>
D. DISABILITY (MENTAL STATUS)
A rapid neurologic evaluation should be utilized to determine the patient's pupillary size and response, as well as the level of consciousness (LOC). Pupils should be equally round and reactive to light. If the pupils are found to be sluggish or nonreactive to light with unilateral or bilateral dilation, one should suspect a head injury and/or inadequate brain perfusion. LOC can be described through either the AVPU or Glasgow Coma Scale (GCS) method:

<table>
<thead>
<tr>
<th>AVPU:</th>
<th>ALERT</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>ALERT</td>
</tr>
<tr>
<td>V</td>
<td>Responds to VERBAL stimuli</td>
</tr>
<tr>
<td>P</td>
<td>Responds to PAINFUL stimuli</td>
</tr>
<tr>
<td>U</td>
<td>UNRESPONSIVE to stimuli</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>GCS: (15 point scale)</th>
<th>EYE OPENING</th>
<th>Motor Response</th>
</tr>
</thead>
<tbody>
<tr>
<td>E</td>
<td>Spontaneous</td>
<td>Obeys Commands</td>
</tr>
<tr>
<td></td>
<td>To speech</td>
<td>Localizes Pain</td>
</tr>
<tr>
<td></td>
<td>To pain</td>
<td>Withdraws (Normal Flexion)</td>
</tr>
<tr>
<td></td>
<td>None</td>
<td>Decorticate (Abnormal Flexion)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Decerebrate (Extension)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>None (Flaccid)</td>
</tr>
<tr>
<td>V</td>
<td>Oriented</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Confused</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>Inappropriate Words</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>Incomprehensible Sounds</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>None</td>
<td>1</td>
</tr>
<tr>
<td>M</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td></td>
<td>4</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>6</td>
<td></td>
</tr>
<tr>
<td></td>
<td>5</td>
<td></td>
</tr>
<tr>
<td></td>
<td>4</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3</td>
<td></td>
</tr>
<tr>
<td></td>
<td>2</td>
<td></td>
</tr>
<tr>
<td></td>
<td>1</td>
<td></td>
</tr>
</tbody>
</table>

E. EXPOSURE / ENVIRONMENTAL CONTROL
The patient should be completely undressed (environment permitting) to facilitate thorough examination and assessment during the secondary survey. Strive to maintain the patient in a normothermic state. Hypothermia prevention is as important as any other resuscitation effort.

III. RESUSCITATION
Resuscitation includes oxygenation, intravenous access, and monitoring.

OXYGEN AND AIRWAY MANAGEMENT
Supplemental oxygen should be administered to all trauma patients in the form of a nonrebreather mask if available. A bag-valve-mask (BVM) should be readily available and used when needed. Definitive airways can be provided through cricothyroidotomy and endotracheal intubation. Endotracheal intubation must be confirmed and documented by at least three of the following methods: 1) visualization of the tube passing through cords, 2) endotracheal esophageal detector (Tube Check), 3) bilateral
breath sounds and absence of epigastric sounds, 4) condensation inside the endotracheal tube, and 5) end-tidal carbon dioxide monitoring.

**IV ACCESS**

A minimum of two 18 gauge IV/saline locks should be started in all multiple trauma patients. The rate of fluid administration is determined by the patient's hemodynamic status and whether or not hemorrhage is controlled. Fluid resuscitation is assessed by improvement in physiologic parameters such as the ventilatory rate, pulse, blood pressure, and urinary output. Trauma patients should receive 1-2 peripheral IV access saline locks. Trauma patients who have **controlled bleeding** and a Systolic BP <90 mm Hg should receive Hextend until the Systolic BP is >90 mm Hg up to a maximum of 1000 ml. Trauma patients with controlled bleeding and a systolic blood pressure >90 mm Hg, or uncontrolled hemorrhage, should receive a saline lock only and fluids TKO. Note that the external jugular vein is considered a peripheral vein. When peripheral access is inaccessible after a minimum of two unsuccessful peripheral IV attempts, a sternal intraosseous “FAST-1” device can be performed on adults who require life-saving fluids and/or medications. When practical, use a permanent marker to label each IV bag with the time initiated and completed, medications placed in the bag, allergies to medications, and the number of IV bags received.

**MONITORING**

All patients followed for multiple trauma wounds should be continuously monitored for vital sign instability. Dysrhythmias are frequently associated with blunt chest trauma and should be treated in the same fashion as arrhythmias secondary to heart disease.

---

### IV. The Secondary Survey

This survey should include a complete history, a head-to-toe physical examination, and a reassessment of vital signs.

**HISTORY**

A patient’s pertinent past medical history must be obtained. A useful mnemonic is the word “**AMPLE**”.

- Allergies
- Medications and nutritional supplements
- Past medical illnesses and injuries
- Last meal
- Events associated to the injury

**PHYSICAL**

The physical exam can be divided into eight parts: Head, Face, C-Spine and Neck, Chest, Abdomen, Perineum and Rectum, Musculoskeletal, and Neurological.

1. **HEAD**

The secondary survey begins with a detailed examination of the scalp and head looking for signs of significant injury to include edema, contusions, lacerations, foreign bodies, evidence of fracture, CSF leak, or hemotympanum. The eyes should be evaluated for
visual acuity, pupillary size, external ocular muscle function, conjunctival and fundal hemorrhage, and contact lenses (remove before edema presents).

2. FACE
Maxillofacial trauma, unassociated with airway compromise and/or major hemorrhage, should be treated after the patient is completely stabilized. If the patient has midface trauma, suspect a cribiform plate fracture. If intubation is required in this scenario then it should be performed orally and NOT via the nasal route.

3. C-SPINE/NECK
Suspect an unstable cervical spine injury in patients with blunt head or maxillofacial trauma and/or mechanism of injury (static-line or freefall jump incident, fastrope or rappelling incident, aircraft mishap, motor vehicle collision, blast injury, fall > 20 feet). An absence of neurological deficits does not rule out spinal injuries. A cervical spine injury should be presumed and the neck immobilized until cleared by a physician and/or radiographic evaluation. Cervical spine tenderness to palpation and spasm of the musculature of the neck can be associated with a cervical spine injury. The absence of neck pain and spasm in a patient who is neurologically intact is good evidence that a C-spine injury does not exist. However, it does not eliminate the need for radiographic cervical spine evaluation. Cervical spine inspection, palpation, and auscultation should also be used to evaluate for subcutaneous emphysema, tracheal deviation, laryngeal fracture, and carotid artery injury. In the absence of hypovolemia, neck vein distension can be suggestive of a tension pneumothorax or cardiac tamponade.

4. CHEST
A complete inspection of the anterior and posterior aspect of the chest must be performed to exclude an open pneumothorax or flail segment. The entire chest wall (rib cage, sternum, clavicles, and posterior and axillary regions) should be palpated to reveal unsuspected fractures or costochondral separation. Auscultation should be utilized to evaluate for the alteration of breath sounds denoting a pneumothorax, tension pneumothorax, or hemothorax. Auscultation of distant heart sounds may be indicative of a cardiac tamponade. Percussion of hypertympanic sounds may indicate tension pneumothorax.

5. ABDOMEN
Any abdominal injury is potentially dangerous. Once identified, these injuries must be treated early and aggressively. The specific diagnosis is not as important as the fact that an abdominal injury exists which may require surgical intervention. Palpation, close observation, and frequent reevaluation of the abdomen are essential in the assessment and management of an intra-abdominal injury. In blunt trauma, the initial examination of the abdomen may be unremarkable. However, serial exams over time may reveal increasing signs of tenderness, rebound pain, guarding, and loss of bowel sounds.

6. RECTUM
A complete rectal examination in a trauma patient is essential and should include an evaluation for rectal wall integrity, prostate position, sphincter tone, and gross or occult blood.
7. EXTREMITIES
Extremities should be inspected for lacerations, contusions, and deformities. Palpation of bones (through rotational or three-point pressure) checking for tenderness, crepitation, or abnormal movements along the shaft, can help to identify non-displaced or occult fractures. Slight pressure **(NO PELVIC ROCK)** with the heels of the hand on the anterior superior iliac spines and on the symphysis pubis can identify pelvic fractures. Peripheral pulses should be assessed on all four extremities. The absence of a peripheral pulse distal to a fracture or dislocation mandates manipulation toward the position of function; if the pulse is still absent, transport immediately.

8. NEUROLOGICAL EXAMINATION
An in-depth neurological examination includes motor and sensory evaluation of each extremity, and continuous re-evaluation of the patient’s level of consciousness and pupil size and response. Any evidence of loss of sensation, weakness, or paralysis suggests a major injury either to the spinal column or peripheral nervous system. Immobilization using a long board and a rigid cervical collar must be immediately established. These patients should be evacuated as soon as possible. Additionally, consider treating patient as a spinal cord injury if distracting injury and consistent with mechanism of injury.

V. REEVALUATION
Trauma patients require serial exams and reevaluation for changed or new signs and symptoms. Continuous observation, monitoring, vital sign assessment, and urinary output maintenance (an average of > 30cc/hour in the adult patient) is also imperative. As initial life-threatening injuries are managed, other equally life-threatening problems may develop. Less severe injuries or underlying medical problems may become evident. A high index of suspicion facilitates early diagnosis and management.

VI. SUMMARY
The injured Ranger must be rapidly and thoroughly evaluated. You must develop an outline of priorities for your patient. These priorities in combat include the primary survey which includes evaluation of circulation, airway and c-spine control, breathing, disability (mental status), and exposure/environment.

Resuscitation should proceed simultaneously with the primary survey. It includes the management of all life-threatening problems, the establishment of intravenous access, the placement of EKG monitoring equipment, and the administration of oxygen.

The secondary survey includes a total evaluation of the injured Ranger from head to toe. During your evaluation you reassess the ABC’s and the interventions provided during the primary survey. Ensure to document your finding and interventions on a Trauma SF 600 or JTF Casualty Card.
TACTICAL COMBAT CASUALTY CARE (TCCC)

Trauma is the leading cause of death in the first four decades of life. Current protocols for civilian trauma care in the US are based on the Advanced Trauma Life Support (ATLS) course, which was initially conducted in 1978. Since that time, ATLS protocols have been accepted as the standard of care for the first hour of trauma management that is taught to both civilian and military providers. ATLS is a great approach in the civilian setting; however, it was never designed for combat application.

Historically, most combat-related deaths have occurred in close proximity to the point of injury prior to a casualty reaching an established medical treatment facility. The combat environment has many factors that affect medical care to include temperature and weather extremes, severe visual limitations, delays in treatment and evacuation, long evacuation distances, a lack of specialized providers and equipment near the scene, and the lethal implications of an opposing force. Thus, a modified approach to trauma management must be utilized while conducting combat operations.

Combat treatment protocols must be directed toward preventable combat death. COL Ron Bellamy researched how people die in ground combat and developed a list of causes of death that can be prevented on the battlefield.

How people die in combat
KIA: 31% penetrating head trauma
KIA: 25% surgically uncorrectable torso trauma
KIA: 10% potentially correctable surgical trauma
KIA: 9% exsanguination from extremity wounds
KIA: 7% mutilating blast trauma
KIA: 5% tension pneumothorax
KIA: 1% airway problems
DOW: 12% (mostly from infections and complications of shock)

Preventable causes of death
60% Bleeding to death from extremity wounds
33% Tension pneumothorax
6% Airway obstruction (maxillofacial trauma)

The tactical environment and causes of combat death dictate a different approach for ensuring the best possible outcome for combat casualties while sustaining the primary focus of completing the mission. CAPT Frank Butler and LTC John Hagmann proposed such an approach in 1996. Their article, “Tactical Combat Casualty Care in Special Operations”, emphasized three major objectives and outlined three phases of care.

Objectives:
✓ Treat the patient
✓ Prevent additional casualties
✓ Complete the mission

Phases of Care:
1. Care Under Fire
2. Tactical Field Care
3. Combat Casualty Evacuation (CASEVAC) Care
Over the past decade, numerous military and civilian medical providers and multiple articles in the medical literature have endorsed the tenets of Tactical Combat Casualty Care (TCCC). TCCC was integrated into the 4th and subsequent editions of the Prehospital Trauma Life Support (PHTLS) textbook that is authored by the National Association of Emergency Medical Technicians in cooperation with the American College of Surgeons Committee on Trauma.

In 2002, the Committee on Tactical Combat Casualty Care (COTCCC) was established by the US Special Operations Command. Since then, the COTCCC has met on a regular basis in order to evaluate, modify, and make recommendations for TCCC protocols, procedures, and guidelines.

The following is a summary of the phases of care which includes updates from the COTCCC through 2006:

### PHASES OF CARE:

#### 1. CARE UNDER FIRE

Care provided at point of injury while under effective enemy fire, limited by equipment carried by provider.

Major goals are to move casualty to safety, prevent further injury to the casualty and provider, stop life threatening external hemorrhage, and **gain and maintain fire superiority – the best medicine on the battlefield!**

- Return fire and take cover, direct casualty to return fire and take cover
- Keep yourself from getting shot and prevent additional wounds to casualty
- Self aid if able and buddy aid if available
- Treat life threatening external hemorrhage with a tourniquet
- If bleeding continues, also use a hemostatic agent and pressure dressing

#### 2. TACTICAL FIELD CARE

Care rendered once casualty is no longer under effective enemy fire or when conducting a mission without hostile fire.

Do not attempt CPR on the battlefield for victims of blast or penetrating trauma who have no pulse, respirations, or other signs of life.

Disarm casualties with altered mental status, place weapon on safe and clear, take radio away from casualty.

- **AIRWAY**
  - Chin-lift or jaw-thrust maneuver, recovery position, and nasopharyngeal airway for unconscious patients
  - Cricothyroidotomy for airway obstruction
  - No C-Spine immobilization for penetrating trauma

- **BREATHING**
  - If torso trauma and respiratory distress, presume tension pneumothorax and needle decompress
  - Treat sucking chest wounds with three-sided dressing during expiration, and monitor for tension pneumothorax
  - Administer chest tube when needed
CIRCULATION
- Assess and control bleeding with tourniquet, hemostatic agent, pressure dressing
- Initiate 18-gauge saline lock (IV); use IO as required
  - Controlled hemorrhage, no shock: NO FLUIDS
  - Controlled hemorrhage, shock: Hextend 500-1000cc
  - Uncontrolled hemorrhage, no shock: NO FLUIDS
- PO fluids permissible if conscious

ENVIRONMENT
- Prevent hypothermia, minimize exposure, external warming devices, IVF warmers

WOUNDS
- Inspect, dress, and check for additional wounds

FRACTURES
- Check pulse, inspect, dress, splint, and recheck pulse

MEDICATIONS (Analgesia and Antibiotics)
- Oral Wound Pill Packs: Mobic 15 mg, Tylenol 650 mg, Moxifloxacin 400 mg
- OTFC: Fentanyl lozenge 800 mcg
- IV Pain Management: Morphine 5 mg IV repeated every 10 minutes as needed for pain; Promethazine 25 mg IV for nausea and synergistic analgesic effect
- IV Antibiotic: Cefotetan 2g q12h or Ertapenem 1 g q24h

MONITOR
- Vital signs and pulse oximetry

DOCUMENT
- Casually Card

3. COMBAT CASUALTY EVACUATION (CASEVAC)

The medical care provided during the evacuation of the casualty. Continue or initiate care as per previous phase. Pre-staged medical assets on CASEVAC should be utilized to provide the same or higher level of care rendered during the mission.

- INITIATE AND CONTINUE CARE AS PER PREVIOUS PHASE
- EVALUATE AND REFINE CARE
  - Airway: Consider combitube or laryngeal mask airway or endotracheal intubation
  - Breathing: Consider oxygen if available
  - Circulation: Convert tourniquets as possible
  - Environment: Adjust temperature in vehicle or aircraft
SECTION TWO

PART A

TRAUMA PROTOCOLS
Medical Patient Assessment Protocol

Indication for a Medical Patient Assessment

Scene Secure?

Yes

Ensure Scene Security or Refer to Tactical Assessment Protocol

No

Provider Precautions

Primary Survey

A – Airway / C-Spine
B – Breathing
C – Circulation
D – Disability
E – Expose/Environment

Detailed Assessment & Documentation

Complete Vital Signs

SOAP Format

Continuous Monitoring Required?

Yes

Consider:

Cardiac Monitoring
Pulsoximetry
Glucometry
IV Access

No

Focused Examination

Based on Chief Complaints

Apply appropriate protocols based on Primary, Detailed and Focused Assessments

Document all findings

Monitor IAW Protocol

Antibiotics as required
Pain Management as required
Contact/Report to Medical Officer
Oxygen if possible
Document
Evacuate IAW Protocol

AVPU Responsiveness Assessment

ALERT
VERBAL – Responds to verbal stimuli
PAIN – Responds to painful stimuli
UNCONSCIOUS – Does not respond to any stimuli

Glasgow Coma Scale

Eye
Spontaneous 4
Opening
To Voice 3
To Pain 2
None 1

Verbal
Oriented 5

Response
Confused 4
Inappropriate Words 3
Incomprehensible Words 2
None 1

Motor
Obey Commands 6
Response
Localizes Pain 5
Withdraws (Pain) 4
Flexion 3
Extension 2
None 1

Document as: E___ + V____ + M____ =____

AMPLE Patient History

A – Allergies
M – Medications
P – Past Medical History
L – Last Meal
E – Events Associated

OPQRST Patient History

Chief Complaint
O – Onset
P – Provocation
Q – Quality
R – Radiation
S – Severity
T – Time

SOAP Format

S – Age/Sex
Chief Complaint
History of Present Illness
Allergies
Medications
Past Medical History
Past Surgical History
Social History
O – Complete Vital Signs
Physical Examination
A – Differential Diagnosis
P – Immediate Plan
Monitoring
Medications
Fluids
Diagnostics
Procedures
Referrals
Transport

Normal Adult Vital Signs

Systolic Blood Pressure:
Male: 120-140
Female: 110-130
Pulse Rate: 60-80
Respiratory Rate: 12-20
Body Temperature: 98.6

Abnormal Finding: Eyes, Ears, Nose
Cerebral Spinal Fluid
Raccoon eyes
Pupil Inequality
Abnormal gaze
Doll’s eye response

Abnormal Finding: Neck
Jugular vein distention
Tracheal deviation
Subcutaneous emphysema

Abnormal Finding: Chest & Breath Sounds
Retractions
Unequal excursion
Subcutaneous emphysema
Erythema
Paradoxical motion
Abnormal breath sounds
Rales
Rhonchi
Wheezing
Stridor
Kussmaul respirations
Cheyne-stokes pattern

Abnormal Finding: Abdominal
Pulsations
Guarding
Pain
Tenderness
Rebound tenderness
Masses
Absence bowel sounds

Signs of Extremity Vascular Compromise
Absent or diminished pulse
Cool extremity
Slow or absent capillary refill
Cyanosis
Dislocation
Inappropriate Angles
Swelling
Discoloration
Airway Management Protocol

Indications for Airway Management

1. Airway Obstruction due to trauma, edema, excess secretions, foreign body, or tongue
2. Apnea
3. Excess work of breathing as indicated by accessory muscle use, fatigue, diaphoresis, or tachypnea when resp failure is imminent
4. Decreased LOC (GCS<8)
5. Hypoxia (SpO2 <90%)
6. Shock
7. Patients not meeting the above criteria may still require airway protection preceding long transport

Yes

Airway Patent?

Reposition Airway Manually (jaw-thrust if c-spine injury) Sweep & Suction as needed Heimlich Maneuver if indicated

Conscious with Spontaneous Respirations (RR <8 or >30)?

Yes

Consider & Implement Immediate Evacuation as required

Is SpO2 >90%?

Yes

DO NOT use nasopharyngeal airway if basal skull fracture is suspected.

Insert Nasopharyngeal AW (NPA)

Supplemental O2 if possible

Assist ventilations with BVM as required

Thoracic Trauma?

Yes

Refer to Thoracic Trauma Management ICW this protocol

Establish More Definitive Airway As Required IAW Procedures

1. Cricothyroidotomy
2. King-LT Airway
See Procedures

Definitive Airway Established?

No

Re-Assess Interventions Provided

Consider other causes of Hypoxia

Monitor IAW Protocol

Antibiotics as required

Pain Management as required

Contact/Report to Medical Officer

Oxygen if possible

Document

Evacuate – Urgent

Monitor Airway Continuously

Sweep & Suction as required

Restart Protocol if respiratory problems arise

No

Airway Patent?

Yes

Conscious with Spontaneous Respirations (RR <8 or >30)?

No

Reposition Airway Manually (jaw-thrust if c-spine injury) Sweep & Suction as needed Heimlich Maneuver if indicated

Monitor

Re-check airway every 5 min Sweep & Suction as needed Supplemental O2 if possible Assist ventilation w/BVM as needed Restart Protocol if problems arise Evac - Priority

Generally, unless a patient has a GCS of <8, intubation will be difficult. The medic should consider immediate cricothyroidotomy to establish a definitive airway.
1. Maintain strict C-Spine precautions if potential for C-Spine Injury exists.
2. Anytime the patient goes 30 seconds without ventilation, stop the procedure and hyperventilate for 30-60 seconds before procedure is re-attempted.
1. **CONTRAINDICATION:** The King-LT-D does not protect the airway from the effects of regurgitation or aspiration. Be prepared to suction as needed.

2. **REMOVAL:**
   a. Suction above the cuff in the oral cavity if indicated
   b. Fully deflate both cuffs before removal of the device
   c. Remove the King LT-D when protective reflexes have returned

---

**Patient Assessment**

**Indication for Supralaryngeal Airway**

Airway Management in patients over 4 ft in height Controlled or Spontaneous Ventilation

---

**Test cuff inflation system for air leak**

**Apply water-soluble lubricant to distal tip**

**Apply chin lift and introduce King-LT-D into corner of mouth**

While holding the King-LT-D in the dominant hand, advance tip under base of tongue, while rotating tube to midline (the blue line faces the chin)

Without exerting excessive force, advance tube until base of connector is aligned with teeth or gums

Inflate cuffs:
- Size 4 or 5 – 80 ml

Attach BVM. While bagging, slowly withdraw tube until ventilation is easy and free-flowing

Adjust cuff inflation as necessary to obtain a seal of the airway at the peak ventilatory pressure employed

Oxygen 100% if available

Check for breath sounds and absence of epigastric sounds

---

**EQUIPMENT NEEDED:**

- King LT-D Airway Device (siz 4 or 5)
- 90cc syringe (accompanying)
- Gloves
- Bag-Valve-Mask (BVM)
- Oxygen if available

---

**DOCUMENTATION:**

- ABC's
- Detailed Assessment
- Vital Signs
- SpO2
- Glasgow Coma Scale
- Lung Sounds
- Absence of Epigastric Sounds
- Skin Color
- Complications Encountered

---

**Glasgow Coma Scale**

<table>
<thead>
<tr>
<th>Eye</th>
<th>Spontaneous</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Opening</td>
<td>To Voice</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>To Pain</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>None</td>
<td>1</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Verbal</th>
<th>Oriented</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td>Response</td>
<td>Confused</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Inappropriate Words</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>Incomprehensible Words</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>None</td>
<td>1</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Motor</th>
<th>Obey Commands</th>
<th>6</th>
</tr>
</thead>
<tbody>
<tr>
<td>Response</td>
<td>Localizes Pain</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td>Withdraws (Pain)</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Flexion</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>Extension</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>None</td>
<td>1</td>
</tr>
</tbody>
</table>

Document as: $E + V + M =$

---

1. **Monitor Continuously**
2. **Antibiotics as required**
3. **Pain Management as required**
4. **Contact/Report to Medical Officer**
5. **Oxygen if possible**
6. **Document**
7. **Evacuate IAW Protocol**

Ensure adequate ventilation with BVM (12 to 20 breaths per minute)
Orotracheal Intubation Procedure

**Indication for Orotracheal Intubation**

- Assure adequate ventilation and oxygenation are in progress and that suctioning equipment is immediately available.
- Check cuff of ET Tube and lubricate tube.
- Connect the laryngoscope blade to the handle and check bulb for brightness. Ensure bulb is secure in the blade.
- Hold laryngoscope in the Left hand.
- Open patient’s mouth with fingers of your Right hand and insert the laryngoscope into the right side of the patient’s mouth, displacing the tongue to the Left.
- Apply upward and outward pressure (lifting the laryngoscope) on the mandible. DO NOT leverage off of the teeth.
- Visually identify the epiglottis and the vocal cords. *Use Selick’s Maneuver if assistance is available*
- Insert and advance the ET Tube into the trachea ensuring the cuff is at least 1 to 2.5 cm below the vocal cords.
- Inflate the cuff on the ET Tube with air using a 10cc syringe (*see Note 6*)

**Patient Assessment**

**Indication for Orotracheal Intubation**

1. Maintain strict C-Spine precautions if potential for C-Spine Injury exists.
2. Avoid applying pressure on the teeth or lips. Never use a prying motion.
3. Anytime the patient goes 30 seconds without ventilation, stop the procedure and hyperventilate for 30-60 seconds before procedure is re-attempted.
4. Intubation is to be only attempted twice. After two unsuccessful attempts are made, transition to a surgical cricothyroidotomy.
5. If assistance is available, use Selick’s maneuver to assist visualization of epiglottis and vocal cords.
6. Inflate with 10cc of normal saline OR only 5cc of air for high altitude environment or high altitude aeromedical evacuation.

**EQUIPMENT NEEDED:**
- Laryngoscope
- Miller and Macintosh Blades
- ET Tube (7.0 or 7.5mm)
- Suction (Manual or Mechanical)
- Oxygen Source (if available)
- Bag-Valve-Mask (BVM)
- Stylet
- Stethoscope
- Syringe, 10cc
- Lubricant (Water Soluble)
- Tube Check Bulb
- Pulsoximeter
- Gloves
- Tape

**DOCUMENTATION:**
- ABC’s
- Detailed Assessment
- Vital Signs
- SpO2
- Glasgow Coma Scale
- Tube Check Results
- Lung Sounds
- Absence of Epigastric Sounds
- Skin Color
- Teeth to ET Tube Tip depth
- Complications Encountered

---

**Glasgow Coma Scale**

<table>
<thead>
<tr>
<th>Eye</th>
<th>Opening</th>
<th>Motor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spontaneous</td>
<td>To Voice</td>
<td>Obeys Commands</td>
</tr>
<tr>
<td>4</td>
<td>3</td>
<td>6</td>
</tr>
<tr>
<td>To Pain</td>
<td>Oriented</td>
<td>Response</td>
</tr>
<tr>
<td>2</td>
<td>5</td>
<td>Confused</td>
</tr>
<tr>
<td>None</td>
<td>Inappropriate Words</td>
<td>Localizes Pain</td>
</tr>
<tr>
<td>1</td>
<td>3</td>
<td>Withdraws (Pain)</td>
</tr>
<tr>
<td></td>
<td>Incomprehensible Words</td>
<td>Flexion</td>
</tr>
<tr>
<td></td>
<td>None</td>
<td>Extension</td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>2</td>
</tr>
</tbody>
</table>

Document as: E___ + V____ + M____ =____

---

1. Maintain strict C-Spine precautions if potential for C-Spine Injury exists.
2. Avoid applying pressure on the teeth or lips. Never use a prying motion.
3. Anytime the patient goes 30 seconds without ventilation, stop the procedure and hyperventilate for 30-60 seconds before procedure is re-attempted.
4. Intubation is to be only attempted twice. After two unsuccessful attempts are made, transition to a surgical cricothyroidotomy.
5. If assistance is available, use Selick’s maneuver to assist visualization of epiglottis and vocal cords.
6. Inflate with 10cc of normal saline OR only 5cc of air for high altitude environment or high altitude aeromedical evacuation.
1. If bleeder is visualized or palpated, apply hemostatic agent directly to site.
2. For truncal bleeding, assume the possibility of intra-abdominal and thoracic injury.
**Patient Assessment**  
Indication for Tourniquet Application  
- Massive External Extremity Bleeding uncontrolled by direct or indirect pressure  
- Amputation

**Tourniquet Application Procedure**

**DOCUMENTATION:**  
- ABC's  
- Detailed Assessment  
- Vital Signs  
- SpO2  
- Complications Encountered

**Massive External Extremity Bleeding**  
- Uncontrolled by direct or indirect pressure  
- Amputation

**Combat Application Tourniquet (CAT)**

**Lower Extremity**  
- Route band around leg and pass the free-running end through the buckle  
- Pass band through the outside slit of the buckle and pull the band tight  
- Securely fasten the band back on itself  
- Twist the Windlass Rod until arterial bleeding has stopped  
- Lock the Windlass Rod with the clip and secure Rod with friction adapter strap

**Upper Extremity**  
- Insert the wounded arm through the loop of the band  
- Pull the band tightly and secure the band back on itself and around the arm  
- **DO NOT adhere the band past the Windlass Clip**  
- Twist the Windlass Rod until arterial bleeding has stopped  
- Lock the Windlass Rod with the clip and secure Rod with friction adapter strap

**Windlass (Sticks & Rags)**  
- Using a cravat or cloth strip approximately 2” wide and 24” length  
- Loop the cravat or cloth around the wounded extremity  
- Tie a tight half-knot and place a stick over the knot  
- Tie a tight full-knot over the stick  
- Twist the stick until arterial bleeding has stopped  
- Using the remaining cravat or cloth ends, tightly secure the stick into place

**Ratchet Tourniquet**  
- Insert the wounded extremity through the loop of the device  
- Pull excess strap as tightly as possible  
- Ratchet maneuver the device until arterial bleeding has stopped  
- Lock the ratchet on itself and wrap excess webbing around the ratchet device

**Document the location and time the tourniquet was applied**  
- Do not cover the tourniquet if possible

**Consider Tourniquet Conversion if:**  
1. Bleeding Controlled  
2. Hemostatic Dressing effective  
3. Extended Evacuation time  
4. Re-locating tourniquet distally

**Monitor IAW Protocol**  
- Antibiotics as required  
- Pain Management as required  
- Contact/Report to Medical Officer  
- Oxygen if possible  
- Document  
- Evacuate IAW Protocol

1. Tourniquet Conversion is to only be performed by a Ranger Medic or Medical Officer. Non-medical personnel are not authorized to convert tourniquets.
2. Tourniquets are to be placed as high as possible on long bones of extremities to ensure adequate hemorrhage control.
3. Tourniquet Pain is difficult to manage – Titrate to appropriate effect.

**APPROVED DATE: 01 OCT 06**  
Dr Kotwal  
Dr Redman  
Dr Cunningham  
Dr Miles

75th Ranger Regiment, US Army Special Operations Command
Hemostatic Agent Application Procedure

Patient Assessment

Indication for Application of Hemostatic Agent

Massive External Extremity Bleeding uncontrolled by direct, indirect pressure or tourniquet.
Massive truncal bleeding uncontrolled by pressure, ligating or clamping
Amputation

Apply direct, firm pressure to wound using sterile dressing or kerlex gauze

Chitosan (Hemcon) Dressing

Cut dressing to appropriate size as indicated by the size of the wound

Apply dressing firmly for 1 to 2 minutes to bleeding site until dressing adheres and bleeding stops

Pack wound with Kerlex gauze

Apply outer bandage to secure dressing on wound site

Quik-Clot

**AVOID contact with wet skin on provider or patient. Avoid breathing product dust or getting in eyes**

Use gauze, sterile sponge or suction to wipe excess blood and moisture from wound area

Immediately start a slow pour of Quik-Clot granules directly into the wound

Stop pouring as soon as dry granules cover the wounded area. Use only enough to stop bleeding

Re-Apply firm pressure using sterile gauze or dressing

Apply outer bandage to secure wound site

Celox

Blot away excess blood from wound with gauze

Immediately pour entire contents of Celox pouch directly into wound

Using gauze, apply FIRM pressure to the wound for 5 minutes

If bleeding persists, apply direct pressure for an additional 5 minutes

Cover wound with trauma dressing and maintain pressure on wound

Emerging or Alternative Product

Document the location and time the hemostatic agent was applied

Assess casualty for Hypovolemic Shock IAW protocol

Monitor IAW Protocol
Antibiotics as required
Pain Management as required
Contact/Report to Medical Officer
Oxygen if possible
Document
Evacuate IAW Protocol

APPROVED
DATE: 01 OCT 06
Dr Kotwal
Dr Redman
Dr Cunningham
Dr Miles
Tourniquet Conversion Procedure

**Patient Assessment**

**Indication for Tourniquet Conversion**

- Bleeding Controlled
- Hemostatic Dressing effective
- Extended evacuation time/distance
- Re-locating Tourniquet distally

**Loosen Proximal Tourniquet**

**Bleeding Controlled?**

**YES**

- Continue to observe for bleeding

**NO**

- Re-Assess for tourniquet re-application as needed

**Re-apply Proximal Tourniquet**

**Apply 2nd Tourniquet 2-4” Above Wound**

**Loosen Proximal Tourniquet**

**Bleeding Controlled?**

**YES**

- Continue to observe for bleeding

**NO**

- Re-Assess for tourniquet re-application as needed

**Re-apply Proximal Tourniquet**

**Consider Cycling Tourniquet for capillary perfusion as needed**

**Monitor IAW Protocol**

- Antibiotics as required
- Pain Management as required
- Contact/Report to Medical Officer
- Oxygen if possible
- Document
- Evacuate IAW Protocol

**EQUIPMENT NEEDED:**

- Tourniquet

**DOCUMENTATION:**

- ABC’s / Airway Status
- Detailed Assessment
- Vital Signs
- Date/Time of procedure
- Skin Color
- Capillary Refil
- Response to procedure
- Complications Encountered

1. Tourniquet Pain is difficult to manage – Titrate to appropriate effect
Thoracic Trauma Management Protocol

S/Sx of Chest Inj
Mech of Inj

Hemorrhage?

Conscious with Spontaneous & Respirations (RR >8 or <30) ?

Penetrating or Blunt Trauma?

Open

Apply Occlusive Dressing

Impalement

Stabilize Object & Apply Occlusive Dressing

Tension or Simple Pneumothorax Suspected?

Open

Penetrating

Tension or Simple Pneumothorax

YES

Needle Decompression Procedure

NO

Assess effectiveness of decompression, breath sounds, and RR

Repeat Needle Decompression as often as necessary

Hemothorax Suspected?

YES

Consider Evac versus Chest Tube

NO

Chest Tube / Pleurovent Decision Criteria:
1. Multiple Unsuccessful Needle Decompressions
2. Extended time before evacuation occurs
3. Extended evacuation distance/time

Chest Tube Procedure (as required)

Monitor IAW Protocol
Antibiotics as required
Pain Management as required
Contact/Report to Medical Officer
Oxygen if possible
Document
Evacuate – Urgent Surgical
Re-Assess for Tension Pneumothorax

Penetrating or Blunt Trauma?

Penetrating

Identify Mechanism

Penetrating or Blunt Trauma?

Blunt

Consider Splinting & Pain Control

Flail Segment Suspected?

YES

Refer to Spinal Management Protocol

NO

Spinal Injury Suspected?

YES

Respiratory Distress?

YES

NO

Refer to Airway Management Protocol ICW this protocol

Thoracic Trauma Management Protocol

Spinal Injury Suspected?

Consider
Splinting & Pain Control

YES

NO

Penetrating or Blunt Trauma?

YES

Refer to Hemorrhage Control Protocol (Truncal Branch) AND Hypovolemic Shock Protocol

NO

YES

Re-Assess after each intervention.

1. If in a multiple casualty situation, consider needle decompression on all significant chest injury casualties.

APPROVED
DATE: 01 OCT 06
Dr Kotwal
Dr Redman
Dr Cunningham
Dr Miles

75th Ranger Regiment, US Army Special Operations Command
1. The provider will make determination on site selection based on injury pattern and overall patient condition.
2. If using, povidine-iodine, wait 2 min before continuing with procedure.
Chest Tube Insertion Procedure

**Patient Assessment**

**Indication for Chest Tube**

**INDICATIONS:**
1. Multiple Unsuccessful Needle Decompressions
2. Extended time before evacuation occurs
3. Extended evacuation distance/time

**ABC’s**
- Oxygen 100% if available
- Assist Ventilations as needed

**Select Site:** Affected side, 5th intercostal space (nipple level), anterior to midaxillary line

**Cleanse site with povidine solution/swab**

**Locally anesthetize the skin, rib periosteum, and pleura**

**Prepare Equipment**
- 9" Peans Forceps (clamp)
- 1-0 Armed Suture
- Povidine Solution/swabs
- Scalpel, #10
- 36 Fr to 38 Fr Chest Tube
- Heimlich Valve
- Sterile 4X4 Sponges
- Petrolatum Gauze
- 18G Needle
- Syringe, 10cc
- Chux
- Lidocain Inj, 1%
- Tape, 2"
- Sterile Gloves

**EQUIPMENT NEEDED:**

**Puncture the parietal pleura with the tip of the clamp (9" Peans) and spread the tissues**

**With the index finger of the non-dominant hand, trace the clamp into the incision to avoid injury to other organs and clear any adhesions or clots**

**With the index finger of the non-dominant hand remaining in place, clamp the proximal end of the chest tube and insert into the chest cavity to the desired length**

**Look for “fogging” of the chest tube with expiration**

**Connect the end of the chest tube to the Heimlich valve**

**Secure the tube in place**
- Suture the tube in place using purse-string technique OR
- Staple the tube in place OR
- Slide tube through ACS valve and apply ACS to chest wall

**Wrap the tube with petrolatum gauze**

**Apply cut 4X4 sponge twice around the tube**

**Tape the dressings in place**
- Tape the tube to the chest

**Monitor IAW Protocol**
- Antibiotics as required
- Pain Management as required
- Contact/Report to Medical Officer
- Oxygen if possible
- Document
- Evacuate IAW Protocol

**DOCUMENTATION:**
- ABC’s / Airway Status
- Detailed Assessment
- Vital Signs
- SpO2
- Lung Sounds before and after tube insertion
- Chest rise/excursion
- Skin Color
- Capillary refill
- Response to treatment
- Complications Encountered

**APPROVED**
- DATE: 01 OCT 06
- Dr Kotwal
- Dr Redman
- Dr Cunningham
- Dr Miles
1. Fluid of choice for shock resuscitation is Colloids. Do not exceed 1000cc of colloids.

2. Normal saline is the preferred crystalloid over Lactated Ringers because it mixes with all medications & blood products.

3. Foley catheters should be packed in vehicle-based trauma bags and utilized based on extended evacuation time.

4. Patient Warming procedures are to be initiated as soon as possible ICW fluid challenges.

Hypovolemic Shock Management Protocol

- Establish IV Access
  - No IV Fluids Required
  - PO Fluids Permissible
  - Refer to appropriate injury protocol
  - Monitor & Evac as needed

- Fluid Challenge #1
  - 500cc Colloid (1st Choice)
  - Or 1000cc Crystalloid

- Assess Response
  - Rapid Response BP >90

- Blood Pressure
  - BP > 90

- Fluid Challenge #2
  - 500cc Colloid (1st Choice)
  - Or 1000cc Crystalloid

- Assess Response
  - Transient or No Response (after 30 min)

- IV TKO
  - Re-Assess all Treatments and Interventions

- Assess & Continue Fluid rates at TKO until Evacuation

- Calculate Estimated Fluid Loss and Document

Patient Warming Procedures

- Monitor IAW Protocol
- Antibiotics as required
- Pain Management as required
- Contact/Report to Medical Officer
- Oxygen if possible
- Document
- Evacuate – Urgent Surgical

Estimated Fluid & Blood Loss (Modified from ATLS)

<table>
<thead>
<tr>
<th>Class</th>
<th>Blood Loss (mL)</th>
<th>% of Blood Volume</th>
<th>Pulse Rate</th>
<th>Blood Pressure</th>
<th>Respiratory Rate</th>
<th>Urine Output</th>
<th>CHS/Mental Status</th>
<th>Fluid Replacement</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>up to 750</td>
<td>up to 15%</td>
<td>&lt; 100</td>
<td>Normal</td>
<td>14 - 28</td>
<td>&gt; 30</td>
<td>Slightly Anxious</td>
<td>Colloid</td>
</tr>
<tr>
<td>II</td>
<td>750 - 1500</td>
<td>15% to 25%</td>
<td>100 - 120</td>
<td>Normal or Increased</td>
<td>25 - 30</td>
<td>20 - 30</td>
<td>Mildly Anxious</td>
<td>Colloid &amp; Blood</td>
</tr>
<tr>
<td>III</td>
<td>1500 - 2000</td>
<td>25% to 40%</td>
<td>&gt; 120</td>
<td>Decreased</td>
<td>5 - 15</td>
<td>5 - 35</td>
<td>Anxious, Confused</td>
<td>Colloid &amp; Blood</td>
</tr>
<tr>
<td>IV</td>
<td>&gt; 2000</td>
<td>&gt; 40%</td>
<td>&gt; 140</td>
<td>Decreased</td>
<td>&gt; 35</td>
<td>N/A</td>
<td>Confused, Inergic</td>
<td>Colloid &amp; Blood</td>
</tr>
</tbody>
</table>

1. Fluid of choice for shock resuscitation is Colloids. Do not exceed 1000cc of colloids.
2. Normal saline is the preferred crystalloid over Lactated Ringers because it mixes with all medications & blood products.
3. Foley catheters should be packed in vehicle-based trauma bags and utilized based on extended evacuation time.
4. Patient Warming procedures are to be initiated as soon as possible ICW fluid challenges.
Saline Lock & Intravenous Access Procedure

**Patient Assessment**

**Indication for Saline Lock and/or IV Infusion**

- Prep Equipment & Don Gloves
- Apply constricting band
- Cleanse / Prep Site with Povidine Swab
- Insert catheter/needle
- Advance catheter and remove needle
- Attach Saline Lock
- Release Constricting Band
- Apply Tegaderm over entire site (including the saline lock hub)
- Flush with 5-10ml Normal Saline

**Indication for IV Infusion**

- Prep IV Equipment
- Apply pressure proximal to saline lock
- Insert catheter/needle into the saline lock port
- Advance catheter into the saline lock port and remove needle
- Attach IV tubing and release pressure
- Open IV Fluids line and ensure adequate flow
- Secure IV tubing with Tape/Raptor/Linebacker
- Administer IV fluids IAW appropriate protocol
- Support splint extremity as needed

**EQUIPMENT NEEDED:**
- Constricting Band
- Povidine-Iodine Swab
- 2 X 18-G IV Catheter/Needle
- 10 cc Syringe
- Saline Lock
- Tegaderm (at least 2.5" X 2.5")
- IV Tubing (10 gtts/ml)
- Raptor/Linebacker IV securing device
- Tape, 2"
- Appropriate IV Fluids
- Gloves

**DOCUMENTATION:**
- ABC's
- Detailed Assessment
- Vital Signs
- SpO2
- IV Site
- IV Gauge
- Date/Time Started
- Fluids Infused / rate
- Complications Encountered

** INDICATION FOR IV INFUSION**

- Prep IV Equipment
- Apply pressure proximal to saline lock
- Insert catheter/needle into the saline lock port
- Advance catheter into the saline lock port and remove needle
- Attach IV tubing and release pressure
- Open IV Fluids line and ensure adequate flow
- Secure IV tubing with Tape/Raptor/Linebacker
- Administer IV fluids IAW appropriate protocol
- Support splint extremity as needed

**Indication rapid removal of IV from saline Lock**

- Monitor IAW Protocol
- Antibiotics as required
- Pain Management as required
- Contact/Report to Medical Officer
- Oxygen if possible
- Document
- Evacuate IAW Protocol

**IV Drip Rates**

- **10 Drops per ml**
  - 10 ml/hr: 1.7 DPM
  - 30 ml/hr: 5.1 DPM
  - 50 ml/hr: 8.3 DPM
  - 70 ml/hr: 12.5 DPM
  - 90 ml/hr: 17.5 DPM
  - 120 ml/hr: 22.6 DPM
  - 150 ml/hr: 28.5 DPM
  - 175 ml/hr: 34.8 DPM
  - 200 ml/hr: 41.5 DPM

- **15 Drops per ml**
  - 10 ml/hr: 2.5 DPM
  - 30 ml/hr: 7.5 DPM
  - 50 ml/hr: 10 DPM
  - 70 ml/hr: 15 DPM
  - 90 ml/hr: 20 DPM
  - 120 ml/hr: 25 DPM
  - 150 ml/hr: 30 DPM
  - 175 ml/hr: 35 DPM
  - 200 ml/hr: 40 DPM

- **20 Drops per ml**
  - 10 ml/hr: 2.9 DPM
  - 30 ml/hr: 7.3 DPM
  - 50 ml/hr: 11.4 DPM
  - 70 ml/hr: 15 DPM
  - 90 ml/hr: 20 DPM
  - 120 ml/hr: 25 DPM
  - 150 ml/hr: 30 DPM
  - 175 ml/hr: 35 DPM
  - 200 ml/hr: 40 DPM

- **25 Drops per ml**
  - 10 ml/hr: 3.5 DPM
  - 30 ml/hr: 9.4 DPM
  - 50 ml/hr: 14.2 DPM
  - 70 ml/hr: 19 DPM
  - 90 ml/hr: 24 DPM
  - 120 ml/hr: 29 DPM
  - 150 ml/hr: 34 DPM
  - 175 ml/hr: 39 DPM
  - 200 ml/hr: 44 DPM

- **30 Drops per ml**
  - 10 ml/hr: 4.2 DPM
  - 30 ml/hr: 12 DPM
  - 50 ml/hr: 16.5 DPM
  - 70 ml/hr: 21 DPM
  - 90 ml/hr: 26 DPM
  - 120 ml/hr: 31 DPM
  - 150 ml/hr: 36 DPM
  - 175 ml/hr: 41 DPM
  - 200 ml/hr: 46 DPM

**Indication rapid removal of IV from saline Lock**

- Unsecure IV Tubing from PT and turn off the IV flow
- Gently remove the IV tubing catheter from the saline lock
- **DO NOT REMOVE THE SALINE LOCK**
- Discard IV Bag/Tubing as appropriate
External Jugular Intravenous Cannulation Procedure

**Patient Assessment**

**Indication for External Jugular Intravenous Cannulation**

- Prep Equipment and don gloves
- Place patient in supine position or modified Trendelenberg position
- C-spine precautions as required
- Turn the patient’s head to the opposite side
- Cleanse the site with povidone solution/swab
- Apply light pressure on the inferior aspect of the external jugular to create a tourniquet effect
- Align needle/catheter/syringe in the direction of the vein with the tip of the needle generally aimed toward the “same-side” nipple
- Insert the catheter/needle into the vein and aspirate
  **NOTE: BLOOD RETURN WHEN ASPIRATING**
  **DO NOT ALLOW AIR TO ENTER THE VEIN**
- Advance catheter and withdraw needle/syringe
- Attach saline lock and flush with normal saline
- Apply Tegaderm covering entire site (including saline lock port)

**EQUIPMENT NEEDED:**
- Constricting Band
- Povidone-Iodine Swab
- 2 X 18-G IV Catheter/Needle
- 10 cc Syringe
- Saline Lock
- Tegaderm (at least 2.5” X 2.5”)
- IV Tubing (10gtts/ml)
- Raptor/Linebacker securing device
- Tape, 2"
- Appropriate IV Fluids
- Gloves

**DOCUMENTATION:**
- ABC’s
- Detailed Assessment
- Vital Signs
- SpO2
- IV Site
- IV Gauge
- Date/Time Started
- Fluids Infused / rate
- Complications Encountered

**Monitor IAW Protocol**
- Antibiotics as required
- Pain Management as required
- Contact/Report to Medical Officer
- Oxygen if possible
- Document
- Evacuate IAW Protocol
Sternal Intraosseous Infusion Procedure

**Patient Assessment**

Indication for Sternal Intraosseous Infusion

Inability to attain vascular access through peripheral extremity or external jugular when life-saving fluids or medications are needed

**Prep Equipment**

- Site Selection: Adult Manubrium – Midline on the manubrium, 1.5 cm below the sternal notch

- Prepare site with local anesthetic if PT is conscious

- Cleanse site with povidone solution/swab

- Use index finger of non-dominant hand to align the target patch with the patient’s sternal notch

- Verify Target Zone is on the midline over the manubrium

**Apply Patch**

With patch securely attached to the patient’s skin, the bone probe cluster is placed in the target zone, perpendicular to the skin

**FAST-1 Insertion**

- With the introducer in hand, apply steady even pressure until infusion tube has penetrated the manubrium (release is felt)

- Attach the infusion tube to the right angle female adapter and secure with protector dome

- Attach syringe to the IV insertion site and aspirate bone marrow

- Marrow Aspirates Freely? NO -> Flush the needle with 5 cc Normal Saline

- Flushes Easily? NO -> Discontinue Procedure and find an alternate means of vascular access

- YES

- Attach IV Tubing and/or saline lock

- Secure Inducer Removal Package to the IV Line and/or Patient

- Push needles of inducer into the accompanying sharps plug

- Administer IV Fluids and/or Medications IAW appropriate protocol

**Monitor IAW Protocol**

- Antibiotics as required
- Pain Management as required
- Contact/Report to Medical Officer
- Oxygen if possible
- Document
- Evacuate IAW Protocol

**EQUIPMENT NEEDED:**

- FAST-1 Sternal Intraosseous (Complete) (6515-01-453-0960)

**DOCUMENTATION:**

- ABC’s
- Detailed Assessment
- Vital Signs
- SpO2
- Complications Encountered
Hypothermia Prevention & Management Kit Procedure

**Patient Assessment**

**Indication for Hypothermia Prevention & Management Kit**

Prevention of Heat Loss in a Trauma Casualty
Active Re-Warming of a Hypothermia Patient

**EQUIPMENT NEEDED:**
- NARP Hypothermia Kit

**DOCUMENTATION:**
- ABC’s
- Detailed Assessment
- Vital Signs
- SpO2
- Skin Color
- Complications Encountered

1. Ensure hemorrhage is controlled and other injuries managed IAW appropriate protocols

2. Place the heat reflective skull cap on the patient’s head

3. Open the heat reflective shell and place on a litter

4. Place the patient inside the reflective shell

5. Remove any wet clothing (Replace with dry clothes if possible)

6. Place the self-heating, four cell shell liner on the torso. **Ensure that there is an article of clothing between the casualty and the self-heating shell liner**

7. Wrap and secure the reflective shell around the casualty

8. Monitor IAW Protocol
   - Antibiotics as required
   - Pain Management as required
   - Contact/Report to Medical Officer
   - Oxygen if possible
   - Document
   - Evacuate IAW Protocol

APPROVED
DATE: 01 OCT 06
Dr Kohwal
Dr Redman
Dr Cunningham
Dr Miles

75th Ranger Regiment, US Army Special Operations Command
Head Injury Management Protocol

1. Oxygen 100% per NRB Mask or BVM if available.
2. Aggressive airway management may be required if ventilations are ineffective.
3. Do not allow BP to drop below 100mmHg.
4. All head injuries involving loss of consciousness will be evaluated and reported to a medical officer.
5. Hyperventilation is not indicated unless PT shows signs of herniation syndrome.
6. Isolated head injuries do not cause shock. If shock is present, look for other causes.
7. If at high altitude, refer to Altitude Emergency Protocol ICW this protocol.
8. Generally, head injuries should be evacuated by air using low altitude or pressurized cabin.
9. Any casualty with GCS <14 should not RTD until GCS resolves to 15 and patient is asymptomatic.
10. Perform serial GCS exams every 5-10 minutes.

Monitor IAW Protocol
Antibiotics as required
Pain Management as required
Contact/Report to Medical Officer
Oxygen if possible
Document
Evacuate IAW Protocol

1. Oxygen 100% per NRB Mask or BVM if available.
2. Aggressive airway management may be required if ventilations are ineffective.
3. Do not allow BP to drop below 100mmHg.
4. All head injuries involving loss of consciousness will be evaluated and reported to a medical officer.
5. Hyperventilation is not indicated unless PT shows signs of herniation syndrome.
6. Isolated head injuries do not cause shock. If shock is present, look for other causes.
7. If at high altitude, refer to Altitude Emergency Protocol ICW this protocol.
8. Generally, head injuries should be evacuated by air using low altitude or pressurized cabin.
9. Any casualty with GCS <14 should not RTD until GCS resolves to 15 and patient is asymptomatic.
10. Perform serial GCS exams every 5-10 minutes.

Monitor IAW Protocol
Antibiotics as required
Pain Management as required
Contact/Report to Medical Officer
Oxygen if possible
Document
Evacuate IAW Protocol

1. Oxygen 100% per NRB Mask or BVM if available.
2. Aggressive airway management may be required if ventilations are ineffective.
3. Do not allow BP to drop below 100mmHg.
4. All head injuries involving loss of consciousness will be evaluated and reported to a medical officer.
5. Hyperventilation is not indicated unless PT shows signs of herniation syndrome.
6. Isolated head injuries do not cause shock. If shock is present, look for other causes.
7. If at high altitude, refer to Altitude Emergency Protocol ICW this protocol.
8. Generally, head injuries should be evacuated by air using low altitude or pressurized cabin.
9. Any casualty with GCS <14 should not RTD until GCS resolves to 15 and patient is asymptomatic.
10. Perform serial GCS exams every 5-10 minutes.

Monitor IAW Protocol
Antibiotics as required
Pain Management as required
Contact/Report to Medical Officer
Oxygen if possible
Document
Evacuate IAW Protocol

1. Oxygen 100% per NRB Mask or BVM if available.
2. Aggressive airway management may be required if ventilations are ineffective.
3. Do not allow BP to drop below 100mmHg.
4. All head injuries involving loss of consciousness will be evaluated and reported to a medical officer.
5. Hyperventilation is not indicated unless PT shows signs of herniation syndrome.
6. Isolated head injuries do not cause shock. If shock is present, look for other causes.
7. If at high altitude, refer to Altitude Emergency Protocol ICW this protocol.
8. Generally, head injuries should be evacuated by air using low altitude or pressurized cabin.
9. Any casualty with GCS <14 should not RTD until GCS resolves to 15 and patient is asymptomatic.
10. Perform serial GCS exams every 5-10 minutes.

Monitor IAW Protocol
Antibiotics as required
Pain Management as required
Contact/Report to Medical Officer
Oxygen if possible
Document
Evacuate IAW Protocol

1. Oxygen 100% per NRB Mask or BVM if available.
2. Aggressive airway management may be required if ventilations are ineffective.
3. Do not allow BP to drop below 100mmHg.
4. All head injuries involving loss of consciousness will be evaluated and reported to a medical officer.
5. Hyperventilation is not indicated unless PT shows signs of herniation syndrome.
6. Isolated head injuries do not cause shock. If shock is present, look for other causes.
7. If at high altitude, refer to Altitude Emergency Protocol ICW this protocol.
8. Generally, head injuries should be evacuated by air using low altitude or pressurized cabin.
9. Any casualty with GCS <14 should not RTD until GCS resolves to 15 and patient is asymptomatic.
10. Perform serial GCS exams every 5-10 minutes.
# Mild Traumatic Brain Injury (Concussion) Management Protocol

## Military Acute Concussion Evaluation (MACE)

### I. Description of Incident
- Ask:
  - a. What happened? Y or N
  - b. Tell me what you remember. Y or N
  - c. Were you dazed or confused? Y or N
  - d. Did you hit your head? Y or N

### II. Cause of Injury
1. Explosion/Blast
2. Fall
3. Blunt object
4. Gunshot wound
5. Motor Vehicle Crash
6. Other
7. Other

### III. Helmet Worn
- Y or N
- Type

### IV. Amnesia Before
- Are there any events just BEFORE the injury that are not remembered? Y or N
- If yes, how long?

### V. Amnesia After
- Are there any events just AFTER the injury that are not remembered? Y or N
- If yes, how long?

### VI. Does Patient report loss of consciousness or "blackout"?
- Y or N
- If yes, how long?

### VII. Symptoms
1. Headache
2. Dizziness
3. Memory problems
4. Nausea/Vomiting
5. Difficulty concentrating
6. Irritability
7. Seizures
8. Visual disturbances
9. Ringing in the ears

### EXAMINATION
- Evaluate each domain. Total possible score is 30.

#### IX. Orientation
- 1 point each correct:
  - Month
  - Date
  - Day of Week
  - Year
  - Time

### X. Immediate Memory
- Read all 5 words and ask PT to recall them in order. Repeat 2 more times for a total of 3 trials.
- Score 1 point for each correct, over 3 trials.

#### LIST
- Bubble
- Carpet
- Apple
- Elbow
- Saddle

### XI. Neurological Screening
- As the tactical & clinical situation permits, check:
  - Eyes – pupillary response and tracking
  - Verbal – speech fluency and word finding
  - Motor – prismator drift, gait/coordination

### XII. Concentration
- Reverse digits (go to next string length if incorrect on first trial. Stop if incorrect on both trials. 1 point for each correct string.

#### LIST
- Bubble
- Carpet
- Apple
- Elbow
- Saddle

### XIII. Delayed Recall
- Ask the PT to recall the 5 words from the earlier memory test (DO NOT re-read the word list).

#### LIST
- Bubble
- Apple
- Saddle
- Elbow

### TBI Symptoms
- Evacuate as needed or directed
- Antibiotics as required
- Pain medication as required
- Contact/Report to Medical Officer

### RED FLAG SIGNS & SYMPTOMS
- Worsening mental status
- Pupillary asymmetry
- Seizures
- Repeated vomiting
- Double vision
- Worsening headache
- Confusion or irritability
- Unsteady on feet
- Weakness/numbness to extremities

### Trauma Assessment

#### Trauma Assessment

### Post-Blast Screening of Involved Personnel

#### Post-Blast Screening of Involved Personnel

### RED FLAG SIGNS & SYMPTOMS

### Evacuate to Higher Medical Capability

### Determine Evacuation Precedence

### Evacuate as needed or directed

### Monitor IAW Protocol

## Post-Blast Screening of Involved Personnel

### TBI Screen: All personnel exposed to or involved in a blast, fall, vehicle crash or direct head impact who becomes dazed, confused or loses consciousness (even momentarily) should be further evaluated for brain injury.
Seizure Management Protocol

1. Other considerations include Alcohol Withdrawal or Malnutrition (Thiamine 100mg).
2. Does patient have history of seizures or epilepsy? Document as required.
3. Be prepared to manage airway.
4. Initiate Cardiac Monitoring if possible.
Spinal Cord Injury Management Protocol

1. In Care Under Fire phase, do not jeopardize mission/men to attain spinal immobilization.
2. Do not administer pain control drugs until after completion of neurovascular check.

**Glasgow Coma Scale**

<table>
<thead>
<tr>
<th>Eye</th>
<th>Spontaneous</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Opening</td>
<td>To Voice</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>To Pain</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>None</td>
<td>1</td>
</tr>
<tr>
<td>Verbal</td>
<td>Oriented</td>
<td>5</td>
</tr>
<tr>
<td>Response</td>
<td>Confused</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Inappropriate Words</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>Incomprehensible Words</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>None</td>
<td>1</td>
</tr>
<tr>
<td>Motor</td>
<td>Obeys Commands</td>
<td>6</td>
</tr>
<tr>
<td>Response</td>
<td>Localizes Pain</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td>Withdraws (Pain)</td>
<td>4</td>
</tr>
<tr>
<td></td>
<td>Flexion</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>Extension</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>None</td>
<td>1</td>
</tr>
</tbody>
</table>

Document as: E____ + V____ + M____ =____

**Neurological Assessment**

- **Mental Status**
  - Orientation
  - Affect
  - Speech (Content & Process)

- **Cranial Nerves**
  1. Olfactory (Identify an odor or distinguish between 2 odors)
  2. Optic (Visual Acuity test)
  3. Oculomotor (Assess 6 cardinal eye movements & pupillary reaction)
  4. Trochlear (Assess 6 cardinal eye movements)
  5. Trigeminal (Facial Sensitivity & Biting/Clinching teeth)
  6. Abducons (Eye movement looking left and right)
  7. Facial (Smile, frown, raise brows, and taste)
  8. Vestibulocochlear (Hearing-rubbing fingers & Equilibrium)
  9. Acoustic (Gag reflex and identify tastes)
  10. Vagus (Gag reflex and speech)
  11. Spinal Accessory (Head movement and shoulder shrugging)
  12. Hypoglossal (stick out tongue and move left and right)

- **Motor Status**
  - Posture
  - Strength in basic muscle movements
  - Resistance to passive movement
  - Tremors or Involuntary Movements

- **Sensation Status**
  - Senses light touch
  - Senses pain or pricks
  - Senses temperature
  - Senses vibration (tuning fork)

- **Coordination**
  - Gait and Stance
  - Finger to nose
  - Heel to shin

- **Reflexes**
  - Deep tendon reflexes (biceps, triceps, knees, ankles)
  - Plantar reflexes

**AVPU Responsiveness Assessment**

- ALERT
- VERBAL – Responds to verbal stimuli
- PAIN – Responds to painful stimuli
- UNCONSCIOUS – Does not respond to any stimuli

**Trauma Assessment**

- S/Sx of Spine Inj or Mechanism of Injury

**Conscious with Spontaneous & Adequate Respiration (RR >8 or <30)?**

- YES
- Refer to Airway Management Protocol ICW this protocol

- NO
- Active Bleeding?
  - YES
  - Refer to Hemorrhage Control Protocol (Truncal Branch) ICW this protocol
  - NO
  - Calculate GCS

**Head Injury or GCS<8?**

- YES
  - Refer to Head Inj & Airway Management Protocol ICW this protocol
  - NO
  - Full Spinal Immobilization
  - Improvise as possible
  - Assess Vital Signs
  - Complete Neurovascular Check
  - Assess for Paralysis

**BP Systolic <90mmHg?**

- YES
  - Refer to Hypovolemic Shock Management protocol ICW this protocol
  - NO
  - Monitor IAW Protocol
  - Antibiotics as required
  - Pain Management as required
  - Contact/Report to Medical Officer
  - Oxygen if possible
  - Document
  - Evacuate – Urgent or Priority
Orthopedic Trauma Management Protocol

Trauma Assessment

Obvious Extremity Injury or Mechanism of Injury

Is there Massive Hemorrhage?

YES

Refer to Hemorrhage Management Protocol

NO

Open or Closed Fracture?

OPEN

Dress Wounds

Neurovascular Intact?

NO

Consider Fracture Reduction with adequate Pain Control & Re-Assess Neurovascular Status

YES

Splint Fracture (consider traction if applicable)

Initiate Saline Lock

Combat Wound Pill Pack & Pain Management IAW Protocol

Administer IV Antibiotics

Cefazolin 1-2g IV TID or Alternatives: Invanz 1-2g IV or Rocephin 1g IV

Re-Assess Neurovascular Status q5-10min

Consider Re-evaluation of Splints & Reductions

Consider Compartment Syndrome

Refer to Fasciotomy Procedure if indicated by extended evacuation time

CLOSED

Neurovascular Intact?

YES

Splint Fracture (consider traction if applicable)

Initiate Saline Lock

Combat Wound Pill Pack & Pain Management IAW Protocol

Administer IV Antibiotics

Cefazolin 1-2g IV TID or Alternatives: Invanz 1-2g IV or Rocephin 1g IV

Re-Assess Neurovascular Status q5-10min

Consider Re-evaluation of Splints & Reductions

Consider Compartment Syndrome

Refer to Fasciotomy Procedure if indicated by extended evacuation time

Consider Fracture Reduction with adequate Pain Control & Re-Assess Neurovascular Status

Dress Wounds

Splint Fracture (consider traction if applicable)

Initiate Saline Lock

Combat Wound Pill Pack & Pain Management IAW Protocol

Administer IV Antibiotics

Cefazolin 1-2g IV TID or Alternatives: Invanz 1-2g IV or Rocephin 1g IV

Re-Assess Neurovascular Status q5-10min

Consider Re-evaluation of Splints & Reductions

Consider Compartment Syndrome

Refer to Fasciotomy Procedure if indicated by extended evacuation time

Monitor IAW Protocol

Antibiotics as required

Pain Management as required

Contact/Report to Medical Officer

Oxygen if possible

Document

Evacuate -

- Urgent-Surg if massive hemorrhage or not neurovascular intact

- Priority if neurovascular intact
**Burn Management Protocol**

**Types of Burns:**
- **Thermal**
  - Remove from environment and extinguish fire
  - Brush off and/or dilute chemical without exposing rescuer
  - Consider need for HAZMAT team
- **Chemical**
  - Make sure victim is de-energized and suspect internal injuries
- **Electrical**
  - Make sure victim is de-energized and suspect internal injuries

**Parkland Formula:**
- The IV fluid required for the first 24 hours = 4 ml/kg of LR x % area burned.
- Give half of the total fluid within the first 8 hours of the burn. Give the second half over the next 16 hours.

**Document:**
- Degree of Burn
- % of Body Burned
- Respiratory Status
- Singed Nares?
- SpO2
- Type of Burn
- Medical History
- Confined Space

1. Make sure rescuers can safely help the victim.
2. Remove clothes, flood with water ONLY if flames or smoldering is present.
3. Consider Carbon Monoxide poisoning if victim was within a confined space. If potential for CO poisoning exists administer Oxygen 100%.
4. If shock is present consider underlying causes.
5. See RSI protocol if conscious. Consider needle cricothyroidotomy if unable to intubate due to edema.
6. Note: the patient's palm represents 1% of their BSA. Use this as a reference.
7. Critical burn = any degree >25% BSA - 3rd degree >10% - respiratory injury - involvement of face, hands, feet, or genitalia - circumferential burns - associated injuries - electrical or deep chemical burns - underlying medical history (cardiac, diabetes) - age <10 or >50 years.
8. Start IVs within unburned areas if possible.
9. Foley catheters should be packed in vehicle-based trauma bags.

**Chemical Burns**
1. Irrigate wound if possible with copious amounts of water to stop burning process and/or to remove chemical from wound.

**Ocular Burns**
1. Irrigate wound if possible with copious amounts of water or saline.
2. Consider administration of ocular anesthetic.

---

**Diagram Notes:**
- ABCs: Airway, Breathing, Circulation
- Detailed Assessment
- Facial Burns?
- Consider immediate Cricothyroidotomy or Oral ET (Refer to Airway Management Protocol)
- Assist Ventilations with BVM
- Oxygen 100% if available
- Refer to Airway Management Protocol
- Yes
- Evaluate degree of burn and % body surface area involved
- Critical burn?
- YES
- Initiate Saline Lock X 2
- IV Bolus of 1000 cc of Crystalloid
- Administer IV fluid per Parkland Formula
- Dress burns with dry, sterile dressings
- Treat associated injuries
- Assess for Shock
- Refer to Hypovolemic Shock Protocol
- For Airway or Respiratory Burns: Consider Albuterol Inhaler or other bronchodilators
- Patient Warming Procedures
- Monitor Urinary Output with Foley if possible
- Consider Escharotomy if extended evacuation time
- Monitor IAW Protocol
- Antibiotics as required
- Pain Management as required
- Contact/Report to Medical Officer
- Oxygen if possible
- Document
- Evacuate IAW Protocol

---


**2-24**

---

**TRAUMA MANAGEMENT TEAM**

**TACTICAL**

---

**DATE:** 01 OCT 06

**Dr Kotwal**
**Dr Redman**
**Dr Cunningham**
**Dr Miles**
Foley Catheterization Procedure

**Patient Assessment**

**Indication for Foley Catheterization**

Requirement to monitor urinary output (primarily in burn patient)

- Unfold wrap and use as a sterile field (gloves and underpad are at top of tray and ready for use)

- Position fenestrated drape on patient

- Prepare patient and describe procedure if conscious

- Don Sterile Gloves

- INFLATE Retention Balloon using 10 cc syringe and DEFLATE

- Pour contents of Betadine onto provided cotton balls

- Disinfect patient’s urethra (start in the center and work outward)

- Lubricate the end of the Foley catheter

- Insert through urethra until urine visualized in tube OR as far as the “Y” junction

- Inflate Retention Balloon with 10 cc Syringe (* See Note 1)

- Pull tube from urethra until resistance is met

- Hang bag below patient level to collect urine

**EQUIPMENT NEEDED:**

- Foley Catheterization Set

**DOCUMENTATION:**

- ABC’s / Airway Status
- Detailed Assessment
- Vital Signs
- Date/Time of procedure
- Amount of urine collected (at least hourly)
- Response to procedure
- Complications Encountered

**Monitor IAW Protocol**

- Antibiotics as required
- Pain Management as required
- Contact/Report to Medical Officer
- Oxygen if possible
- Document
- Evacuate IAW Protocol

1. Inflate with 10cc of normal saline for high altitude environment or high altitude aeromedical evacuation.
1. Severity of pain is subjective from person to person, pain management should be based on individuals and injuries and not this protocol alone.

2. Do not administer Celebrex if suspected allergy to Sulfa products.
1. Bee sting: gently remove stinger if still present
2. All cases of suspected anaphylaxis will be reported to a medical officer.
3. Urgent evacuation if symptoms do not resolve after aggressive treatment with epinephrine or any airway compromise.
4. Priority evacuation if mild/moderate/localized symptoms have not resolved after 6 hours.

**Patient Assessment**

- Mild / Moderate / Localized Sx/Sx
  - Auscultate Breath Sounds
  - Administer PO or IM or IV Antihistamine (H1 & H2)
    - Cetirizine (Zyrtec)
    - Fexofenadine (Allegra)
    - Loratadine (Claritin)
  - Dexamethasone 8mg IM/IV
  - Prednisone 60mg PO QD for 5 Days

- Sx/Sx of Anaphylactic Shock?
  - YES
    - Administer Epinephrine
      - 1 X Epi-Pen IM
      - or 1:1000 (0.3cc) SQ or IM
      - or 1:10000 IV
  - NO

- Re-Assess / Observe for 1-2 Hours

- Shortness of Breath
- Wheezes
- Hoarseness
- Hives
- Unexplained Itching
- Chest Tightness
- Abdominal Cramps
- Generalized or Local Edema
- Tongue Edema

- Refer to Airway Management Protocol and/or Current ACLS/BLS

- Pulse and Breathing?
  - YES
  - Initiate Cardiac Monitoring if possible
  - Supplemental O2 if possible
  - Initiate saline Lock
  - Oxygen 100% if available
  - Assist ventilations w/BVM as required
  - Consider Airway management As Required: Administer Epinephrine (As per above)
  - Administer Albuterol MDI 2 puffs q 4-6 hours
  - Monitor Closely

- Bilateral wheezes, diminished or absent breath sounds

- Normal Breath Sounds

- Oxygen 100% if available
  - Assist ventilations w/BVM as required
  - Monitor Closely

- BP Systolic <90mmHg?
  - YES
  - IV Crystalloid or Colloid Bolus of 500-1000cc
  - Maintain IV TKO or Flow to maintain BP>90 with routine checks of peripheral pulses and lung auscultation
  - Monitor IAW Protocol
  - Antibiotics as required
  - Pain Management as required
  - Contact/Report to Medical Officer
  - Oxygen if possible
  - Document
  - Evacuate - Urgent

- NO

- H1 Antihistamines
  - Cetirizine (Zyrtec)
  - Fexofenadine (Allegra)
  - Loratadine (Claritin)

- H2 Antihistamines
  - Cimetidine (Tagamet)
  - Ranitidine (Zantac)

- Re-Initiate entire protocol
  - Consider Evacuation as Priority

- Symptoms Resolved?
  - YES
  - Monitor for at least 6 hours
  - Report to MO
  - Return-to-Duty
  - YES
  - NO
  - Re-Initiate entire protocol

- Itching, Flushing or Hives?
  - YES
  - Administer PO or IM or IV Antihistamine (H1 & H2)
  - Consider PO or IV Steroid as dictated by evacuation criteria
  - Dexamethasone 8mg IM/IV
  - Prednisone 60mg PO for 5 Days
  - Prednisone 60mg PO QD for 5 Days

- NO

- Generalized or Local Edema
  - Administer Decadron 8mg IM/IV
  - Prednisone 60mg PO QD for 5 Days

- Monitor for at least 6 hours

- Report to MO

- Return-to-Duty

**Anaphylactic Shock Management Protocol**

- APPROVED
  - DATE: 01 OCT 06
  - Dr Kotwal
  - Dr Redman
  - Dr Cunningham
  - Dr Miles

75th Ranger Regiment, US Army Special Operations Command
Hyperthermia (Heat) Management Protocol

AMES Patient History

A – Allergies
M – Medications
P – Past Medical History
L – Last Meal
E – Events Associated

Other Pertinent Patient History
Nutritional Supplements?
Prior Heat Injury?
Duration of Acclimatization?
Event leading to heat injury?
Recent illnesses?
Recent fluid intake?

AMPLE Patient History

A – Allergies
M – Medications
P – Past Medical History
L – Last Meal
E – Events Associated

Other Pertinent Patient History
Nutritional Supplements?
Prior Heat Injury?
Duration of Acclimatization?
Event leading to heat injury?
Recent illnesses?
Recent fluid intake?

75th Ranger Regiment, US Army Special Operations Command
Hypothermia Prevention & Management Protocol

Patient Assessment

S/Sx of Hypothermia or Cold Weather Injury

Assess Responsiveness
Airway
Breathing
Circulation

- Remove wet clothing
- Prevent heat loss/wind chill
- Maintain horizontal position
- Avoid rough movement
- Monitor core temperature
- Monitor cardiac rhythm

Pulse & Breathing?

NO

Start CPR
Refer to current ACLS Guidelines
Defibrillate if available
- 1 X shock at 360J (monophasic) or 150J (biphasic)
Refer to Airway Management Protocol
Ventilate with warm, humid O2 if available
Repeat defibrillation if core temp >86
Continue CPR as required

YES

Assess Core Temperature

Active External Re-warming
- Blizzard Blanket
- Ranger Rescue Wrap
- Thermo-Lite
- Ranger Buddy/Sleeping Bag

Consider Active Internal Re-warming
- Warm IV fluid
- Thermal Angel
- MRE Heater
- Warm, humidified oxygen if available

Monitor IAW Protocol
Antibiotics as required
Pain Management as required
Contact/Report to Medical Officer
Oxygen if possible
Document
Evacuate IAW Protocol

- Notify receiving hospital ASAP
- Monitor Cardiac Rhythm, Core Temp, VS, SpO2
- Support Respiratory Effort
- Transport ASAP

Document:
- Signs & Symptoms
- Vital Signs, SpO2
- Cardiac Rhythm
- Core Temp
- Mechanism of Injury
- Treatment
- Response to Treatment

1 Other Methods include: electrical or charcoal warming devices, hot water baths, heating pads, radiant heat sources and warming beds.
2 Give IV medications at longer than standard intervals.
3 Do not defibrillate a second time until core temperature >86F
Behavioral Emergency Management Protocol

**Medical Patient Assessment**

**Head Injury Suspected?**
- Refer to Head Injury Management Protocol ICW this protocol

**S/Sx of Acute Behavioral Changes**

**Remove weapons or potential weapons from patient**

**Hyoxia?**
- YES : Check Pulsox; If <90 Refer to Airway Management Protocol and Initiate Continuous Monitoring
- NO

**Fever, Seizures or Suspected Meningitis?**
- YES : Refer to Seizure Management Protocol
- NO: **Initiate**
  - Glucometry
  - Initiate saline
  - Auscultate Lungs
  - Initiate NS IV & push 1 ampule (25g) D50 at max of 10ml/min and continue glucose monitoring every 30 min

**Hypoglycemia Suspected?**
- YES : Glucometry
- Initiate saline
- Lock
- Auscultate Lungs
- NO: **Initiate**
  - NS IV
  - NO

**Aggressive, Combative, or Violent?**
- YES: Restrain PT with at least 4 personnel
- NO: **Establish** Saline Lock if possible and administer
  - Diazepam 10mg IV
  - OR
  - Diazepam 10mg IM every 30 min PRN

**WARNING: If sedated or restrained, watch for changes in hemodynamic status of airway problems**

**Verbal Calming Techniques**
- (Reassurance & Establish Rapport)

**Monitor IAW Protocol (continuous if retrained or sedated)**
- Antibiotics as required
- Pain Management as required
- Contact/Report to Medical Officer/Psychologist
- Oxygen if possible
- Document
- Evacuate – Priority or Urgent (if sedated)

**AVPU Responsiveness Assessment**
- ALERT – Responds to verbal stimuli
- VERBAL – Responds to painful stimuli
- UNCONSCIOUS – Does not respond to any stimuli

**Glasgow Coma Scale**

<table>
<thead>
<tr>
<th>Eye</th>
<th>4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Opening</td>
<td>3</td>
</tr>
<tr>
<td>To Voice</td>
<td>2</td>
</tr>
<tr>
<td>To Pain</td>
<td>1</td>
</tr>
<tr>
<td>None</td>
<td>0</td>
</tr>
</tbody>
</table>

| Verbal Response | 5 |
| Confused | 4 |
| Inappropriate Words | 3 |
| Incomprehensible Words | 2 |
| None | 1 |

| Motor Response | 6 |
| Obeys Commands | 5 |
| Localizes Pain | 4 |
| Withdraws (Pain) | 3 |
| Flexion | 2 |
| Extension | 1 |
| None | 0 |

**Document as: E____ + V____ + M____ =____**

**AMSIT Patient History**

**Appearance, Behavior & Speech** (ill or distressed, posture & body language, willingness to talk, manner, evidence of emotions, attention span, speech patterns)
- Mood and Affect (anger, fear, anxiety, elation, intensity and changes in mood)
- Sensorium (oriented to time and place, recent and remote events, concentration and calculation)
- Intellectual Function (education, vocabulary use, appropriate for age)
- Thought (logical, reasonable, speed, hallucinations, self-image, insight awareness)

**Neurological Assessment**

**Mental Status**
- Orientation
- Affect
- Speech (Content & Process)

**Cranial Nerves**
- I Olfactory (Identify an odor or distinguish between 2 odors)
- II Optic (Visual Acuity test)
- III Oculomotor (Assess 6 cardinal eye movements & pupillary reaction)
- IV Trochlear (Assess 6 cardinal eye movements)
- V Trigeminal (Facial Sensitivity & Biting/Clinching teeth)
- VI Abducens (Eye movement looking left and right)
- VII Facial (Smile, frown, raise brows, and taste)
- VIII Acoustic (Hearing-rubbing fingers & Equilibrium)
- IX Glossopharyngeal (Gag reflex and identify tastes)
- X Vagus (Gag reflex and speech)
- XI Spineral Accessory (Head movement and shoulder shrugging)
- XII Hypoglossal (stick out tongue and move left and right)

**Motor Status**
- Posture
- Strength in basic muscle movements
- Resistance to passive movement
- Tremors or Involuntary Movements

**Sensory Status**
- Senses light touch
- Senses pain or prickles
- Senses temperature
- Senses vibration (tuning fork)

**Coordination**
- Gait and Stance
- Finger to nose
- Heel to shin

**Reflexes**
- Deep tendon reflexes (biceps, triceps, knees, ankles)
- Plantar reflexes

1. Do not give valium if Meningitis is suspected.
2. Be prepared to manage airway.
Altitude Medical Emergency Management Protocol

1. AMS usually occurs at altitude greater than 8000 ft and higher.
2. Altitude emergencies are usually preceded by 6-12 hours latent period after ascent.
3. AMS can be avoided by limiting ascent to no higher than 8000 ft, then 1000 ft per day thereafter.
4. HACE is rare below 11000 ft.
5. HAPE is the most common cause of death at altitude and usually occurs above 8000 ft.
6. Any respiratory distress at high altitude should be assumed as HAPE until proven otherwise.
7. Do not re-ascend until cleared by a medical officer.
8. Consider Acetazolamide (250mg PO BID or TID) prophylaxis beginning 24-48 hours out if mission planned at/above 10,000 feet or if drastic rapid ascent (air insertion) with medical officer approval.
9. Minimize the physical exertion of the casualty during descent using litters if possible.
10. Do not administer Diamox if suspected allergy to Sulfa products.

Headache/Nausea/Vomiting/Insomnia
Altered Mental Status
Dry Cough or Hemoptysis
Fatigue/Weakness
Unsteady/Unbalanced Gait (Ataxia)
Disoriented/Hallucinations
Cranial Nerve Palsy/Hemiparesia
Unconsciousness

Headache/Nausea/Vomiting/Insomnia
Altered Mental Status
Unsteady/Unbalanced Gait (Ataxia)
Disoriented/Hallucinations
Cranial Nerve Palsy/Hemiparesia
Unconsciousness

75th Ranger Regiment, US Army Special Operations Command
SECTION TWO

PART B

TACTICAL MEDICAL EMERGENCY PROTOCOLS
# RANGER MEDIC Tactical Medical Emergency Protocols (TMEPs):

( Based on USSOCOM TMEPs dated 18 September 2006)

**TMEP Properties:** Relatively common, acute onset, life-threatening, adversely affects mission readiness, and/or rapid diagnosis and initial therapy can improve outcome.

**TMEP Assumptions:** Austere environment, absence of medical officer, patient is team member/coalition partner/detainee, evacuation is difficult, the problem may worsen if treatment is delayed, a medical officer will be contacted as soon as feasible, treatment is conducted IAW protocol, limited medications are available, and appropriate documentation will be conducted.

| 1. ACUTE (SURGICAL) ABDOMEN | 21. GASTROENTERITIS |
| 2. ACUTE DENTAL PAIN | 22. GASTROESOPHAGEAL REFLUX DISEASE |
| 3. ACUTE MUSCULOSKELETAL BACK PAIN | 23. HEADACHE |
| 4. ALLERGIC RHINITIS | 24. INGROWN TOENAIL |
| 5. ASTHMA (REACTIVE AIRWAY DISEASE) | 25. JOINT INFECTION |
| 6. BRONCHITIS | 26. LACERATION |
| 7. CELLULITIS | 27. MALARIA |
| 8. CHEST PAIN (CARDIAC ORIGIN SUSPECTED) | 28. OTITIS EXTERNA |
| 9. COMMON COLD | 29. OTITIS MEDIA |
| 10. CONJUNCTIVITIS | 30. PERITONSILLAR ABSCESS |
| 11. CONSTIPATION | 31. PNEUMONIA |
| 12. CONTACT DERMATITIS | 32. PULMONARY EMBOLISM |
| 13. CORNEAL ABRASION & CORNEAL ULCER | 33. RENAL COLIC/KIDNEY STONES |
| 14. COUGH | 34. SEPSIS/SEPTIC SHOCK |
| 15. CUTANEOUS ABSCES | 35. SMOKE INHALATION |
| 16. DEEP VENOUS THROMBOSIS (DVT) | 36. SPRAINS & STRAINS |
| 17. DIARRHEA | 37. SUBUNGAL HEMATOMA |
| 18. EPIGLOTTITIS | 38. SYNCOPE |
| 19. EPISTAXIS | 39. TESTICULAR PAIN |
| 20. FUNGAL SKIN INFECTION | 40. TONSILLOPHARYNGITIS |
| 21. GASTROENTERITIS | 41. URINARY TRACT INFECTION (UTI) |
1. ACUTE (SURGICAL) ABDOMEN

Definition: Common causes in young healthy adults include appendicitis, cholecystitis, pancreatitis, perforated ulcer, diverticulitis, or bowel obstruction

S/S: Severe, persistent or worsening abdominal pain; rigid abdomen, rebound tenderness, fever, anorexia, nausea/vomiting, absent bowel sounds, mild diarrhea if present

MGMT: 1. Keep patient NPO, except for water and meds, 2. NS IV at 150cc/hr, 3. Ertapenem (Invanz) or Ceftriaxone (Rocephin) 1gm IV/IM q24h, 4. Acetaminophen (Tylenol) 1000mg PO q6h prn pain, 5. Ondansetron (Zofran) 4mg IV over 2-5 minutes or IM bid or Phenergan (Promethazine) 12.5-25mg IV q4-6h for nausea/vomiting, 6. For severe pain, use Fentanyl Oral Lozenge (Actiq) 800mcg or Morphine Sulfate (MSO4) 5-10mg IV initially, then 5mg q30-60min prn pain, medicate to keep patient comfortable without loss of sensorium

Disposition: Urgent evacuation to facility with surgical capability

2. ACUTE DENTAL PAIN

Definition: Common causes are deep decay, fractures of tooth crown or root, or periapical abscess

S/S: Intermittent or continuous pain; heat or cold sensitivity; visibly broken tooth; severe pain on percussion; swelling or abscess

MGMT: 1. Acetaminophen (Tylenol) 1000mg PO q6h or Ibuprofen (Motrin) 800mg PO q8h prn pain, 2. If signs and symptoms of infection, Clindamycin (Cleocin) 300-450mg PO q6h or Amoxicillin/Clavulanic Acid (Augmentin) 500/125mg PO tid or 875/125mg PO bid or Ceftriaxone (Rocephin) 1gm IV/IM daily x 7d

Disposition: Evacuation usually not required; Routine evacuation if no response to therapy

3. ACUTE MUSCULOSKELETAL BACK PAIN

Definition: Back pain resulting from injury due to mechanical stress or functional demands

S/S: Acute or gradual onset of back pain that can be severe and debilitating; with or without radiation; aggravated by movement or certain positions, alleviated with rest; usually history of previous back pain

MGMT: 1. Acetaminophen (Tylenol) 500mg PO qid or Ibuprofen (Motrin) 800mg PO tid or Naproxen (Naprosyn) 500mg PO bid, 2. Cyclobenzaprine (Flexeril) 10mg PO tid or Methocarbamol (Robaxin) 1500mg PO qid, 3. Encourage fluid hydration, avoid bed rest, use ice pack if acute or heat pack if subacute, stretch as tolerated, 4. If acute and severe back pain and spasm, provide KETOROLAC (Toradol) 15-30mg IV/IM and Diazepam (Valium) 5-10mg IV, and repeat once in 6-8h if needed, 5. Refer to Spinal Trauma protocol if abnormal neurological exam

Disposition: Evacuation usually not required; Routine evacuation if no response to therapy or acute lumbar disk disorder suspected; Urgent if neurological involvement (weakness, numbness, bowel or bladder dysfunction)
4. **ALLERGIC RHINITIS**

**Definition:** Inflammation of the nasal passages due to environmental allergy

**S/S:** Rhinorrhea with clear discharge, boggy or inflamed nasal mucosa, +/- nasal congestion, sneezing, nasal pruritus; +/- concurrent watery, pruritic, or red eyes; history of environmental allergy

**MGMT:** 1. Fluticasone (Flonase) 2 sprays in each nostril daily, 2. Antihistamines and decongestants prn, 3. Increase PO fluid intake

**Disposition:** Evacuation usually not required

---

5. **ASTHMA (REACTIVE AIRWAY DISEASE)**

**Definition:** Inflammatory disorder of the airway with bronchiolar hyper-responsiveness and narrowing of the distal airways; acute exacerbation seen with change in environment or level of allergen or irritant

**S/S:** Wheezing, dyspnea, chest tightness, decreased oxygen saturation, respiratory distress

**MGMT:** 1. Albuterol (Proventil) MDI 2-3 puffs q5min x 3 doses, 2. If no response, Epinephrine 0.5mg (0.5ml of 1:1000 solution) IM, repeat in 5-10 minutes if needed, 3. Saline lock, 4. Dexamethasone (Decadron) 10mg IV/IM, 5. Oxygen (if available), 6. Monitor with pulse ox, 7. If fever, chest pain, and cough, consider and treat as per Pneumonia protocol; if airway compromise refer to Airway protocol

**Disposition:** If adequate response, continue Albuterol q6h and Dexamethasone daily; if poor response, Urgent evacuation

---

6. **BRONCHITIS**

**Definition:** Inflammation of trachea, bronchi, and bronchioles resulting from upper respiratory tract infection (URI) or chemical irritant; viruses are the most common cause

**S/S:** Preceding URI symptoms, cough (initially unproductive, then productive), fatigue, +/- fever > 100.4, +/- dyspnea, injected pharynx

**MGMT:** 1. Hydrate, 2. Acetaminophen (Tylenol) 1000mg PO q6h prn fever, 3. Treat symptoms with antitussive, decongestants, expectorant, as needed, 3. Albuterol (Proventil) MDI 2 puffs q4-6hrs, 4. Smoking cessation, 5. If symptoms worsen or persist, consider and treat as per Pneumonia protocol

**Disposition:** Evacuation usually not required
7. CELLULITIS

**Definition:** Acute superficial spreading bacterial skin infection due to trauma or scratching of other lesions

**S/S:** Local warmth, pain, erythema, swelling with well-demarcated borders, +/- fever/chills, +/- lymphadenopathy; if rapidly spreading and very painful consider necrotizing fasciitis (life-threatening deep tissue infection) and treat per Bacterial Sepsis protocol

**MGMT:** 1. Acetaminophen (Tylenol) 1000mg PO q6h or Ibuprofen (Motrin) 800mg PO q8h prn pain, 2. Clindamycin (Cleocin) 300-450mg PO q6h or TMP-SMZ (Septra) DS PO bid or Moxifloxacin (Avelox) 400mg PO qd x 10 d, or Azithromycin (Zithromax) 250mg 2 tabs PO day 1 then 1 tab PO day 2-5, 3. Clean/dress wound, 4. Use marker to demarcate infection border, 5. Limit activity as feasible, 6. Reevaluate at least daily, 7. Identify and drain abscess if present, and 8. If severe or no response, use Ceftriaxone (Rocephin) or Ertapenem (Invanz) 1gm IV/IM qd and continue PO antibiotics

**Disposition:** *Priority* evacuation if infection fails to improve or worsens within 24-48hrs on antibiotics

---

8. CHEST PAIN (CARDIAC ORIGIN SUSPECTED)

**Definition:** Possible heart attack or myocardial infarction (MI)

**S/S:** Usually in patients over 40; history of hypertension, diabetes, smoking, elevated cholesterol, obesity; family history of MI at a young age; substernal pressure/squeezing chest pain +/- radiation to left arm or jaw, dyspnea, diaphoresis (sweating)

**MGMT:** 1. “MONA”: Morphine Sulfate (MSO4) 4mg IV initially then 2mg IV q5-15min prn pain, Oxygen (if available), NTG (if available) 0.4mg SL initially, repeat q5min for total of 3 doses, Acetylsalicylic Acid (Aspirin) 325mg chew 2 tabs and swallow 2 tabs, 2. IV access, 3. Pulse oximetry and cardiac monitor (if available)

**Disposition:** *Urgent* evacuation on platform with ACLS personnel, medications, and equipment

---

9. COMMON COLD

**Definition:** Inflammation of nasal passages due to a respiratory virus

**S/S:** Nasal congestion, sneezing, sore throat, cough, hoarseness, malaise, headache, low-grade fever

**MGMT:** 1. Increase PO hydration, 2. Acetaminophen (Tylenol) 1000mg PO q6h, 3. Treat symptoms with decongestants, antihistamines, cough suppressants, and other symptomatic relief medications prn

**Disposition:** Evacuation usually not required
10. CONJUNCTIVITIS

**Definition:** Eye conjunctiva inflammation due to allergic, viral, or bacterial cause

**S/S:** All causes (burning, irritation, tearing); allergic (bilateral, serous or mucoid discharge, itching, redness); viral (unilateral, redness, watery discharge, conjunctival swelling, tender preauricular node, photophobia, foreign body sensation, associated URI); bacterial (unilateral, eye injection, mucopurulent or purulent discharge with morning crusting)

**MGMT:** 1. Discontinue contact lenses if applicable, 2. Cleanse with warm, wet wash cloth qid, 3. If allergy or viral, other than herpetic, artificial tears prn and Naphazolin/Pheniramine (Naphcon-A) 2 drops in affected eye qid, 4. If bacterial, Gatifloxacin (Zymar) 0.3% 1 drop in affected eye qid

**Disposition:** Evacuation usually not required

11. CONSTIPATION

**Definition:** Infrequent, hard, dry stools

**S/S:** Infrequent, hard, dry stools with possible pain/straining with defecation, abdominal fullness, and poorly localized cramping abdominal pain; if pain becomes severe with N/V and lack of flatus or stools consider bowel obstruction; if acute onset, severe pain, rigid board-like abdomen, rebound or point tenderness, and/or fever, consider other disorders (appendicitis, bowel obstruction, cholecystitis, diverticulitis, pancreatitis, and ulcer) and treat as per Acute (Surgical) Abdomen protocol

**MGMT:** 1. Increase PO fluids and fiber – fruits, bran, vegetables, 2. Docusate (Colace) 100mg PO bid, 3. Acetaminophen (Tylenol) 1000mg PO q6h prn pain (no narcotics – they cause constipation!), 4. If impacted or no response give 500cc NS enema per rectum (lubricate IV tubing), 5. If continued no response, perform digital rectal exam (DRE) and digital disimpaction, 6. Consider parasitic infection

**Disposition:** Routine evacuation if no response to treatment; Urgent evacuation if acute abdomen

12. CONTACT DERMATITIS

**Definition:** Skin reaction to external substance (plants, metals, chemicals, topical medications)

**S/S:** Acute onset of skin erythema and pruritis; may see edema, papules, vesicles, bullae, and possible discharge and crusting; evaluate and monitor for secondary bacterial infection and treat per Cellulitis protocol if suspected; consider insect bite and fungal infection in differential diagnosis

**MGMT:** 1. Remove offending agent and evaluate pattern, 2. Wash area with soap and water, 3. Change and/or wash clothes, 4. Topical cold wet compress AAA, 5. Topical calamine lotion AAA, 6. Topical high-potency steroid cream AAA qid (low-potency on face), 7. Diphenhydramine (Benadryl) 25-50mg PO qid prn pruritis, 8. If severe, Solu-Medrol 125 mg IM x 1; or Dexamethasone (Decadron) 10mg IM daily x 5 d; or Prednisone 60mg PO daily x 5 d burst or taper dose down every 3 days for a 14-21 day course

**Disposition:** Priority evacuation if severe, eye or mouth involved, or > 50% BSA involved
13. CORNEAL ABRASION & CORNEAL ULCER

**Definition:** A traumatic disruption of the epithelial covering of the cornea; three major concerns: intense eye pain, corneal ulcer (vision-threatening infection), and potential for ruptured globe

**S/S:** History of eye trauma or contact lens wear with eye pain; redness, tearing, blurred vision, light sensitivity, positive fluorescein stain/cobalt blue light (bright yellow area on cornea); increasing pain and white or gray spot on cornea with tangential penlight indicative of corneal ulcer; blood in anterior chamber, bulging subconjunctival hemorrhage (chemosis), and peaked pupil indicative of ruptured globe; if history of LASIK, consider flap dislocation

**MGMT:** 1. Examine eye, to include eyelid eversion, and remove any foreign body, 2. Gatifloxacin (Zymar) 0.3% 1 drop in affected eye qid until after 24h fluorescein negative (q2h if corneal ulcer), 3. If available, Tetracaine 0.5% 2 drops in affected eye for pain (do not give bottle to patient), 4. Acetaminophen (Tylenol) 1000mg PO q6h prn pain, 5. No patching, 6. Reduce light exposure/stay indoors/wear sunglasses as feasible, 7. Monitor daily with fluorescein

**Disposition:** *Routine* evacuation if not improving; *Priority* evacuation if corneal ulcer; *Urgent* evacuation and eye shield if ruptured globe suspected; *Urgent* evacuation if LASIK flap dislocation

14. COUGH

**Definition:** Usually viral etiology, but may occur with HAPE, pneumonia, GERD, and smoking history

**S/S:** Cough with or without scant sputum production, often accompanied by other URI S/S (sore throat, rhinorrhea, post-nasal drip)

**MGMT:** 1. Treat symptomatically if history and physical exam do not suggest pneumonia, 2. Increase PO hydration, 3. Avoid respiratory irritants (smoke, aerosols, etc), 4. Benzonatate (Tessalon perles) 100mg PO tid or Dextromethorphan (Robitussin DM) 30mg PO bid pm cough, 5. Albuterol (Proventil) MDI 3-4 puffs q4h can help if cough continues; Treat per Pneumonia protocol if fever, chest pain, dyspnea, colored sputum (green, dark yellow, red-tinged)

**Disposition:** Evacuation usually not required

15. CUTANEOUS ABSCESS

**Definition:** Cutaneous abscess

**S/S:** Focal pain, erythema, warmth, tenderness, swelling, and fluctuance

**MGMT:** 1. Clindamycin (Cleocin) 300-450mg PO q6h or TMP-SMZ (Septra) DS PO bid or Moxifloxacin (Avelox) 400mg PO qd x 10 d, or Azithromycin (Zithromax) 250mg PO 2 tabs PO day 1 then 1 tab PO day 2-5, 2. I&D if not on eyelid, face, or neck (sterilize site with betadine, anesthetize with 1% Lidocaine, incise parallel to skin tension lines with scalpel and make opening large enough to allow purulence to drain, pack with iodoform gauze or nu-gauze, cover with loose bandage; check, redress, and wick q12-24hrs); Do not suture, drainage is the key to treatment!

**Disposition:** Evacuation usually not required; If condition worsens treat per Cellulitis protocol and evacuate as *Priority*
16. DEEP VENOUS THROMBOSIS (DVT)

**Definition:** Potentially life-threatening condition in which a clot is present in the large veins of a leg and may dislodge and localize in the pulmonary system, a pulmonary embolism (PE)

**S/S:** History of recent trauma, air travel, altitude exposure, birth control pills, or family history of DVT; pain, swelling, and warmth seen in legs (usually calf), but may occur in any deep vein; palpable venous “cord”; pain with passive stretching or dorsiflexion of the foot

**MGMT:** 1. Acetylsalicylic acid (Aspirin) 325mg PO q4-6h, 2. Immobilize and do not allow to walk on affected extremity, 3. Monitor with pulse oximetry (sudden decrease suggests PE), if tachypnea, tachycardia, respiratory distress, and chest pain develop, treat per *Pulmonary Embolism protocol*

**Disposition:** *Priority* evacuation; *Urgent* if PE suspected

17. DIARRHEA

**Definition:** Loose bowel movements (BM); abrupt onset in healthy individuals usually related to infectious cause (viral, bacterial, parasitic)

**S/S:** Loose or watery BMs, +/- blood or mucous, +/- fever, abdominal cramping, discomfort, and/or distension; possible S/S of dehydration (decreased and/or dark urine output, lightheadedness, headache, dry mucosa, poor skin turgor, degradation in performance)

**MGMT:** 1. Replace lost fluids and electrolytes, PO if tolerated, if not then IV LR or NS, 2. Loperamide (Imodium) 4mg PO initially, then 2mg after every loose BM, max of 16mg/day, 3. If diarrhea persists > 24 hrs, give Azithromycin (Zithromax) 500mg or Moxifloxacin (Avelox) 400mg PO qd or Ciprofloxacin (Cipro) 500mg PO bid x 3d, 4. If diarrhea > 3 days, treat as Giardia or Amebiasis with Tinidazole (Tindamax) 2gm PO qd or Metronidazole (Flagyl) 500mg PO tid x 3d

**Disposition:** Evacuation usually not required, if dehydration despite therapy or antibiotic-related diarrhea, evacuate as *Priority*. Grossly bloody stools or circulatory compromise require *Urgent* evacuation

18. EPIGLOTTITIS

**Definition:** Inflammation of the epiglottis

**S/S:** Sore throat, difficulty speaking and swallowing, drooling, respiratory distress, erythematous pharynx; first symptom of severe sore throat progresses to epiglottal swelling and potential for airway obstruction

**MGMT:** 1. Place patient in sitting or comfortable position, 2. IV access, 3. Ceftriaxone (Rocephin) 2gm IV/IM q12h, 4. Dexamethasone (Decadron) 8mg IV/IM x 1, 5. Pulse oximetry, 6. Oxygen if available, 7. Do not manipulate airway unless required, let the patient protect his own airway, 8. If definitive airway is needed, make one attempt at intubation, and if failed, perform a cricothyroidotomy

**Disposition:** *Urgent* evacuation
19. EPISTAXIS

**Definition:** Nosebleed

**S/S:** Nosebleed, often with previous history of nosebleeds; common at altitude and in desert environments due to mucosal drying; may be anterior or posterior; posterior epistaxis may be difficult to stop and may cause respiratory distress due to blood flowing into airway; posterior epistaxis is more commonly seen in older hypertensive patients

**MGMT:** 1. Clear airway by having patient sit up and lean forward, 2. Oxymetazoline (Afrin) 2-3 sprays intranasally and pinch anterior area of nose firmly for full 10 minutes without releasing pressure, 3. If bleeding continues, insert Afrin-soaked nasal sponge along floor of nasal cavity, remove 30 minutes after bleeding is controlled, and apply Mupirocin (Bactroban) bid-tid, 5. If severe nosebleed and bleeding continues, initiate saline lock or NS TKO and consider inserting 14 French Foley catheter intranasally for 72h, 6. If packing and/or catheter required for >12h, treat with Moxifloxacin (Avelox) 400mg PO qd

**Disposition:** Evacuation not required for mild, anterior, and resolving epistaxis; *Priority* evacuation for severe epistaxis not responding to therapy or if Foley used

20. FUNGAL SKIN INFECTION

**Definition:** Fungal skin infection

**S/S:** Scaling plaques, erythema, pruritic, slow spreading, irregular or circumferential borders; often initially diagnosed as contact dermatitis but gets worse with steroid cream; most common sites of infection are feet ("athlete’s foot" or tinea pedis), groin ("jock itch" or tinea cruris), scalp (tinea capitus), and torso or extremities ("ring worm" or tinea corporis); differential diagnosis includes eczema, insect bites, cellulitis, and contact dermatitis

**MGMT:** 1. Antifungal cream AAA tid until one week after lesion resolves, 2. In moderate to severe cases, use Fluconazole (Diflucan) 150 mg PO qwk x 2 wks or Ketoconazole (Nizoral) 200-400 mg PO qd or Terbinafine (Lamisil) 250 mg PO qd

**Disposition:** Evacuation not required

21. GASTROENTERITIS

**Definition:** Usually due to an acute viral infection of the GI tract, but bacteria or parasite infections are common in deployed environments

**S/S:** Sudden onset of N/V/D, abdominal cramping, +/- fever

**MGMT:** 1. Loperamide (Imodium) 4mg PO initially, then 2mg after every loose BM, max of 16mg/day (do not use if bloody stools or fevers), 2. If nausea/vomiting, Promethazine (Phenergan) 12.5-25mg PO/IM/IV or Ondansetron (Zofran) 4mg IV over 2-5 minutes or IM bid, 3. If diarrhea persists >24 hrs, give Azithromycin (Zithromax) 500mg PO daily or Moxifloxacin (Avelox) 400mg PO daily or Ciprofloxacin (Cipro) 500mg PO bid; Azithromycin new primary agent due to emerging quinolone resistance among enteropathogenic E. coli, 4. PO hydrate with ORS, Cyralyte, Gatorade, Powerade, and water, 5. 1-2 liters NS or LR IV if PO not tolerated and titrate fluid intake to regain normal urine frequency and color, good skin turgor, and moist mucous membranes, 6. If diarrhea >3 days treat as Giardia or Amebiasis treat with Tinidazole (Tindamax) 2gm PO qd or Metronidazole (Flagyl) 500mg PO tid x 3d

**Disposition:** Evacuation usually not required; *Priority* evacuation if dehydration despite therapy or antibiotic-related diarrhea; *Urgent* evacuation if grossly bloody stools or circulatory compromise
22. GASTROESOPHAGEAL REFLUX DISEASE (GERD)

Definition: Reflux of gastroduodenal contents into esophagus due to improper lower esophageal sphincter relaxation

S/S: Heartburn, regurgitation, dysphagia

MGMT: 1. Avoid high-fat food, onion, tomato chocolate, peppermint, citrus, tobacco, coffee, alcohol, 2. Elevate head on bed when sleeping and do not eat just before bedtime, 3. Ranitidine (Zantac) 150mg or Cimetidine (Tagamet) 400mg PO bid, or Rabeprazole (Aciphex) or Omeprazole (Prilosec) 20mg PO qd or bid, 4. If on Doxycycline for malaria chemoprophylaxis, take the doxy early in the day with a meal

Disposition: Evacuation usually not required

23. HEADACHE

Definition: Headache

S/S: Episodic or chronic, secondary to stressor; unilateral or bilateral, localized or general, dull or band-like, with or without nausea/vomiting; sometimes associated with caffeine withdrawal, neck muscle tightness, teeth grinding; if atypical, check for elevated blood pressure, fever, neck rigidity, visual symptoms, photophobia, mental status changes, neurological weakness, rash, and hydration and treat per appropriate protocol

MGMT: 1. If caffeine withdrawal, consider caffeine 100-200mg (1-2 cups coffee), 2. Acetaminophen (Tylenol) 1000mg PO q6hrs or Ibuprofen (Motrin) 800mg PO tid or Naproxen (Naprosyn) 500mg PO bid, 3. If nausea/vomiting, Promethazine (Phenergan) 12.5-25mg PO/IM/IV or Ondansetron (Zofran) 4mg IV over 2-5 minutes or IM bid, 4. If dehydration suspected, PO or IV hydration, 5. If new-onset migraine suspected, refer to a medical officer; usually benign, but consider AMS, intracranial bleed, or meningitis

Disposition: Evacuation usually not required; Urgent evacuation if acute headache with fever, severe nausea/vomiting, mental status changes, focal neuro signs, or preceding seizures, LOC, or history of “it’s the worst headache of my life”

24. INGROWN TOENAIL

Definition: Usually big toe; due to trimming nails in curved fashion, nail deformity, tight fitting shoes, and rotational toe deformity

S/S: Pain, edema, erythema, hyperkeratosis at lateral nail fold; pressure on nail margin increases pain

MGMT: 1. Partial toenail removal: clean site with soap, water, and betadine; local anesthesia through digital block using 1% lidocaine without epinephrine; apply tourniquet at base; remove lateral ¼ of nail toward cuticle, using sharp scissors; separate nail from the underlying matrix and remove; curette posterior and lateral nail grooves to remove debris; rub matrix with silver nitrate stick; apply Mupirocin (Bactroban) and cover with nonadherent and dry sterile dressings; wash, clean, recheck wound and change dressing daily, 2. Acetaminophen (Tylenol) 1000mg PO q6h prn pain, 3. Systemic antibiotics usually not needed, however use Moxifloxacin (Avelox) 400mg PO qd x 10d or Azithromycin (Zithromax) 250mg 2 tabs PO day 1 then 1 tab PO day 2-5 if in tactical setting or infection (increasing pain, redness, and swelling)

Disposition: Evacuation usually not required
25. JOINT INFECTION

**Definition:** Bacterial joint infection, septic arthritis, septic joint; may result from penetrating trauma

**S/S:** Fever and red swollen painful joint; pain with axial load; inability to straighten joint; history of animal or human bite, needle aspiration of joint effusion, gonorrhea

**MGMT:** 1. Immobilize joint, 2. Ertapenem (Invanz) 1gm IV/IM daily or Ceftriaxone (Rocephin) 2gm IV/IM bid, 3. Acetaminophen (Tylenol) 1000mg PO q6h or Ibuprofen (Motrin) 800mg PO tid prn pain

**Disposition:** Priority evacuation

26. LACERATION

**Definition:** Skin laceration

**S/S:** Simple uncomplicated laceration of skin without involvement of deeper structures

**MGMT:** 1. Irrigate and clean wound thoroughly, 2. Prepare area in sterile fashion, 3. Provide local anesthesia with 1% Lidocaine, 4. Close with absorbable suture, non-absorbable suture, dermabond, or steri-strips as dependent on depth of wound, 5. If dirty wound or environment, Clindamycin (Cleocin) 300-450mg PO q6h or TMP-SMZ (Septra) DS PO bid or Moxifloxacin (Avelox) 400mg PO qd x 10 d, 6. Check tetanus status and treat as needed; do not suture if wound is > 12 h old (> 24 h on face), or if puncture/bite wound

**Disposition:** Evacuation usually not required

27. MALARIA

**Definition:** Protozoan infection transmitted by Anopheles mosquito; prevention through personal protective measures is the key (anti-malarial meds, DEET, permethrin, minimize exposed skin)

**S/S:** History of travel to malaria-endemic area, non-compliance with anti-malarial meds and/or personal protective measures; malaise, fatigue, and myalgia followed by recurrent episodes of fevers, chills, rigors, profuse sweats, headache, backache, nausea, vomiting, diarrhea; tachycardia, orthostatic hypotension, tender hepatomegaly, moderate splenomegaly, and delirium

**MGMT:** 1. If available, attempt to diagnosis with lab (serial blood smears and rapid test); if unavailable and malaria suspected, empirically treat with Mefloquine (Larium) 750mg PO initially followed by 500mg PO 12h later or Malarone 4 tabs PO daily with food x 3 days or Chloroquine 10mg/kg base PO x 2 days then 5mg/kg PO x 1 day (concomitant Primaquine may also be required) 2. Acetaminophen (Tylenol) 1000mg PO q6h prn fever

**Disposition:** Routine evacuation for uncomplicated cases; Urgent evacuation if cerebral, pulmonary, or vital sign instability
28. OTITIS EXTERNA

**Definition:** Bacterial or fungal infection of external ear canal, “swimmer’s ear”

**S/S:** Ear pain and pain with passive ear movement; swelling, erythema, pruritis in area; possible exudate and erythema in ear canal, decreased auditory acuity, sensation of fullness and moisture in ear

**MGMT:** 1. Gatifloxacin (Zymar) 0.3% 4 drops in affected ear q2h while awake and laying on side for at least 5 minutes; ophthalmic used to minimize meds carried, but if available, Cortisporin otic 5 drops tid-qid until 48h after symptoms resolve. 2. Sterile dry dressing wick into ear canal. 3. (Acetaminophen) TYLENOL 1000mg PO q6h prn pain. 4. If no response or worsens, use MOXIFLOXACIN (Avelox) 400mg PO daily x 10d or AZITHROMYCIN (Zithromax) 250mg 2 tabs PO day 1 then 1 tab PO day 2-5. 5. No internal hearing protection until resolution

**Disposition:** Evacuation usually not required; *Priority* evacuation if “malignant” otitis externa (Severe headache, otorrhea (purulent ear drainage), cranial nerve palsy)

---

29. OTITIS MEDIA

**Definition:** Eustachian tube dysfunction, viral infection, or bacterial infection of middle ear

**S/S:** Ear pain, +/- fever, decreased hearing, sensation of ear fullness; erythema and bulging of TM are hallmark signs, increased pressure may cause TM rupture and discharge; often noted with accompanying URI symptoms, recent air travel, or recent ascent to altitude

**MGMT:** 1. Acetaminophen (Tylenol) 1000mg PO q6h or Ibuprofen (Motrin) 800mg PO tid prn pain. 2. Oxymetazoline (Afrin) nasal spray 2 squirts per nostril bid (max 3 days). 3. If grossly apparent, or no resolution in 1-2 d, add antibiotics: MOXIFLOXACIN (Avelox) 400mg PO daily or TMP-SMZ (Septra) DS PO bid x 10d or AZITHROMYCIN (Zithromax) 250mg 2 tabs PO day 1 then 1 tab PO day 2-5

**Disposition:** Evacuation usually not required; *Routine* evacuation for TM rupture or complicated cases not responding to therapy

---

30. PERITONSILLAR ABSCESS

**Definition:** Infection with abscess formation and pus collection between anterior and posterior tonsillar pillars, usually following acute episode of tonsillopharyngitis

**S/S:** Extreme sore throat or neck pain, dysphagia, dysphonia, fever, erythema, edema, asymmetry of oropharynx with deviation of uvula

**MGMT:** 1. CLINDAMYCIN (Cleocin) 300-450mg PO q6h or AMOXICILLIN/CLAVULANIC ACID (Augmentin) 500/125mg PO tid or 875/125mg PO bid or CEFTRIAXONE (Rocephin) 1gm IV/IM daily x 7d. 2. Acetaminophen (Tylenol) 1000mg PO q6h or Ibuprofen (Motrin) 800mg PO tid prn pain/fever. 3. If unresolving or worsening symptoms to include airway obstruction, the patient must be evacuated for needle aspiration or I&D (caution must be used to avoid carotid artery perforation)

**Disposition:** *Routine* evacuation; *Priority* evacuation if airway obstruction
31. PNEUMONIA

**Definition:** Acute lung infection due to virus, mycoplasma, or other bacteria

**S/S:** Fever, chills, productive cough (dark yellow, green, red tinged), chest pain, malaise, wheezes, rhonchi and/or rales, decreased breath sounds, dyspnea, tachypnea, SOB

**MGMT:**
1. If mild to moderate, Azithromycin (Zithromax) 250mg 2 tabs PO day 1 then 1 tab PO day 2-5 or Moxifloxacin (Avelox) 400mg PO daily x 5d or Doxycycline 100mg PO bid x 10 d; If severe, start with Ceftriaxone (Rocephin) 2gm q12h or Ertapenem (Invanz) daily IM/IV, then oral antibiotic regimen,
2. Acetaminophen (Tylenol) 1000mg PO q6h prn pain/fever,
3. Albuterol (Proventil) MDI 2 puffs qid prn wheezing,
4. PO hydration,
5. Pulse oximetry,
6. Oxygen if hypoxic,
7. If at altitude > 8000 ft, descend 1,500 – 3,000 feet; differential diagnosis should include HAPE, PE, and pneumothorax

**Disposition:** *Priority evacuation*; *Urgent evacuation* for severe dyspnea

32. PULMONARY EMBOLUS (PE)

**Definition:** Usually occurs when leg DVT dislodges and enters pulmonary arterial circulation

**S/S:** Acute onset of dyspnea, tachypnea, tachycardia, localized chest pain, anxiety, diaphoresis (sweating), decreased oxygen saturation, full breath sounds with no wheezing, no prominent cough, and low-grade fever; usually proceeded by DVT with lower extremity pain, swelling, and tenderness with history of trauma, air travel, or long periods in sitting positions

**MGMT:**
1. Monitor with pulse oximetry and provide oxygen (if available),
2. Acetylsalicylic Acid (Aspirin) 325mg chew 2 tabs,
3. Morphine Sulfate (MSO4) 4mg IV initially then 2mg IV q5-15min prn pain,
4. Consider Myocardial Infarction and treat as per Chest Pain protocol,
5. If at altitude > 8,000ft, descend 1500–3000 ft as per HAPE protocol

**Disposition:** *Urgent evacuation*

33. RENAL COLIC / KIDNEY STONES

**Definition:** Spasmodic kidney pain typically caused by kidney stone; may be associated with preceding lower urinary tract infection (UTI) or obstruction

**S/S:** Back pain, flank pain, nausea/vomiting, CVAT, fever, chills, frequency, urgency, dysuria

**MGMT:**
1. Moxifloxacin (Avelox) 400mg PO daily x 7d or Azithromycin (Zithromax) 250mg 2 tabs PO day 1 then 1 tab PO day 2-5; If PO not tolerated, Ceftriaxone (Rocephin) 2gm q12h or Ertapenem (Invanz) daily IM/IV,
2. Acetaminophen (Tylenol) 1000mg PO q6h or Ibuprofen (Motrin) 800mg PO tid prn pain,
3. Promethazine (Phenergan) 12.5-25mg IV or Ondansetron (Zofran) 4mg IV over 2 to 5 minutes or IM bid prn nausea/vomiting,
4. PO hydration, NS or LR IV at 250cc/hr if unable to tolerate PO,
5. monitor urine output

**Disposition:** *Priority evacuation*; may progress to life-threatening systemic infection and septic shock
34. SEPSIS/SEPTIC SHOCK

**Definition:** Severe life-threatening bacterial blood infection, rapid onset, death may occur within 4-6 hrs without antibiotic therapy

**S/S:** Hypotension, fever, chills, tachycardia, altered mental status, dyspnea, possible purpuric skin rash

**MGMT:** 1. IV or IO access, 2. Ertapenem (Invanz) 1gm IV/IM daily or Ceftiraxone (Rocephin) 2gm IV/IM daily, q12hrs if considering meningitis, 3. If hypotensive, give 2L NS or LR bolus (if unavailable, give 1L Hextend), 4. If hypotension continues, give Epinephrine (1:1000) 0.5mg IM, repeat 2L NS bolus, and titrate fluids to maintain SBP > 90 mmHg (NOTE: May require 10L crystalloid fluids within first 24 hrs), 5. Monitor urine output with goal of 30cc/hr (insert foley catheter if available), 6. Monitor mental status and be prepared to manage airway

**Disposition:** *Urgent evacuation*

35. SMOKE INHALATION

**Definition:** Common after closed space exposure to fire; consider airway burns, carbon monoxide poisoning, other toxin inhalation, and need for hyperbaric oxygen

**S/S:** History of smoke exposure, burns, singed nares, facial burns, coughing, respiratory distress

**MGMT:** 1. Refer to *Airway Management* protocol and consider early cricothyroidotomy or intubation, 2. Albuterol (Proventil) MDI 2-4 puffs q4-6h, 3. Dexamethasone (Decadron) 10mg IV/IM daily x 2 days, 4. Oxygen if available, 5. Limit exertion and activity

**Disposition:** *Priority evacuation if significant inhalation; Urgent evacuation if respiratory distress*

36. SPRAINS & STRAINS

**Definition:** Sprain or strain of musculoskeletal structures

**S/S:** Swelling, pain, erythema, ecchymosis, tenderness, decreased range of motion

**MGMT:** 1. “RICE” (Rest, Ice, Compression, Elevation), 2. Orthosis/splint/crutches for pain relief and stability, 3. Ibuprofen (Motrin) 800mg PO tid or Naproxen (Naprosyn) 500mg PO bid prn pain, 4. If no fracture, initiate rehab immediately; active range of motion exercises as tolerated; encourage weight bearing as tolerated; suspect occult fracture if no improvement within one week

**Disposition:** Evacuation usually not required
### 37. SUBUNGAL HEMATOMA

**Definition:** Collection of blood under the nail; typically occurs after trauma to fingernail or toenail

**S/S:** Pain and purplish-black discoloration under nail

**MGMT:** 1. Decompress nail with large gauge needle introduced through nail over discolored area with a gentle but sustained rotating motion until underlying blood and pressure is relieved; gentle pressure to the nail immediately after the procedure may evacuate additional blood, 2. Acetaminophen (Tylenol) 1000mg PO q6h prn pain, 3. Tape/splint if fracture suspected

**Disposition:** Evacuation usually not required

### 38. SYNCOPE

**Definition:** Orthostatic hypotension; fainting as a result of vasovagal response

**S/S:** Sudden and brief loss of consciousness, without seizures, and with return to normal mentation

**MGMT:** 1. Supportive care; place in supine position and ensure airway is open, should regain consciousness within a few seconds, if not: 2. Check blood glucose, and use oral glucose gel or sugar sublingually, 3. If no response, consider heat injury, anaphylaxis, cardiac, and pulmonary etiologies and treat as per protocol, 4. Check vitals and pulse oximetry, 5. Oxygen if available, 6. Cardiac monitoring

**Disposition:** Evacuation usually not required; unless other diagnosis or symptoms continue/recur

### 39. TESTICULAR PAIN

**Definition:** Testicular pain due to torsion, epididymitis, orchitis, STDs, hernias, masses, and trauma

**S/S:** Torsion: sudden onset of pain, pain-induced nausea/vomiting, swelling, abnormal lie of testicle, symptoms increase with elevation, associated with activity; Epididymitis: gradual onset of worsening pain, +/- fever, +/- dysuria, +/- trauma

**MGMT:** 1. If torsion suspected, manually detorse by rotating outward "open the book", if pain increases attempt once to rotate in opposite direction, 2. If other cause suspected, consider and treat as per *Urinary Tract Infection* protocol and treat pain as per *Pain Management* protocol

**Disposition:** *Urgent* evacuation for unrelieved torsion; *Priority* evacuation for relieved torsion; for other causes consider evacuation as symptoms warrant or treatment fails
40. TONSILLOPHARYNGITIS

**Definition:** Acute bacterial or viral infection/inflammation of the pharynx, ¼ caused by Group A Beta Hemolytic Streptococcus (GABHS)

**S/S:** Sore throat, enlarged and edematous tonsils, erythema and exudates, palatal petechiae, anterior cervical lymphadenopathy; fever > 102.5 suggestive of bacterial cause; throat culture is most accurate test for GABHS

**MGMT:** 1. Salt water gargles, 2. Acetaminophen (Tylenol) 1000mg PO q6h, 3. If bacterial suspected, Azithromycin (Zithromax) 500mg PO daily x 3 days, 4) Observe and treat as per Peritonsillar Abscess protocol as required, 5) Consider concurrent infection with Ebstein-Barr virus (Infectious Mononucleosis)

**Disposition:** Evacuation usually not required

41. URINARY TRACT INFECTION (UTI)

**Definition:** Infection of urinary tract; more common in females, tactical setting, dehydration, kidney stones

**S/S:** Frequency, urgency, dysuria; no CVAT/back/flank pain, no fever; possible cloudy malodorous or dark urine, suprapubic discomfort

**MGMT:** 1. Moxifloxacin (Avelox) 400mg PO daily x 3d and Azithromycin (Zithromax) 1000mg x 1 dose (to treat for STDs), 2. Acetaminophen (Tylenol) 1000mg q6h prn pain, 3. PO hydration, 4. If fever, CVAT, back pain, or flank pain, suspect and treat per Renal Colic protocol

**Disposition:** Evacuation usually not required; *Routine* evacuation if symptoms worsen or no resolution
SECTION THREE

RMED

PHARMACOLOGY

SECTION I

“PROFICIENT AND ALWAYS CARRIED”
# PHARMACOLOGY SECTION I: “PROFICIENT AND ALWAYS CARRIED”

<table>
<thead>
<tr>
<th></th>
<th>Name</th>
<th>Dosage/Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>ACETAMINOPHEN (TYLENOL)</td>
<td>325-650 mg PO q4-6h prn (max: 4 g/d)</td>
</tr>
<tr>
<td>2.</td>
<td>DEXAMETHASONE</td>
<td>0.25–4 mg PO bid-qid; 8–16 mg IM/IV q1–3wks</td>
</tr>
<tr>
<td>3.</td>
<td>DIAZEPAM (VALIUM)</td>
<td>2-10 mg PO tid-qid; 5-10 mg slow IV push</td>
</tr>
<tr>
<td>4.</td>
<td>DIPHENHYDRAMINE (BENADRYL)</td>
<td>25-50 mg IV/IM/PO q4-6h</td>
</tr>
<tr>
<td>5.</td>
<td>EPINEPHRINE</td>
<td>0.1–0.5 mL SC/IM q10–15min (1:1000 soln = 1mg/1ml)</td>
</tr>
<tr>
<td>6.</td>
<td>ERTAPENEM (INVANZ)</td>
<td>1g IV/IM q24h</td>
</tr>
<tr>
<td>7.</td>
<td>FENTANYL ORAL LOZENGES (ACTIQ)</td>
<td>400-800 mcg (max: 1600 mcg/d)</td>
</tr>
<tr>
<td>8.</td>
<td>GATIFLOXACIN (TEQUIN)</td>
<td>400 mg IV/PO daily</td>
</tr>
<tr>
<td>9.</td>
<td>HETASTARCH (HEXTEND)</td>
<td>500–1000 mL IV</td>
</tr>
<tr>
<td>10.</td>
<td>IBUPROFEN (MOTRIN, ADVIL)</td>
<td>400–800 mg PO tid-qid (max: 3200 mg/d)</td>
</tr>
<tr>
<td>11.</td>
<td>KETOROLAC (TORADOL)</td>
<td>15-30 mg IV/IM q6h</td>
</tr>
<tr>
<td>12.</td>
<td>LIDOCAINE (XYLOCAINE)</td>
<td>Infiltration 0.5%–2% injection</td>
</tr>
<tr>
<td>13.</td>
<td>MELOXICAM (MOBIC)</td>
<td>7.5–15 mg PO daily</td>
</tr>
<tr>
<td>14.</td>
<td>MORPHINE SULFATE (MSO4)</td>
<td>5–15mg slow IV push, titrate to pain</td>
</tr>
<tr>
<td>15.</td>
<td>MOXIFLOXACIN (AVELOX)</td>
<td>400 mg PO/IV daily</td>
</tr>
<tr>
<td>16.</td>
<td>NALOXONE (NARCAN)</td>
<td>0.4–2.0 mg IV, repeat q2–3min up to 10 mg prn</td>
</tr>
<tr>
<td>17.</td>
<td>PROMETHAZINE (PHENERGAN)</td>
<td>12.5-25 mg PO/IM/IV q4-6h prn</td>
</tr>
<tr>
<td>18.</td>
<td>SODIUM CHLORIDE, 0.9% (NS)</td>
<td>500–1000 mL IV; 5-50 mL IV for med dilution or flush</td>
</tr>
</tbody>
</table>
### 1. ACETAMINOPHEN (TYLENOL)

**Class:** CNS agent – non-narcotic, analgesic, antipyretic

**Action:** Analgesia action possibly through peripheral nervous system; fever reduction through direct action on hypothalamus heat-regulating center resulting in peripheral vasodilation, sweating, and dissipation of heat; has minimal effect on platelet aggregation, bleeding time, and gastric bleeding

**Dose:** 325–650 mg PO q4–6h (max: 4 g/d)

**Indications:** For mild to moderate pain management, headache, fever reduction

**Contraindications:** Acetaminophen hypersensitivity; use with alcohol; pregnancy category B

**Adverse Effects:** Negligible with recommended dose; rash; acute poisoning: anorexia, nausea, vomiting, dizziness, lethargy, diaphoresis, chills, epigastric or abdominal pain, diarrhea; hepatotoxicity: elevation of liver function tests; hypoglycemia, hepatic coma, acute renal failure; chronic ingestion: neutropenia, pancytopenia, leukopenia, thrombocytopenic purpura, renal damage

**Interactions:** Cholestyramine may decrease absorption; barbiturates, carbamazepine, phenytoin, rifampin, and excessive alcohol use may increase potential for hepatotoxicity

### 2. DEXAMETHASONE

**Class:** Hormones and synthetic substitutes – steroid; adrenocorticoid; glucocorticoid

**Action:** Long-acting synthetic adrenocorticoid with intense glucocorticoid activity and minimal mineralocorticoid activity; Antiinflammatory and immunosuppression properties; prevents accumulation of inflammatory cells at sites of infection; inhibits phagocytosis, lysosomal enzyme release, and synthesis of selected chemical mediators of inflammation; reduces capillary dilation and permeability

**Dose:** 0.25–4 mg PO bid-qid; 8–16 mg IM/IV q1–3wks

**Indications:** For inflammatory conditions, allergic states, and cerebral edema

**Contraindications:** Systemic fungal infection, acute infections, tuberculosis, vaccinia, varicella, live virus vaccines (to patient, family members), amebiasis; pregnancy category C

**Adverse Effects:** Euphoria, insomnia, convulsions, increased ICP, vertigo, headache, psychic disturbances; CHF, hypertension, edema; hyperglycemia; cushingoid state; hirsutism; cataracts, increased IOP, glaucoma, exophthalmos; peptic ulcer or perforation, abdominal distension, nausea, increased appetite, heartburn, dyspepsia, pancreatitis, bowel perforation, oral candidiasis; muscle weakness, loss of muscle mass, vertebral compression fracture, pathologic fracture of long bones, tendon rupture; acne, impaired wound healing, petechiae, ecchymoses, diaphoresis, dermatitis, hypo- or hyperpigmentation, skin atrophy

**Interactions:** May inhibit antibody response to vaccines and toxoids
3. DIAZEPAM (VALIUM) - CONTROLLED SUBSTANCE: SCHEDULE IV

**Class:** CNS agent – benzodiazepine; anticonvulsant; anxiolytic

**Action:** Anticonvulsant and antianxiety psychotherapeutic drug with action at both limbic and subcortical levels of CNS; increases total sleep time, but shortens REM and stage 4 sleep

**Dose:** 2-10 mg po tid-qid; 5-10 mg slow IV push, repeat in 3-4h

**Indications:** For anxiety, seizures, skeletal muscle spasm relief; also used as an amnesic, for treatment of restless leg syndrome, acute alcohol withdrawal, and is the drug of choice for status epilepticus

**Contraindications:** Shock, coma, alcohol intoxication, depressed vital signs; acute narrow-angle glaucoma, untreated open-angle glaucoma; MAOIs; pregnancy category D

**Adverse Effects:** Throat and chest pain; drowsiness, fatigue, ataxia, confusion, paradoxic rage, dizziness, vertigo, amnesia, vivid dreams, headache, slurred speech, tremor; EEG changes, tardive dyskinesia; hypotension, tachycardia, edema, cardiovascular collapse; blurred vision, diplopia, nystagmus; xerostomia, constipation, hepatic dysfunction; incontinence, urinary retention, gynecomastia (prolonged use); hiccups, coughing, laryngospasm; venous thrombosis, phlebitis

**Interactions:** Alcohol, CNS depressants, anticonvulsants, and herbals (kava kava, valerian) potentiate CNS depression; cimetidine increases levels and toxicity; may decrease effects of levodopa; may increase phenytoin levels; smoking decreases sedative and antianxiety effects

---

4. DIPHENHYDRAMINE (BENADRYL)

**Class:** ENT agent – H₁-blocker; antihistamine

**Action:** H₁-receptor antagonist and antihistamine as it competes for H₁-receptor sites on effector cells; significant central anticholinergic activity as it prolongs action of dopamine by inhibiting its reuptake and storage, thus decreasing parkinsonism and drug-induced extrapyramidal symptoms

**Dose:** 25-50 mg IV/IM/PO q4-6h

**Indications:** For allergic conditions, treatment or prevention of motion sickness, vertigo, blood or plasma reactions, treatment of Parkinsonism and drug-induced extrapyramidal reactions; also used with epinephrine for anaphylaxis, as a cough suppressant, a sedative-hypnotic, and for intractable insomnia

**Contraindications:** Antihistamine hypersensitivity; lower respiratory tract symptoms, asthma; narrow-angle glaucoma; prostatic hypertrophy, bladder neck obstruction; GI obstruction; pregnancy category C

**Adverse Effects:** Drowsiness, dizziness, headache, fatigue, disturbed coordination, tingling, heaviness and weakness of hands, tremors, euphoria, nervousness, restlessness, insomnia; confusion; excitement, fever, palpitation, tachycardia, hypo- or hypertension, cardiovascular collapse, tinnitus, vertigo, dry nose, throat, nasal stuffiness; blurred vision, diplopia, photosensitivity, dry eyes, dry mouth, nausea, epigastric distress, anorexia, vomiting, constipation, diarrhea; urinary frequency or retention, dysuria; thickened bronchial secretions, wheezing, chest tightness

**Interactions:** Alcohol, other CNS depressants, and MAOIs compound CNS depression
5. EPINEPHRINE

**Class:** Autonomic nervous system agent – natural and synthetic catecholamine; alpha- and beta-adrenergic agonist; bronchodilator

**Action:** Sympathomimetic that acts directly on both alpha and beta receptors; the most potent activator of alpha receptors; strengthens myocardial contraction; increases systolic but may decrease diastolic blood pressure; increases cardiac rate and output; constricts bronchial arterioles and inhibits histamine release, thus reducing congestion and edema and increasing tidal volume and vital capacity

**Dose:** 0.1–0.5 mL SC/IM q10–15min (1:1000 soln = 1mg/1ml)

**Indications:** For hypersensitivity and anaphylactic reactions, acute asthma attack, bronchospasm, mucosal congestion, syncope due to heart block or carotid sinus hypersensitivity, and to restore cardiac rhythm in cardiac arrest; prolong action and delay absorption of anesthetics; control superficial bleeding

**Contraindications:** Sympathomimetic amine hypersensitivity; narrow-angle glaucoma; hemorrhagic, traumatic, or cardiogenic shock; cardiac dilatation, cerebral arteriosclerosis, coronary insufficiency, arrhythmias, organic heart or brain disease; do NOT use with local anesthesia of fingers, toes, ears, nose, genitalia; pregnancy category C

**Adverse Effects:** Nervousness, restlessness, sleeplessness, fear, anxiety, tremors, headache, CVA, weakness, dizziness, syncope, pallor, sweating, dyspnea; nausea, vomiting; precordial pain, palpitations, hypertension, MI, tachyarrhythmias; bronchial and pulmonary edema; urinary retention; tissue necrosis; metabolic acidoses; altered state of perception and thought, psychosis

**Interactions:** May increase hypotension in circulatory collapse; additive toxicities with other medications

6. ERTAPENEM (INVANZ)

**Class:** Antimicrobial – antibiotic, carbapenem, beta-lactam

**Action:** Broad-spectrum antibiotic that inhibits cell wall synthesis of gram-positive and gram-negative bacteria by its strong affinity for bacterial cell wall penicillin-binding proteins (PBPs); highly resistant to most bacterial beta-lactamases; effective against most Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter spp; poorly effective against Enterococci, particularly vancomycin-resistant strains

**Dose:** 1g IV/IM q24h (For IV reconstitute with 10mL NS; for IM 3.2mL 1.0% lidocaine without epinephrine)

**Indications:** For complicated infections of abdomen, pelvis, urinary tract, and skin; also used for community-acquired pneumonia

**Contraindications:** Carbapenem, beta-lactam, or amide-type local anesthetic (ie. Lidocaine) hypersensitivity; pregnancy category B

**Adverse Effects:** Injection site phlebitis or thrombosis; asthenia, fatigue, death, fever, leg pain, anxiety, altered mental status, dizziness, headache, insomnia; chest pain, hypo- or hypertension, tachycardia, edema; abdominal pain, diarrhea, acid reflux, constipation, dyspepsia, nausea, vomiting, increased LFTs; cough, dyspnea, pharyngitis, rales, rhonchi, respiratory distress; erythema, pruritus, rash

**Interactions:** Probenecid decreases renal excretion
### 7. FENTANYL ORAL LOZENGES (ACTIQ) - CONTROLLED SUBSTANCE: SCHEDULE II

**Class:** CNS agent - potent narcotic (opiate) agonist  
**Action:** Action similar to morphine with more rapid and less prolonged analgesia and sedation, but less emetic effect  
**Dose:** 400-800 mcg oral-tranmucosally, titrate to pain up to max 1600 mcg/d; lozenge on a stick to be placed in mouth between cheek and lower gum and sucked, not chewed (have opioid antagonist [naloxone] immediately available!)  
**Indications:** For moderate to severe pain management  
**Contraindications:** MAOIs; myasthenia gravis; pregnancy category C  
**Side Effects:** Sedation, euphoria, dizziness, diaphoresis, delirium, convulsions; bradycardia, hypotension, circulatory depression, cardiac arrest; miosis, blurred vision; nausea, vomiting, constipation, ileus; muscle and thoracic muscle rigidity; urinary retention, rash; laryngospasm, bronchoconstriction, respiratory depression or arrest have  
**Interactions:** Alcohol and other CNS depressants potentiate effects; MAOIs may precipitate hypertensive crisis

### 8. GATIFLOXACIN (TEQUIN)

**Class:** Antimicrobial – antibiotic; quinolone  
**Action:** Broad spectrum bactericidal agent that inhibits DNA-gyrase topoisomerase II, an enzyme necessary for bacterial replication, transcription, repair and recombination; effective against methicillin-resistant *Staphylococcus aureus* (MRSA), penicillin resistant *Streptococcus pneumoniae*, *Pseudomonas aeruginosa*, and *cocci* resistant to other quinolones  
**Dose:** 400 mg PO/IV daily x 1–14 days (duration dependent on diagnosis)  
**Indications:** For acute bacterial exacerbation of chronic bronchitis; acute sinusitis; community-acquired pneumonia; urinary tract infections; pyelonephritis; gonorrhea  
**Contraindications:** Quinolone hypersensitivity; pregnancy category C  
**Adverse Effects:** Headache, allergic reactions, chills, fever; back pain, chest pain; dizziness, abnormal dreams, insomnia, paresthesia, tremor, vasodilatation, vertigo; palpitation; peripheral edema; nausea, vomiting, diarrhea, abdominal pain, constipation, dyspepsia, glossitis, stomatitis; dyspnea, pharyngitis; rash, sweating; dysuria; hematuria; abnormal vision; taste perversion; tinnitus; increased seizure risk  
**Interactions:** Ferrous sulfate and aluminum or magnesium containing antacids reduce absorption; may cause false positive on opiate screening tests
### 9. HETASTARCH (HEXTEND)

**Class:** Plasma volume expander – colloid; synthetic starch resembling human glycogen  

**Action:** Increases colloidal osmotic pressure and expands plasma volume similar to albumin, but with less potential for anaphylaxis or interference with cross matching or blood typing procedures; remains in the intravascular space increasing arterial and venous pressures, heart rate, cardiac output, urine output; not a blood or plasma substitute  

**Dose:** 500–1000 mL IV (max rate: 20 mL/kg/h, max dose: 1500 mL/day); max rate used for acute hemorrhagic shock, reduced rates used with burns or septic shock  

**Indications:** For fluid replacement and plasma volume expansion when blood or plasma is not available, and for adjunctive treatment of shock caused by hemorrhage, burns, surgery, sepsis, or other trauma  

**Contraindications:** Severe bleeding disorders, CHF, renal failure with oliguria and anuria, treatment of shock without hypovolemia, pregnancy category C  

**Adverse Effects:** Peripheral edema, circulatory overload, heart failure; prolonged PT/PTT, clotting time, and bleeding time with large doses; decreased Hb/Hct, platelets, calcium, and fibrinogen; dilution of plasma proteins, hyperbilirubinemia, increased sedimentation rate; pruritus, anaphylactoid reactions (periorbital edema, urticaria, wheezing), vomiting, fever, chills, flu-like symptoms, headache, muscle pains, submaxillary and parotid gland swelling  

**Interactions:** No clinically significant interactions established

### 10. IBUPROFEN (MOTRIN, ADVIL)

**Class:** CNS agent – NSAID (cox-1); anti-inflammatory, analgesic, antipyretic  

**Action:** Propionic acid inhibitor prototype that blocks prostaglandin synthesis, modulates T-cell function, inhibits inflammatory cell chemotaxis, decreases release of superoxide radicals or increases scavenging of these compounds at inflammatory sites, inhibits platelet aggregation and prolongs bleeding time  

**Dose:** 400–800 mg PO tid-qid (max: 3200 mg/d)  

**Indications:** For mild to moderate pain management, symptomatic relief of arthritis, and to reduce fever  

**Contraindications:** NSAID or aspirin induced urticaria, severe rhinitis, bronchospasm, angioedema, nasal polyps; active peptic ulcer, bleeding abnormalities; pregnancy category B  

**Adverse Effects:** Headache, dizziness, light-headedness, anxiety, emotional lability, fatigue, malaise, drowsiness, anxiety, confusion, depression, aseptic meningitis; hypertension, palpitation, CHF; peripheral edema; amblyopia (blurred vision, decreased visual acuity, scotomas, changes in color vision); nystagmus, visual-field defects; tinnitus, impaired hearing; dry mouth, gingival ulcers, dyspnea, heartburn, nausea, vomiting, anorexia, diarrhea, constipation, bloating, flatulence, epigastric or abdominal discomfort or pain, GI ulceration, occult blood loss; thrombocytopenia, neutropenia, hemolytic or aplastic anemia, leukopenia; decreased Hgb/Hct; acute renal failure, polyuria, azotemia, cystitis, hematuria, nephrotoxicity, decreased creatinine clearance; maculopapular and vesicobullous skin eruptions, erythema multiforme, pruritus, acne; fluid retention with edema, Stevens-Johnson syndrome, toxic hepatitis, hypersensitivity reactions, anaphylaxis, bronchospasm, serum sickness, SLE, angioedema  

**Interactions:** Oral anticoagulants and heparin may prolong bleeding time; may increase lithium and methotrexate toxicity; herbals (feverfew, garlic, ginger, ginkgo) may increase risk of bleeding; do not take aspirin concurrently; concurrent alcohol use may increase risk of GI ulceration and bleeding tendencies
## 11. KETOROLAC (TORADOL)

**Class:** CNS agent – NSAID; anti-inflammatory, analgesic, antipyretic  
**Action:** Inhibits prostaglandin synthesis  
**Dose:** 15-30 mg IV/IM q6h (max: 150 mg/d on first day, then 120 mg subsequent days); 10 mg PO q6h (max: 40 mg/d); max duration all routes 5 days  
**Indications:** For moderate pain management  
**Contraindications:** Ketorolac hypersensitivity; nasal polyps; angioedema or bronchospastic reaction to aspirin or other NSAIDs; severe renal impairment or renal failure due to volume depletion; patients with risk of bleeding; active peptic ulcer disease; pre- or intraoperatively; pregnancy category B  
**Adverse Effects:** Drowsiness, dizziness, headache; nausea, dyspepsia, GI pain, hemorrhage; edema, sweating  
**Interactions:** May increase methotrexate and lithium levels and toxicity; herbals (feverfew, garlic, ginger, ginkgo) increase bleeding potential

## 12. LIDOCAINE (XYLOCAINE)

**Class:** Amide-type local anesthetic; cardiovascular agent; class IB antiarrhythmic  
**Action:** Anesthetic effect similar to procaine; class IB antiarrhythmic action by suppressing automaticity in the His-Purkinje system and by elevating the electrical stimulation threshold of ventricles during diastole  
**Dose:** For local anesthesia, infiltrate 0.5%–2% injection with and without epinephrine  
**Indications:** For surface, infiltration, and nerve block anesthesia; also used for rapid control of ventricular arrhythmias  
**Contraindications:** Amide-type local anesthetic hypersensitivity; systemic injection in presence of severe trauma or sepsis, blood dyscrasias, supraventricular arrhythmias, untreated sinus bradycardia, severe degrees of sinoatrial, atrioventricular, and intraventricular heart block; pregnancy category B  
**Adverse Effects:** Drowsiness, dizziness, light-headedness, restlessness, confusion, disorientation, irritability, apprehension, euphoria, wild excitement, numbness of lips or tongue, hot and cold parasthesia, chest heaviness, difficulty speaking, difficulty breathing or swallowing, muscular twitching, tremors, psychosis; convulsions, respiratory depression and arrest, hypotension, bradycardia, conduction disorders, heart block, cardiovascular collapse, and cardiac arrest in high doses; tinnitus, decreased hearing; blurred or double vision, impaired color perception; local erythema and edema; anorexia, nausea, vomiting; excessive perspiration, thrombophlebitis; urticaria, rash, edema, anaphylactoid reaction  
**Interactions:** Barbiturates decrease activity; cimetidine, beta blockers, quinidine increase effects; phenytoin increases cardiac depressant effects; procainamide compounds neurologic and cardiac effects
13. MELOXICAM (MOBIC)

**Class:** CNS agent – NSAID; anti-inflammatory, analgesic, antipyretic

**Action:** Inhibits cyclooxygenase

**Dose:** 7.5–15 mg PO daily

**Indications:** For mild to moderate pain management, osteoarthritis, rheumatoid arthritis

**Contraindications:** NSAID or salicylate hypersensitivity; rhinitis, urticaria, angioedema, asthma; severe renal or hepatic disease; pregnancy category C (1st/2nd trimester) and category D (3rd trimester)

**Adverse Effects:** Edema, flu-like syndrome, pain; abdominal pain, diarrhea, dyspepsia, flatulence, nausea, constipation, ulceration, GI bleed; anemia; arthralgia; dizziness, headache, insomnia; pharyngitis, upper respiratory tract infection, cough; rash, pruritus; urinary frequency, UTI

**Interactions:** May decrease effect of ACE inhibitors and diuretics; may increase lithium levels and toxicity; aspirin may increase GI bleed risk; warfarin and herbs (feverfew, garlic, ginger, ginkgo) may increase bleeding

14. MORPHINE SULFATE (MSO4) - CONTROLLED SUBSTANCE: SCHEDULE II

**Class:** CNS agent – narcotic (opiate) agonist; analgesic

**Action:** Natural opium alkaloid with agonist activity as it binds with 3 types of the same receptors as endogenous opioid peptides; analgesia at supraspinal level, euphoria, respiratory depression and physical dependence; sedation and miosis; dysphoric, hallucinogenic, and cardiac stimulant effects

**Dose:** 5–15 mg slow IV push, titrate to pain (have opioid antagonist [naloxone] immediately available!)

**Indications:** For severe acute and chronic pain management, MI pain relief, preanesthesia and as adjunct to anesthesia, and for relief of dyspnea from acute left ventricular failure and pulmonary edema

**Contraindications:** Opiate hypersensitivity; increased ICP; seizures; acute alcoholism; acute bronchial asthma, chronic pulmonary disease, severe respiratory depression; chemical-irritant induced pulmonary edema; BPH; diarrhea due to poisoning until toxic material has been eliminated; undiagnosed acute abdominal conditions; following biliary tract surgery and surgical Anastomosis; pancreatitis; acute ulcerative colitis; severe liver or renal insufficiency; hypothyroidism; pregnancy category B

**Adverse Effects:** Pruritus, rash, urticaria, edema, anaphylactoid reaction; sweating, skeletal muscle flaccidity; cold, clammy skin, hypothermia; euphoria, insomnia, disorientation, visual disturbances, dysphoria, paroxysmal CNS stimulation (restlessness, tremor, delirium, insomnia), convulsions; decreased cough reflex, drowsiness, dizziness, deep sleep, coma, miosis; bradycardia, palpitations, syncope; flushing of face, neck, and upper thorax; orthostatic hypotension, cardiac arrest; constipation, anorexia, dry mouth, biliary colic, nausea, vomiting, elevated LFTs; urinary retention or urgency, dysuria, oliguria, reduced libido or potency; severe respiratory depression or arrest; pulmonary edema

**Interactions:** CNS depressants, sedatives, barbiturates, alcohol, benzodiazepines, and TCAs potentiate CNS depressant effects; MAOIs may precipitate hypertensive crisis; phenothiazines may antagonize analgesia; herbs (Kava-kava, valerian, St. John's wort) may increase sedation
15. MOXIFLOXACIN (AVELOX)

Class: Antimicrobial – antibiotic; fluoroquinolone

Action: Broad spectrum bactericidal agent that inhibits DNA-gyrase topoisomerase II, an enzyme necessary for bacterial replication, transcription, repair and recombination; effective against gram-positive and gram-negative organisms, Staphylococcus aureus, Streptococcus pneumonia, Haemophilus influenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydia pneumoniae, Mycoplasma pneumoniae, and other microbes

Dose: 400 mg PO/IV daily x 5-10 days

Indications: For acute bacterial exacerbation of chronic bronchitis, acute sinusitis, community-acquired pneumonia, skin infections

Contraindications: Quinolone hypersensitivity; hepatic insufficiency; syphilis; arrhythmias; myocardial ischemia or infarction; QTc prolongation, hypokalemia, or those receiving Class IA or Class III antiarrhythmic drugs; pregnancy category C

Adverse Effects: Dizziness, headache, peripheral neuropathy, nausea, diarrhea, abdominal pain, vomiting, taste perversion, abnormal LFTs, dyspepsia, tendon rupture

Interactions: Iron, zinc, antacids, aluminum, magnesium, calcium, sucralfate decrease absorption; atenolol, cisapride, erythromycin, antipsychotics, TCAs, quinidine, procainamide, amiodarone, sotalol may prolong QTc interval; may cause false positive on opiate screening tests

16. NALOXONE (NARCAN)

Class: CNS agent – narcotic (opiate) antagonist

Action: A "pure" narcotic antagonist, essentially free of agonistic (morphine-like) properties; thus, produces no significant analgesia, respiratory depression, psychotomimetic effects, or miosis when administered in the absence of narcotics and possesses more potent narcotic antagonist action

Dose: 0.4–2.0 mg IV, repeat q2–3min up to 10 mg prn

Indications: For narcotic opiate overdose and reversal of effects of natural and synthetic narctotics (opiates), including respiratory depression, sedation, and hypotension; drug of choice when depressant drug is unknown and for diagnosis of suspected acute opioid overdose

Contraindications: Non-opioid drug respiratory depression; pregnancy category B

Adverse Effects: Analgesia reversal, tremors, hyperventilation, drowsiness, sweating; increased BP, tachycardia; nausea, vomiting; elevated PTT

Interactions: Reverses analgesic effects of narcotic (opiate) agonists and agonist-antagonists
17. PROMETHAZINE (PHENERGAN)

**Class:** GI agent – phenothiazine; antiemetic, antivertigo

**Action:** Long-acting phenothiazine derivative with prominent sedative, amnesic, antiemetic, and anti-motion-sickness actions and marked antihistamine activity; antiemetic action due to depression of CTZ in medulla; as with other antihistamines, it exerts antiserotonin, anticholinergic, and local anesthetic action

**Dose:** 12.5-25 mg PO/IM/IV q4-6h prn

**Indications:** For symptomatic relief from nausea, vomiting, motion sickness, and allergic conditions; also used for pre- and postoperative sedation, and as adjunct to analgesics for control of pain

**Contraindications:** Phenothiazine hypersensitivity; narrow-angle glaucoma; stenosing peptic ulcer, pyloroduodenal obstruction; BPH; bladder neck obstruction; epilepsy; bone marrow depression; comatose or severe depressed states; Reye's syndrome, encephalopathy, hepatic diseases; pregnancy category C

**Adverse Effects:** Deep sleep, coma, convulsions, cardiorespiratory symptoms, extrapyramidal reactions, nightmares, CNS stimulation, abnormal movements; irregular respirations, respiratory depression; sedation drowsiness, confusion, dizziness, disturbed coordination, restlessness, tremors; transient mild hypo- or hypertension; anorexia, nausea, vomiting, constipation; leukopenia, agranulocytosis; blurred vision, dry mouth, nose, or throat; photosensitivity; urinary retention

**Interactions:** Alcohol and other CNS depressants add to CNS depression and anticholinergic effects

18. SODIUM CHLORIDE, 0.9% (NORMAL SALINE)

**Class:** Plasma volume expander – crystalloid; isotonic salt solution

**Action:** Each mL contains 9 g sodium chloride (Na+ 154 mEq/L; Cl¯ 154 mEq/L); pH 5.7; expands circulating volume by approximating sodium content of the blood; but, it remains in the intravascular space for only a very limited time as it diffuses rapidly throughout the extracellular space

**Dose:** 500–1000 mL IV; 5-50 mL IV for medication dilution or as flush

**Indications:** For fluid replacement and plasma volume expansion when blood or plasma is not available, and for adjunctive treatment of shock and hypovolemic states caused by hemorrhage, burns, surgery, sepsis, trauma, dehydration, or heat injury; also used for dilution of medications, as IV flush agent, for saline locks, and irrigation of eyes and wounds

**Contraindications:** CHF

**Adverse Effects:** Fluid overload, CHF, edema, electrolyte imbalance, hyperchloremic metabolic acidosis, hypertension

**Interactions:** No clinically significant interactions established
SECTION THREE

RMED

PHARMACOLOGY

SECTION II

“PROFICIENT”
## PHARMACOLOGY SECTION II: "PROFICIENT"

<table>
<thead>
<tr>
<th>No.</th>
<th>Medication</th>
<th>Dosage/Usage</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>ACETAZOLAMIDE (DIAMOX)</td>
<td>250 mg PO q8–12h from 1-2 d prior, to ≥ 5d at alt.</td>
</tr>
<tr>
<td>2.</td>
<td>ACETYLSALICYLIC ACID (ASPIRIN)</td>
<td>325–650 mg PO/PR q4h</td>
</tr>
<tr>
<td>3.</td>
<td>ALBUTEROL (PROVENTIL)</td>
<td>MDI 2 puffs q4–6h prn</td>
</tr>
<tr>
<td>4.</td>
<td>BACITRACIN</td>
<td>Topical ointment to AAA bid-tid</td>
</tr>
<tr>
<td>5.</td>
<td>BENZONATATE (TESSALON PERLES)</td>
<td>100-200 mg PO tid prn (max 600 mg/d)</td>
</tr>
<tr>
<td>6.</td>
<td>CEFTRIAXONE (ROCEPHIN)</td>
<td>1–2 g IV/IM q12–24h (max: 4 g/d)</td>
</tr>
<tr>
<td>7.</td>
<td>CETIRIZINE (ZYRTEC)</td>
<td>5–10 mg PO qd</td>
</tr>
<tr>
<td>8.</td>
<td>CIMETIDINE (TAGAMET)</td>
<td>300 mg IV/IM/PO q6-8h or 400 mg po bid</td>
</tr>
<tr>
<td>9.</td>
<td>CLINDAMYCIN (CLEOCIN)</td>
<td>150–450 mg PO q6h; 600–900 mg IM/IV q6–8h</td>
</tr>
<tr>
<td>10.</td>
<td>DEXTROMETHORPHAN (ROBITUSSIN DM)</td>
<td>10–20 mg PO q4h or 30 mg q6–8h (max: 120 mg/d)</td>
</tr>
<tr>
<td>11.</td>
<td>DEXTROSE (D50)</td>
<td>0.5-1 g/kg (1-2 ml/kg) up to 25 g (50 mL) IV</td>
</tr>
<tr>
<td>12.</td>
<td>DOXYCYCLINE</td>
<td>100 mg PO qd from 1-2 d prior to 4 wks after expos</td>
</tr>
<tr>
<td>13.</td>
<td>FEXOFENADINE (ALLEGRA)</td>
<td>60 mg PO bid or 180 mg PO qd</td>
</tr>
<tr>
<td>14.</td>
<td>GUAIFENESIN</td>
<td>100–400 mg PO q4h or 600-1200 mg XR PO q12h</td>
</tr>
<tr>
<td>15.</td>
<td>HYDROCORTISONE</td>
<td>Topically AAA qd-qid</td>
</tr>
<tr>
<td>16.</td>
<td>HYDROMORPHONE (DILAUDID)</td>
<td>1–4 mg PO/SC/IM/IV q4–6h prn</td>
</tr>
<tr>
<td>17.</td>
<td>LACTATED RINGER'S (LR)</td>
<td>500-1000 mL IV</td>
</tr>
<tr>
<td>18.</td>
<td>LEVOFLOXACIN (LEVAQUIN)</td>
<td>250-750 mg PO/IV daily</td>
</tr>
<tr>
<td>19.</td>
<td>LOPERAMIDE (IMODIUM)</td>
<td>4 mg PO, then 2 mg with loose BM (max: 16 mg/d)</td>
</tr>
<tr>
<td>20.</td>
<td>LORATADINE (CLARITIN)</td>
<td>10 mg PO daily</td>
</tr>
<tr>
<td>21.</td>
<td>MECLIZINE (ANTIVERT)</td>
<td>25–50 mg PO 1 h before travel</td>
</tr>
<tr>
<td>22.</td>
<td>MEFLOQUINE (LARIUM)</td>
<td>250 mg PO once/wk from 1 wk prior to 4 wks after</td>
</tr>
<tr>
<td>23.</td>
<td>ONDANSETRON (ZOFRAN)</td>
<td>8-16 mg PO q8h prn; 4mg slow IVP or IM q8h prn</td>
</tr>
<tr>
<td>24.</td>
<td>PRIMAQUINE</td>
<td>30 mg base PO daily x 14 d, after malaria exposure</td>
</tr>
<tr>
<td>25.</td>
<td>PSEUDOEPHEDRINE (SUDAFED)</td>
<td>30-60 mg PO q4–6h or 120 mg XR PO q12h</td>
</tr>
<tr>
<td>26.</td>
<td>RANITIDINE (ZANTAC)</td>
<td>75-150 mg PO bid or 150-300 mg PO qhs</td>
</tr>
<tr>
<td>27.</td>
<td>TMP-SMZ (BACTRIM, SEPTRA)</td>
<td>160 mg TMP/800 mg SMZ (DS) PO bid</td>
</tr>
<tr>
<td>28.</td>
<td>ZOLPIDEM (AMBIEN)</td>
<td>5–10 mg PO qhs, limited to 7–10 days</td>
</tr>
</tbody>
</table>
1. **ACETAZOLAMIDE (DIAMOX)**

**Class:** CNS Agent – carbonic anhydrase inhibitor; diuretic, anticonvulsant

**Action:** Diuretic effect due to inhibition of carbonic anhydrase activity in proximal renal tubule, preventing formation of carbonic acid; anticonvulsant action effect thought to involve inhibition of CNS carbonic anhydrase, retarding abnormal paroxysmal discharge from CNS neurons

**Dose:** 250 mg PO q8–12h; 500 mg SR q12–24h; start 1-2 d prior, continue for ≥ 5 d while at high altitude

**Indications:** For acute high-altitude sickness, seizures, drug-induced edema, and for CHF edema

**Contraindications:** Sulfonamide and thiazide hypersensitivity; marked renal and hepatic dysfunction; adrenocortical insufficiency; hyponatremia, hypokalemia, hyperchloremic acidosis; pregnancy category C

**Adverse Effects:** Paresthesias, sedation, malaise, disorientation, depression, fatigue, muscle weakness, flaccid paralysis; anorexia, nausea, vomiting, weight loss, dry mouth, thirst, diarrhea; agranulocytosis, bone marrow depression, hemolytic anemia, aplastic anemia, leukopenia, pancytopenia; hyperglycemia; hyperuricemia; increased calcium, potassium, magnesium, sodium excretion; gout exacerbation, dysuria, glycosuria, urinary frequency, polyuria, hematuria, crystalluria; metabolic acidosis; hepatic dysfunction

**Interactions:** Renal excretion of amphetamines, ephedrine, flecainide, quinidine, procainamide, TCAs may be decreased, thereby enhancing or prolonging their effects; renal excretion of lithium and phenobarbital is increased; amphotericin B and corticosteroids may accelerate potassium loss; increased risk for salicylate and digitalis toxicity

2. **ACETYLSALICYLIC ACID (ASPIRIN)**

**Class:** CNS agent – NSAID; salicylate; anti-inflammatory, analgesic, antipyretic

**Action:** Inhibits prostaglandin synthesis involved in the production of inflammation, pain, and fever; enhances antigen removal and reduces spread of inflammation; peripheral analgesic action with limited CNS action in the hypothalamus; antipyretic by indirect centrally mediated peripheral vasodilation and sweating; powerfully inhibits platelet aggregation and ability of blood to clot; high levels can impair hepatic synthesis of blood coagulation factors VII, IX, and X, possibly by inhibiting action of vitamin K

**Dose:** 325-650 mg PO/PR q4-6h (max: 4 g/d); MI prophylaxis PO 80-325 mg/d (chewable or coated)

**Indications:** For mild to moderate pain management, fever reduction, and to decrease inflammation; also used for acute rheumatic fever, Systemic Lupus, rheumatoid arthritis, osteoarthritis, bursitis, calcific tendonitis, to reduce recurrence of TIA and risk of stroke, as prophylaxis and to prevent recurrence of MI

**Contraindications:** Salicylate and NSAID hypersensitivity; patients with "aspirin triad" (aspirin sensitivity, nasal polyps, asthma); chronic rhinitis or urticaria; GI ulcer, bleeding; hypoprothrombinemia, vitamin K deficiency, hemophilia, bleeding disorders; CHF; pregnancy category D; do NOT use in children or teenagers with viral illnesses due to link with Reye's syndrome

**Adverse Effects:** Rash, urticaria, easy bruising, petechiae, bronchospasm, laryngeal edema; confusion, dizziness, drowsiness; tinnitus, hearing loss; nausea, vomiting, diarrhea, anorexia, heartburn, stomach pain, GI bleeding, ulceration; thrombocytopenia, hemolytic anemia, prolonged bleeding time

**Interactions:** Aminosalicylic acid and carbonic anhydrase inhibitors increase risk of toxicity; ammonium chloride, acidifying agents decrease renal elimination and increase toxicity; oral hypoglycemic agents increase hypoglycemic activity; corticosteroids increase ulcer potential; methotrexate toxicity is increased; anticoagulants and herbs (feverfew, garlic, ginger, ginkgo) increase bleeding potential
3. **ALBUTEROL (PROVENTIL)**

**Class:** Autonomic nervous system agent – sympathomimetic, beta-adrenergic agonist, bronchodilator  

**Action:** Acts more prominently on beta_2 receptors (particularly smooth muscles of bronchi, uterus, and vascular supply to skeletal muscles) than on beta_1 (heart) receptors; minimal or no effect on alpha-adrenergic receptors; inhibits histamine release by mast cells; produces bronchodilation, by relaxing smooth muscles of bronchial tree which decreases airway resistance, facilitates mucus drainage, and increases vital capacity  

**Dose:** MDI 2 puffs q4–6h prn; NEB 0.5 mL of 0.5% soln (2.5 mg) in 5 mL NS nebulized tid-qid  

**Indications:** For prevention of exercise-induced bronchospasm, or relief of bronchospasm associated with acute or chronic asthma, bronchitis, or other reversible obstructive airway disease; also used 20–30 minutes before inhaled steroids to allow for deeper penetration of the steroids into the lungs  

**Contraindications:** Pregnancy category C  

**Adverse Effects:** Hypersensitivity reaction, tremor, anxiety, nervousness, restlessness, convulsions, weakness, headache, hallucinations; palpitation, hyper- or hypotension, bradycardia, reflex tachycardia; blurred vision, dilated pupils; nausea, vomiting; muscle cramps, hoarseness  

**Interactions:** Additive effect with epinephrine and other sympathomimetic bronchodilators; MAOIs and TCAs potentiate action on vascular system; beta-adrenergic blockers antagonize effects

---

4. **BACITRACIN**

**Class:** Antimicrobial – antibiotic  

**Action:** Polypeptide derived from *Bacillus subtilis* culture; bactericidal/bacteriostatic that appears to inhibit cell wall synthesis; activity similar to penicillin; active against many gram-positives including *Streptococci*, *Staphylococci*, *Pneumococci*, *Corynebacteria*, *Clostridia*, *Neisseria*, *Gonococci*, *Meningococci*, *Haemophilus influenzae*, and *Treponema pallidum*; ineffective against most other gram-negatives  

**Dose:** Topical ointment to AAA bid-tid, clean affected area prior to application  

**Indications:** For topical treatment of superficial skin infections  

**Contraindications:** Atopic individuals; pregnancy category C  

**Adverse Effects:** Bacitracin hypersensitivity (erythema, anaphylaxis)  

**Interactions:** No clinically significant interactions established when given topically
5. BENZONATATE (TESSALON PERLES)

Class: ENT agent – antitussive

Action: Nonnarcotic antitussive chemically related to tetracaine; does not inhibit respiratory center at recommended doses; decreases frequency and intensity of nonproductive cough

Dose: 100-200 mg PO tid prn (max 600 mg/d)

Indications: For management of nonproductive cough in acute and chronic respiratory conditions

Contraindications: Pregnancy category C

Adverse Effects: Drowsiness, sedation, headache, mild dizziness; constipation, nausea; rash, pruritus

Interactions: Swallow whole; do not chew or dissolve as mouth, tongue, pharynx will be anesthetized

6. CEFTRIAXONE (ROCEPHIN)

Class: Antimicrobial – antibiotic; third-generation cephalosporin

Action: Preferentially binds to penicillin-binding proteins (PBP) and inhibits bacterial cell wall synthesis; effective against most Enterobacteriaceae, gram-positive aerobic cocci, Neisseria meningitides and gonorrhoeae; some effect against Treponema pallidum

Dose: For moderate to severe infections, 1–2 g IV/IM q12–24h (max: 4 g/d); for meningitis, 2 g IV/IM q12h; for uncomplicated gonorrhea 250 mg IM x 1; dilute in 1% lidocaine for IM

Indications: For infections of the middle ear, lower respiratory tract, skin and skin structures, bones and joints, meningitis, intra-abdominal, urogenital tract, pelvis, septicemia; used for surgical prophylaxis

Contraindications: Cephalosporin hypersensitivity; pregnancy category B

Adverse Effects: Pruritus, fever, chills, pain, induration at IM site; phlebitis at IV site; diarrhea, abdominal cramps, pseudomembranous colitis, biliary sludge

Interactions: Probenecid decreases renal elimination; alcohol produces disulfiram reaction

7. CETIRIZINE (ZYRTEC)

Class: ENT agent – H1-receptor antagonist; non-sedating antihistamine

Action: Potent H1-receptor antagonist and antihistamine; low lipophilicity and H1-receptor selectivity and thus no significant anticholinergic or CNS activity; reduces local and systemic effects of histamine release

Dose: 5–10mg PO qd

Indications: Seasonal and perennial allergic rhinitis and chronic idiopathic urticaria

Contraindications: H1-receptor antihistamine hypersensitivity; pregnancy category B

Adverse Effects: Constipation, diarrhea, dry mouth; drowsiness, sedation, headache, depression

Interactions: Theophylline may decrease clearance leading to toxicity; do not use in combination with OTC antihistamines
8. CIMETIDINE (TAGAMET)

Class: GI agent – antisecretory H2-receptor antagonist

Action: Antihistamine with high selectivity for reversible competitive inhibition of histamine H2-receptors on parietal cells of the stomach (minimal effect on H1-receptors) and thus decreases gastric acid secretion, raises the pH of the stomach, and indirectly reduces pepsin secretion

Dose: 300 mg IV/IM/PO q6-8h or 400 mg po bid or 400-800 mg qhs

Indications: For treatment of duodenal/gastric ulcer, prevention of ulcer recurrence, gastroesophageal reflux, chronic urticaria, acetaminophen toxicity

Contraindications: H2 receptor antagonists hypersensitivity; pregnancy category B

Adverse Effects: Fever; cardiac arrhythmias and cardiac arrest after rapid IV bolus; diarrhea, constipation, abdominal discomfort; increased prothrombin time; neutropenia, thrombocytopenia, aplastic anemia; hypospermia; exacerbation of preexisting arthritis; dizziness, light-headedness, depression, headache, reversible confusional states, paranoid psychosis; rash, Stevens-Johnson syndrome, reversible alopecia; gynecomastia, galactorrhea, reversible impotence

Interactions: Decreases hepatic metabolism of warfarin, phenobarbital, phenytoin, diazepam, propranolol, lidocaine, theophylline, thus increasing their activity and toxicity; antacids may decrease absorption

9. CLINDAMYCIN (CLEOCIN)

Class: Antimicrobial – antibiotic

Action: Suppresses protein synthesis by binding to 50 S subunits of bacterial ribosomes; effective against strains of anaerobic streptococci, Bacteroides (especially B. fragilis), Fusobacterium, Actinomyces israelii, Peptococcus, Clostridium sp, and aerobic gram-positive cocci, including Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus (except S. faecalis), and Pneumococci

Dose: Cleocin: 150–450 mg PO q6h; 600–900 mg IM/IV q6–8h (max: 2700 mg/d), each IM injection ≤ 600 mg; Cleocin T: topically AAA BID

Indications: For moderate to severe infections; topical applications used in treatment of acne vulgaris

Contraindications: Clindamycin or lincomycin hypersensitivity; history of regional enteritis, ulcerative colitis, or antibiotic-associated colitis; pregnancy category B

Adverse Effects: Fever, serum sickness, sensitization, swelling of face, generalized myalgia, superinfections, proctitis, pain, induration, sterile abscess; thrombophlebitis; hypotension, cardiac arrest (rapid IV); diarrhea, abdominal pain, flatulence, bloating, nausea, vomiting, pseudomembranous colitis; esophageal irritation, loss of taste, medicinal taste (high IV doses), jaundice, abnormal liver function tests; leukopenia, eosinophilia, agranulocytosis, thrombocytopenia; skin rashes, urticaria, pruritus, dryness, contact dermatitis, gram-negative folliculitis, irritation, oily skin

Interactions: Chloramphenicol and erythromycin are possibly antagonistic; neuromuscular blocking action enhanced by neuromuscular blocking agents (atracurium, tubocurarine, pancuronium)
10. DEXTROMETHORPHAN (ROBITUSSIN DM)

**Class:** ENT agent – Antitussive

**Action:** Nonnarcotic derivative that depresses the cough center in the medulla; chemically related to morphine but without central hypnotic or analgesic effect or capacity to cause tolerance or addiction; antitussive activity comparable to that of codeine but is less likely than codeine to cause constipation, drowsiness, or GI disturbance

**Dose:** 10–20 mg PO q4h or 30 mg q6–8h (max: 120 mg/d)

**Indication:** For temporary relief or control of cough spasms in nonproductive coughs due to colds, pertussis, or influenza

**Contraindications:** Asthma; productive or persistent cough; liver impairment; pregnancy category C

**Adverse Effects:** Dizziness, drowsiness, CNS depression with very large doses; excitability; GI upset, constipation, abdominal discomfort

**Interactions:** MAOIs can cause excitation, hypotension, and hyperpyrexia; CNS depressants can cause dizziness and drowsiness

11. DEXTROSE (D50)

**Class:** Endocrine agent – caloric, monosaccharide

**Action:** Needed for adequate utilization of amino acids, decreases protein and nitrogen loss, and prevents ketosis

**Dose:** 0.5-1 g/kg (1-2 ml/kg) up to 25 g (50 mL) of 50% solution IV; if tolerating PO, provide glucose tabs

**Indication:** For treatment of hypoglycemic episode

**Contraindications:** Hyperglycemia, delirium tremens, cranial or spinal hemorrhage, CHF

**Adverse Effects:** Confusion, loss of consciousness, dizziness; hypertension, CHF, pulmonary edema; glycosuria, osmotic diuresis; hyperglycemia, rebound hypoglycemia; chills, flushing, rash, urticaria

**Interactions:** No clinically significant interactions established
12. DOXYCYCLINE

**Class:** Antimicrobial – antibiotic; tetracycline

**Action:** Semisynthetic broad-spectrum antibiotic derived from oxytetracycline, but more completely absorbed with effective blood levels maintained for longer periods and excreted more slowly than most other tetracyclines, thus it requires smaller and less frequent dosing; primarily bacteriostatic in effect

**Dose:** As antimalarial, 100 mg PO qd starting 1-2 days prior to 4 wks after exposure; as antimicrobial, 100 mg PO q12h on day 1, then 100 mg qd; for travelers’ diarrhea, 100 PO QD during risk period; for gonorrhea, 200 mg PO immediately, followed by 100 mg bid x 3 d; for syphilis 100 mg PO tid x 10 d; for acne, 100 mg PO qd-bid

**Indications:** For suppression and chemoprophylaxis of chloroquine-resistant *Plasmodium falciparum* malaria, short-term prophylaxis and treatment of travelers' diarrhea caused by enterotoxigenic strains of *Escherichia coli*, Chlamydial and mycoplasmal infections, gonorrhea, syphilis in penicillin-allergic patients, rickettsial diseases, acute exacerbations of chronic bronchitis, and treatment of acne

**Contraindications:** Tetracycline hypersensitivity; use during period of tooth development including last half of pregnancy causes permanent yellow discoloration of teeth, enamel hypoplasia, and retardation of bone growth, pregnancy category D

**Adverse Effects:** Interference with color vision; anorexia, nausea, vomiting, diarrhea, enterocolitis; esophageal irritation; rashes, photosensitivity reaction; superinfections

**Interactions:** Antacids, iron preparation, calcium, magnesium, zinc, kaolin-pectin, sodium bicarbonate can significantly decrease absorption; effects of both doxycycline and desmopressin antagonized; increases digoxin absorption and risk of toxicity; methoxyflurane increases risk of renal failure

13. FEXOFENADINE (ALLEGRA)

**Class:** ENT agent – H1-receptor antagonist; non-sedating antihistamine

**Action:** Competitively antagonizes histamine at the H1-receptor site; does not bind with histamine to inactivate it; not associated with anticholinergic or sedative properties; inhibits antigen-induced bronchospasm and histamine release from mast cells

**Dose:** 60 mg PO bid or 180 mg PO qd

**Indications:** For symptom relief from seasonal allergic rhinitis (nasal congestion and sneezing; watery or red eyes; itching nose, palate, or eyes) and chronic urticaria

**Contraindications:** Fexofenadine hypersensitivity; pregnancy category C

**Adverse Effects:** Headache, drowsiness, fatigue; nausea, dyspepsia, throat irritation

**Interactions:** No clinically significant interactions established
14. **GUAIFENESIN**

**Class:** ENT agent – antitussive, expectorant  
**Action:** Enhances reflex outflow of respiratory tract fluids by irritation of gastric mucosa; aids in expectoration by reducing adhesiveness and surface tension of secretions  
**Dose:** 100–400 mg PO q4h or 600-1200 mg XR PO q12h (max: 2.4 g/d)  
**Indications:** Relief of dry, nonproductive coughs associated with colds and bronchitis  
**Contraindications:** Guaifenesin hypersensitivity; pregnancy category C  
**Adverse Effects:** Low incidence of nausea; drowsiness  
**Interactions:** By inhibiting platelet function, may increase risk of bleeding in patients receiving heparin

15. **HYDROCORTISONE**

**Class:** Skin and mucous membrane agent – synthetic hormone; adrenal corticosteroid, glucocorticoid, mineralocorticoid, antiinflammatory  
**Action:** Stabilizes leukocyte lysosomal membranes, inhibits phagocytosis and release of allergic substances, suppresses fibroblast formation and collagen deposition  
**Dose:** Topically AAA qd-qid  
**Indications:** To reduce inflammation in various skin conditions  
**Contraindications:** Steroid hypersensitivity, viral or bacterial diseases of skin; varicella or vaccinia on surfaces with compromised circulation; pregnancy category C  
**Adverse Effects:** Anaphylactoid reaction; aggravation or masking of infections; skin thinning and atrophy, acne, impaired wound healing; petechiae, ecchymosis, easy bruising; hypopigmentation or hyperpigmentation, hirsutism, acneiform eruptions, subcutaneous fat atrophy; allergic dermatitis, urticaria, angioneurotic edema, increased sweating  
**Interactions:** Estrogens potentiate effects; immune response to vaccines may be decreased
16. HYDROMORPHONE (DILAUDID) - CONTROLLED SUBSTANCE: SCHEDULE II

Class: CNS agent – narcotic (opiate) agonist; analgesic

Action: Semisynthetic derivative structurally similar to morphine with 8–10 times more potent analgesic effect, more rapid onset, shorter duration of action, less hypnotic effect, and less tendency to produce nausea and vomiting; also has antitussive properties

Dose: 1–4 mg PO/SC/IM/IV q4–6h prn

Indications: For moderate to severe pain management, and control of persistent nonproductive cough

Contraindications: Opiate hypersensitivity; acute bronchial asthma, COPD, decreased respiratory reserve, severe respiratory depression, opiate-naïve patients; pregnancy category C

Adverse Effects: Nausea, vomiting, constipation; euphoria, dizziness, sedation, drowsiness; hypotension, bradycardia, tachycardia; respiratory depression; blurred vision

Interactions: Alcohol and other CNS depressants compound sedation and CNS depression; herbal (St. John's wort) may increase sedation

17. LACTATED RINGER’S (LR)

Class: Plasma volume expander – crystalloid; isotonic salt solution

Action: Each liter contains 6.0 g Sodium Chloride (Na+ 130 mEq/L, Cl¯ 109 mEq/L) and other electrolytes (K+ 4 mEq/L, Ca++ 3 mEq/L, Lactate 28 mEq/L, and 9 kcal/L); pH 6.4; remains in the intravascular space for only a very limited time as it diffuses rapidly throughout the extracellular space

Dose: 500–1000 mL IV

Indications: For fluid replacement and plasma volume expansion when blood or plasma is not available, and for adjunctive treatment of shock and hypovolemic states caused by hemorrhage, burns, surgery, sepsis, trauma, dehydration, or illness; also used for irrigation

Contraindications: CHF; do not use with blood or blood products

Adverse Effects: Fluid overload, CHF, edema, electrolyte imbalance, hypertension

Interactions: Calcium in LR can bind to other drugs and reduce efficacy, also has potential for creating emboli if given with blood or blood products
### 18. LEVOFLOXACIN (LEVAQUIN)

**Class:** Antimicrobial – antibiotic; fluoroquinolone

**Action:** Broad-spectrum antibiotic that inhibits DNA bacterial topoisomerase II, an enzyme required for DNA replication, transcription, repair, and recombination; prevents replication of certain bacteria resistant to beta-lactam antibiotics

**Dose:** 250–750 mg PO/IV daily; for community-acquired pneumonia: 750 mg PO qd x 5 d; for chronic bacterial prostatitis: 500 mg PO qd x 28 d; for skin infections: 750 mg PO qd x 14 d

**Indications:** For treatment of maxillary sinusitis, acute exacerbations of bacterial bronchitis, community-acquired pneumonia, uncomplicated skin/skin structure infections, UTI, acute pyelonephritis; chronic bacterial prostatitis; bacterial conjunctivitis

**Contraindications:** Quinolone hypersensitivity; hypokalemia; tendon pain; syphilis; viral infections; phototoxicity; pregnancy category C

**Adverse Effects:** Headache, insomnia, dizziness; nausea, diarrhea, constipation, vomiting, abdominal pain, dyspepsia; rash, pruritus; decreased vision, foreign body sensation, transient ocular burning, ocular pain, photophobia; chest or back pain, fever, pharyngitis.

**Interactions:** Magnesium or aluminum-containing antacids, sucralfate, iron, and zinc may decrease absorption; NSAIDs may increase risk of CNS reactions including seizures; may cause hyper- or hypoglycemia in patients on oral hypoglycemic agents; may cause false positive on opiate screening tests; avoid exposure to excess sunlight or artificial UV light; avoid NSAIDs while taking levofloxacin

---

### 19. LOPERAMIDE (IMODIUM)

**Class:** GI agent – antidiarrheal

**Action:** Synthetic piperidine derivative that inhibits GI peristaltic activity by direct action on circular and longitudinal intestinal muscles; prolongs intestinal content transit time, increases consistency of stools, and reduces fluid and electrolyte loss

**Dose:** 4 mg PO, followed by 2 mg after each unformed stool (max: 16 mg/d)

**Indications:** For acute nonspecific diarrhea, chronic diarrhea associated with inflammatory bowel disease

**Contraindications:** Conditions in which constipation should be avoided, severe colitis, acute diarrhea caused by broad-spectrum antibiotics (pseudomembranous colitis) or from organisms that penetrate the intestinal mucosa (toxigenic *Escherichia coli, Salmonella, or Shigella*); pregnancy category B

**Adverse Effects:** Rash; fever; drowsiness, fatigue, dizziness, CNS depression with overdose; abdominal distension, discomfort or pain, bloating, constipation, nausea, vomiting, anorexia, dry mouth; toxic megacolon in patients with ulcerative colitis

**Interactions:** No clinically significant interactions established
20. LORATADINE (CLARITIN)

**Class:** ENT agent – H₁-receptor antagonist – non-sedating antihistamine

**Action:** Long-acting histamine antagonist with selective peripheral H₁-receptor sites that blocks histamine release; disrupts capillary permeability, edema formation, and constriction of respiratory, GI, and vascular smooth muscle

**Dose:** 10 mg PO daily, take on an empty stomach

**Indications:** Symptom relief from seasonal allergic rhinitis; idiopathic chronic urticaria

**Contraindications:** Loratadine hypersensitivity; pregnancy category B

**Adverse Effects:** Dizziness, dry mouth, fatigue, headache, somnolence, altered salivation and lacrimation, thirst, flushing, anxiety, depression, impaired concentration; hypo- or hypertension, palpitations, syncope, tachycardia; nausea, vomiting, flatulence, abdominal distress, constipation, diarrhea, weight gain, dyspepsia; arthralgia, myalgia; blurred vision, earache, eye pain, tinnitus; rash, pruritus, photosensitivity

**Interactions:** No clinically significant interactions established

---

21. MECLIZINE (ANTIVERT)

**Class:** H₁-Receptor antagonist; antihistamine, anti-vertigo agent

**Action:** Long-acting piperazine antihistamine with marked effect in blocking histamine-induced vasopressive response, but only slight anticholinergic action; marked depressant action on labyrinthine excitability and on conduction in vestibular-cerebellar pathways; exhibits CNS depression, antispasmodic, antiemetic, and local anesthetic activity

**Dose:** For motion sickness, 25–50 mg PO 1 h before travel, may repeat q24h prn for duration of journey; for vertigo, 25–100 mg/d PO in divided doses

**Indications:** For management of nausea, vomiting, and dizziness associated with motion sickness and vertigo associated with diseases affecting the vestibular system

**Contraindications:** Hypersensitivity to meclizine; pregnancy category B

**Adverse Effects:** Drowsiness; dry mouth; blurred vision; fatigue

**Interactions:** Alcohol and CNS depressants may potentiate sedative effects; do not drive or engage in potentially hazardous activities until response to drug is known
22. MEFLOQUINE (LARIUM)

Class: Antimicrobial – antimalarial

Action: Antimalarial agent structurally related to quinine; effective against all types of malaria including chloroquine resistant malaria

Dose: For malaria prophylaxis, 250 mg PO once/wk (beginning 1 wk before travel and ending 4 wks after leaving endemic area; for malaria treatment, 1250 mg (5 tablets) PO x 1 single dose

Indications: For prevention of chloroquine-resistant malaria caused by Plasmodium falciparum and P. vivax, and treatment of mild to moderate acute malarial infections

Contraindications: Mefloquine hypersensitivity; calcium channel blockers, severe heart arrhythmias, history of QTc prolongation; aggressive behavior; active or history of depression or suicidal ideation; anxiety disorder, psychosis, schizophrenia, or other major psychiatric disorder; seizure disorder; pregnancy category C

Adverse Effects: Arthralgia, chills, fatigue, fever; dizziness, nightmares, visual disturbances, headache, syncope, confusion, psychosis, aggression, suicide ideation; bradycardia, ECG changes to include QTc prolongation, first-degree AV block; nausea, vomiting, abdominal pain, anorexia, diarrhea; rash, itching

Interactions: Can prolong cardiac conduction in patients taking beta blockers, calcium channel blockers, and possibly digoxin; quinine may decrease plasma levels; may decrease valproic acid levels by increasing hepatic metabolism; administration with chloroquine may increase risk of seizures; increased risk of cardiac arrest and seizures with quinidine; do not give concurrently with quinine or quinidine

23. ONDANSETRON (ZOFRAN)

Class: GI agent – 5-HT₃ antagonist, antiemetic

Action: Selective serotonin (5-HT₃) receptor antagonist, acting centrally in the chemoreceptor trigger zone (CTZ) and peripherally on the vagal nerve terminals; serotonin is released from the wall of the small intestine, stimulates the vagal efferents through the serotonin receptors, and initiates the vomiting reflex

Dose: 8-16 mg PO q8h prn; 4mg slow IVP or IM q8h prn

Indications: Prevention of nausea and vomiting associated with anesthesia, postoperative state, and chemotherapy

Contraindications: Hypersensitivity to ondansetron; pregnancy category B

Adverse Effects: Dizziness, light-headedness, headache, sedation; diarrhea, constipation, dry mouth

Interactions: Rifampin may decrease ondansetron levels
24. PRIMAQUINE

**Class:** Antimicrobial – antimalarial

**Action:** Acts on primary exoerythrocytic forms of *Plasmodium vivax* and *Plasmodium falciparum* by an incompletely known mechanism. Destroys late tissue forms of *P. vivax* and thus effects radical cure (prevents relapse).

**Dose:** 30 mg base PO daily x 14 d beginning immediately after leaving malarious area; screen for G6PD deficiency prior to providing; give with meal or with antacid to prevent or relieve gastric irritation

**Indication:** For gametocidal activity against all species of plasmodia that infect man; interrupts transmission of malaria; used to prevent relapse of *P. vivax* and *P. ovale* malarias and to prevent attacks after departure from areas where *P. vivax* and *P. ovale* malarias are endemic

**Contraindications:** G6PD deficiency; rheumatoid arthritis; SLE; hemolytic drugs, bone marrow depression; quinacrine; NADH methemoglobin reductase deficiency; pregnancy category C

**Adverse Effects:** Hematologic reactions to include acute hemolytic anemia if G6PD deficient (an inherited error of metabolism carried on the X chromosome, present in about 10% of American black males and certain ethnic groups: Sardinians, Sephardic Jews, Greeks, and Iranians; whites manifest more intense hemolytic reaction); early hemolytic reaction symptoms include darkening of urine, red-tinged urine, decrease in urine volume, chills, fever, precordial pain, cyanosis; leukocytosis, leukopenia, anemia, granulocytopenia, agranulocytosis; nausea, vomiting, epigastric distress, abdominal cramps; pruritus; methemoglobinemia (cyanosis); headache, confusion, mental depression; visual accommodation disturbances; hypertension, arrhythmias

**Interactions:** Increased toxicity of both quinacrine and primaquine

25. PSEUDOEPHEDRINE (SUDAFED)

**Class:** Autonomic nervous system agent–sympathomimetic; alpha/beta-adrenergic agonist, decongestant

**Action:** Sympathomimetic amine that, like ephedrine, produces decongestion of respiratory tract mucosa by stimulating the sympathetic nerve endings including alpha-, beta-1 and beta-2 receptors; unlike ephedrine, also acts directly on smooth muscle and constricts renal and vertebral arteries; has fewer adverse effects, less pressor action, and longer duration of effects than ephedrine

**Dose:** 30-60 mg PO q4–6h or 120 mg XR PO q12h

**Indications:** Symptomatic relief of nasal and eustachian tube congestion, rhinitis, and sinusitis

**Contraindications:** Sympathomimetic amine hypersensitivity; severe hypertension; coronary artery disease; MAOIs; glaucoma; hyperthyroidism; BPH; pregnancy category C

**Adverse Effects:** Stimulation, tremulousness, difficulty voiding; arrhythmias, palpitation, tachycardia; nervousness, dizziness, headache, sleeplessness, numbness; anorexia, dry mouth, nausea, vomiting

**Interactions:** Sympathomimetics and beta blockers increase pressor effects and toxicity; MAOIs may precipitate hypertensive crisis; decreases antihypertensive effects of guanethidine, methyldopa, reserpine
26. RANITIDINE (ZANTAC)

**Class:** GI agent – antisecretory H2-receptor antagonist

**Action:** Antihistamine with high selectivity for reversible competitive inhibition of histamine H2-receptors on parietal cells of the stomach (minimal effect on H1-receptors) and thus decreases gastric acid secretion, raises the pH of the stomach, and indirectly reduces pepsin secretion

**Dose:** 75-150 mg PO bid or 150-300 mg PO qhs; 50 mg IV/IM q6–8h

**Indications:** For treatment of duodenal/gastric ulcers and gastroesophageal reflux disease

**Contraindications:** Ranitidine hypersensitivity; acute porphyria; pregnancy category B

**Adverse Effects:** Headache, malaise, dizziness, somnolence, insomnia, vertigo, mental confusion, agitation, depression, hallucinations in older adults; bradycardia (with rapid IV push); constipation, nausea, abdominal pain, diarrhea; rash; reversible decrease in WBC count, thrombocytopenia

**Interactions:** May reduce absorption of cefpodoxime, cefuroxime, delavirdine, ketoconazole, itraconazole; long-term therapy may lead to vitamin B12 deficiency

27. TRIMETHOPRIM-SULFAMETHOXAZOLE (TMP-SMZ, BACTRIM, SEPTRA)

**Class:** Antimicrobial – antibacterial, sulfonamide

**Action:** Fixed combination of TMP and SMZ, synthetic folate antagonists and enzyme inhibitors that prevent bacterial synthesis of essential nucleic acids and proteins; effective against *Pneumocystis carinii* pneumonitis, *Shigellosis enteritis*, most strains of *Enterobacteriaceae*, *Nocardia, Legionella micdadei*, and *Legionella pneumophila*, and *Haemophilus ducreyi*

**Dose:** 160 mg TMP/800 mg SMZ (DS) PO bid

**Indication:** For cellulitis, pneumonitis, enteritis, severe complicated UTIs, acute otitis media, acute episodes of chronic bronchitis, prevention of traveler's diarrhea, cholera

**Contraindications:** TMP, SMZ, sulfonamide, or bisulfite hypersensitivity; group A beta-hemolytic streptococcal pharyngitis; megaloblastic anemia due to folate deficiency; use caution with severe allergy or bronchial asthma, G6PD deficiency, and sulfonamide derivative drug (acetazolamide, thiazides, tolbutamide) hypersensitivity; pregnancy category C

**Adverse Effects:** Rash, toxic epidermal necrolysis; nausea, vomiting, diarrhea, anorexia, hepatitis, pseudomembranous enterocolitis, stomatitis, glossitis, abdominal pain; kidney failure, oliguria, anuria, crystalluria; agranulocytosis, aplastic anemia, megaloblastic anemia, hypoprothrombinemia, thrombocytopenia; weakness, arthralgia, myalgia, photosensitivity, allergic myocarditis

**Interactions:** May effect and toxicity of oral anticoagulants and methotrexate
## 28. ZOLPIDEM (AMBIEN) - CONTROLLED SUBSTANCE: SCHEDULE IV

<table>
<thead>
<tr>
<th>Class:</th>
<th>CNS agent – non-benzodiazepine; anxiolytic, sedative-hypnotic</th>
</tr>
</thead>
<tbody>
<tr>
<td>Action:</td>
<td>Nonbenzodiazepine hypnotic that does not have muscle relaxant or anticonvulsant effects; preserves deep sleep (stages 3 and 4) at hypnotic doses</td>
</tr>
<tr>
<td>Dose:</td>
<td>5–10 mg PO qhs, limited to 7–10 days</td>
</tr>
<tr>
<td>Indications:</td>
<td>For short-term treatment of insomnia</td>
</tr>
<tr>
<td>Contraindications:</td>
<td>Pregnancy category B</td>
</tr>
<tr>
<td>Adverse Effects:</td>
<td>Headache on awakening, drowsiness or fatigue, lethargy, drugged feeling, depression, anxiety, irritability, dizziness, double vision; doses &gt;10 mg may be associated with anterograde amnesia or memory impairment; dyspepsia, nausea, vomiting; myalgia</td>
</tr>
<tr>
<td>Interactions:</td>
<td>CNS depressants, alcohol, and phenothiazines augment CNS depression; food significantly decreases extent and rate of absorption, do NOT give with or immediately after a meal</td>
</tr>
</tbody>
</table>
SECTION THREE

RMED

PHARMACOLOGY

SECTION III

“FAMILIAR”
### PHARMACOLOGY SECTION III: “FAMILIAR”

<table>
<thead>
<tr>
<th>No.</th>
<th>Drug Name</th>
<th>Dose/Dosage Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.</td>
<td>AZITHROMYCIN (ZITHROMAX)</td>
<td>500 mg PO on day 1, then 250 mg qd x 4 days</td>
</tr>
<tr>
<td>2.</td>
<td>CELECOXIB (CELEBREX)</td>
<td>100–200 mg PO qd-bid</td>
</tr>
<tr>
<td>3.</td>
<td>CHLORPHENIRAMINE</td>
<td>2–4 mg PO tid-qid or 8–12 mg PO bid-tid</td>
</tr>
<tr>
<td>4.</td>
<td>CIPROFLOXACIN (CIPRO)</td>
<td>250-750 mg PO bid or 200-400 mg IV q8-12h</td>
</tr>
<tr>
<td>5.</td>
<td>CYCLOBENZAPRINE (FLEXERIL)</td>
<td>5–10 mg PO tid</td>
</tr>
<tr>
<td>6.</td>
<td>DICLOFENAC (VOLTAREN)</td>
<td>25-75mg PO bid-tid</td>
</tr>
<tr>
<td>7.</td>
<td>DOCUSATE (COLACE)</td>
<td>50–500 mg/day PO divided qd-qid</td>
</tr>
<tr>
<td>8.</td>
<td>HYDROCODONE (VICODIN w/ TYLENOL)</td>
<td>5–10 mg PO q4–6h</td>
</tr>
<tr>
<td>9.</td>
<td>KETOCONAZOLE (NIZORAL)</td>
<td>Topically, AAA qd-bid; 200–400 mg PO daily</td>
</tr>
<tr>
<td>10.</td>
<td>METHOCARBAMOL (ROBAXIN)</td>
<td>1.5 g PO qid x 2-3 d</td>
</tr>
<tr>
<td>11.</td>
<td>M ethylprednisolone (SOLU-MEDROL)</td>
<td>2–60 mg/d PO; 4–80 mg/wk IM; 10–250 mg IV</td>
</tr>
<tr>
<td>12.</td>
<td>METRONIDAZOLE (FLAGYL, METROGEL)</td>
<td>250 mg PO tid x 5-7 d; topically AAA bid</td>
</tr>
<tr>
<td>13.</td>
<td>MUPIROCIN (BACTROBAN)</td>
<td>topically AAA tid-qid</td>
</tr>
<tr>
<td>14.</td>
<td>NAPHAZOLINE (CLEAR EYES)</td>
<td>1 drop in each eye qid</td>
</tr>
<tr>
<td>15.</td>
<td>NAPROXEN (NAPROSYN)</td>
<td>250–500 mg PO bid (max: 1000 mg/d)</td>
</tr>
<tr>
<td>16.</td>
<td>OMEPRAZOLE (PRILOSEC)</td>
<td>20 mg PO qd</td>
</tr>
<tr>
<td>17.</td>
<td>OXYCODONE</td>
<td>5–10 mg PO q6h</td>
</tr>
<tr>
<td>18.</td>
<td>RABEPRAZOLE (ACIPHEX)</td>
<td>20 mg PO qd</td>
</tr>
<tr>
<td>19.</td>
<td>SCOPOLAMINE (TRANSDERM-SCOP)</td>
<td>transdermal patch behind ear 12 h before travel</td>
</tr>
<tr>
<td>20.</td>
<td>TERBINAFINE (LAMISIL)</td>
<td>Topically AAA qd-bid; 250 mg PO qd</td>
</tr>
<tr>
<td>21.</td>
<td>TINIDAZOLE (TINDAMAX)</td>
<td>2 g PO qd</td>
</tr>
<tr>
<td>22.</td>
<td>TRAMADOL (ULTRAM)</td>
<td>50–100mg PO q4–6h prn (max: 400 mg/d)</td>
</tr>
</tbody>
</table>
1. AZITHROMYCIN (ZITHROMAX)

**Class:** Antimicrobial – antibiotic; macrolide

**Action:** Reversibly binds to 50S ribosomal subunit of susceptible organisms inhibiting protein synthesis; effective against mild to moderate infections caused by pyogenic streptococci, *Streptococcus pneumoniae*, *Haemophilus influenzae*, *Mycobacterium avium-intracellulare*, and *Staphylococcus aureus*

**Dose:** For most bacterial infections, 500 mg PO on day 1, then 250 mg qd x 4 days; for acute bacterial sinusitis, 500 mg qd x 3 days; for gonorrhea, 2 g PO as single dose

**Indications:** For pneumonia, lower respiratory tract infections, pharyngitis, tonsillitis, gonorrhea, nongonococcal urethritis, skin infections, otitis media, and acute bacterial sinusitis

**Contraindications:** Macrolide hypersensitivity; pregnancy category B

**Adverse Effects:** Headache, dizziness; nausea, vomiting, diarrhea, abdominal pain; hepatotoxicity

**Interactions:** Antacids may decrease peak level; may increase toxicity of ergotamine; food will decrease the amount of azithromycin absorbed by 50%

2. CELECOXIB (CELEBREX)

**Class:** CNS agent – COX-2 inhibitor; NSAID, anti-inflammatory, analgesic, antipyretic

**Action:** Inhibits prostaglandin synthesis by inhibiting cyclooxygenase-2 (COX-2); does not inhibit cyclooxygenase-1 (COX-1); reduces pain of rheumatoid and osteoarthritis

**Dose:** 100–200 mg PO qd-bid

**Indications:** For mild to moderate pain management, also used for osteoarthritis and rheumatoid arthritis

**Contraindications:** Celecoxib hypersensitivity; severe hepatic impairment; asthmatic patients with aspirin triad; advanced renal disease; concurrent use of diuretics and ACE inhibitors; anemia; pregnancy category C (D in 3rd trimester)

**Adverse Effects:** Back pain, peripheral edema; abdominal pain, diarrhea, dyspepsia, flatulence, nausea; dizziness, headache, insomnia; pharyngitis, rhinitis, sinusitis, rash

**Interactions:** May decrease effectiveness of ACE inhibitors; fluconazole and lithium increases concentrations; may increase INR with warfarin
3. CHLORPHENIRAMINE (+ SUDAFED = DECONAMINE)

**Class:** ENT agent – H₁-receptor antagonist, antihistamine

**Dose:** 2–4 mg PO tid-qid or 8–12 mg PO bid-tid (max: 24 mg/d)

**Actions:** Competes with histamine for H₁-receptor sites on effector cells; promotes capillary permeability, edema formation, and constrictive action on respiratory, gastrointestinal, and vascular smooth muscles

**Indications:** For symptomatic relief of uncomplicated allergic conditions, to prevent transfusion and drug reactions in susceptible patients, and as an adjunct to epinephrine and other standard measures in anaphylactic reactions

**Contraindications:** Antihistamine hypersensitivity, lower respiratory tract symptoms, narrow-angle glaucoma, obstructive prostatic hypertrophy or other bladder neck obstruction, GI obstruction or stenosis, MAOIs; pregnancy category B (D in 3rd trimester)

**Adverse Effects:** Sensation of chest tightness, palpitations, tachycardia, mild hypo- or hypertension; epigastric distress, anorexia, nausea, vomiting, constipation, diarrhea; drowsiness, sedation, headache, dizziness, vertigo, fatigue, disturbed coordination, tremors, euphoria, nervousness, restlessness, insomnia; dryness of mouth, nose, and throat; tinnitus, vertigo, acute labyrinthitis, thickened bronchial secretions, blurred vision, diplopia; urinary frequency or retention, dysuria.

**Interactions:** Alcohol and other CNS depressants produce additive sedation and CNS depression

4. CIPROFLOXACIN (CIPRO)

**Class:** Antimicrobial – antibiotic; quinolone

**Action:** Synthetic broad spectrum bactericidal agent; inhibits DNA-gyrase, an enzyme necessary for bacterial DNA replication, transcription, repair, recombination, and transposition; effective against many gram-positive and gram-negative organisms including *Citrobacter diversus, Enterobacter cloacae, Enterobacter aerogenes, Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, Neisseria gonorrhoeae, Proteus mirabilis, Proteus vulgaris, Pseudomonas aeruginosa, Serratia marcescens, Staphylococcus aureus, Streptococcus pyogenes, Staphylococcus aureus, Shigella, and Salmonella*; less active against gram-positive than gram-negative bacteria, although active against many gram-positive aerobic bacteria, including penicillinase-producing, non-penicillinase-producing, and methicillin-resistant *Staphylococci*; however, many strains of *Streptococci* are relatively resistant; inactive against most anaerobic bacteria; resistant to some strains of methicillin-resistant *Staphylococcus aureus* (MRSA)

**Dose:** 250-750 mg PO bid or 200-400 mg IV q8-12h

**Indications:** For infections of the lower respiratory tract, skin and skin structures, bone and joints, GI tract, urinary tract, prostate; also used for nosocomial pneumonia, acute sinusitis, and post-exposure prophylaxis for anthrax

**Contraindications:** Quinolone hypersensitivity; syphilis, viral infection; tendon inflammation or tendon pain; pregnancy category C

**Adverse Effects:** Nausea, vomiting, diarrhea, cramps, gas, pseudomembranous colitis; tendon rupture; headache, vertigo, malaise, peripheral neuropathy, seizures

**Interactions:** May increase theophylline levels; antacids, sulcralfate, iron decrease absorption; may increase PT for patients on warfarin; may cause false positive on opiate screening tests
5. CYCLOBENZAPRINE (FLEXERIL)

**Class:** Autonomic nervous system agent – central acting; skeletal muscle relaxant

**Action:** Structurally and pharmacologically related to TCAs; relieves skeletal muscle spasm of local origin without interfering with muscle function; believed to act primarily within CNS at brainstem with some action at spinal cord level; depresses tonic somatic motor activity, although both gamma and alpha motor neurons are affected; increases circulating norepinephrine by blocking synaptic reuptake, thus producing antidepressant effect; has sedative effect and potent central and peripheral anticholinergic activity

**Dose:** 5–10 mg PO tid prn muscle spasm (max: 60 mg/d); do not use longer than 2-3 wks

**Indications:** As adjunct to rest and physical therapy for short-term relief of muscle spasm associated with acute musculoskeletal conditions

**Contraindications:** Recovery phase of MI; cardiac arrhythmias, heart block or conduction disturbances; CHF, hyperthyroidism; pregnancy category B

**Adverse Effects:** Tongue and face edema, sweating, myalgia, hepatitis, alopecia; toxic potential of TCAs; tachycardia, syncope, palpitation, vasodilation, chest pain, orthostatic hypotension, dyspnea; arrhythmias; dry mouth, indigestion, unpleasant taste, coated or discolored tongue, vomiting, anorexia, abdominal pain, flatulence, diarrhea, paralytic ileus; drowsiness, dizziness, weakness, fatigue, asthenia, paresthesias, tremors, muscle twitching, insomnia, euphoria, disorientation, mania, ataxia; pruritus, urticaria, rash; increased or decreased libido, impotence

**Interactions:** Alcohol, barbiturates, other CNS depressants enhance CNS depression; potentiates anticholinergic effect of phenothiazine and other anticholinergics; MAOIs may precipitate hypertensive crisis

6. DICLOFENAC (VOLTAREN)

**Class:** CNS Agent – NSAID, anti-inflammatory, analgesic, antipyretic,

**Action:** Potent inhibitor of cyclooxygenase, decreases prostaglandin synthesis

**Dose:** 25-75mg PO bid-tid

**Indications:** For mild to moderate pain management, reduction of fever, and for symptomatic relief of rheumatoid arthritis, osteoarthritis, acute gout, bursitis, myalgias, sciatica, tendonitis, acute soft tissue injuries including sprains and strains, headache, migraines, dental and other minor surgical pain, photophobia associated with refractive surgery

**Contraindications:** NSAID or aspirin hypersensitivity, NSAID or aspirin induced asthma, urticaria, angioedema, bronchospasm, severe rhinitis, or shock; pregnancy category B

**Adverse Effects:** Dizziness, headache, drowsiness; tinnitus; rash, pruritus; dyspepsia, nausea, vomiting, abdominal pain, cramps, constipation, diarrhea, indigestion, abdominal distension, flatulence, peptic ulcer; increased LFTs; fluid retention, hypertension, CHF; asthma; back, leg, or joint pain; hyperglycemia; prolonged bleeding time, inhibits platelet aggregation

**Interactions:** Increases cyclosporine-induced nephrotoxicity; increases methotrexate, lithium, and digoxin levels and toxicity; may decrease BP-lowering effects of diuretics; herbals (feverfew, garlic, ginger, ginkgo) may increase risk of bleeding
7. DOCUSATE (COLACE)

Class: GI agent – stool softener

Action: Anionic surface-active agent with emulsifying and wetting properties; detergent action lowers surface tension, permitting water and fats to penetrate and soften stools for easier passage

Dose: 50–500 mg/day PO divided qd-qid

Indications: For treatment of constipation associated with hard and dry stools, also used prophylactically in patients taking narcotics or patients who should avoid straining during defecation

Contraindications: Atonic constipation, nausea, vomiting, abdominal pain, fecal impaction, structural anomalies of colon and rectum, intestinal obstruction or perforation; patients on sodium restriction or with renal dysfunction; concomitant use of mineral oil; pregnancy category C

Adverse Effects: Mild abdominal cramps, diarrhea, nausea, bitter taste; rash

Interactions: Increases systemic absorption of mineral oil

8. HYDROCODONE (VICODIN w/ TYLENOL) - CONTROLLED SUBSTANCE: SCHEDULE III

Class: CNS agent – narcotic (opiate) agonist; analgesic; antitussive

Action: Morphine derivative similar to codeine but more addicting and with slightly greater antitussive and analgesic effect; CNS depressant with moderate to severe relief of pain; suppresses cough reflex by direct action on cough center in medulla

Dose: 5–10 mg PO q4–6h prn (max: 15 mg/dose); common ingredient in a variety of proprietary mixtures, only available in the US as combination with other drugs

Indications: For moderate to severe pain management, and for hyperactive or nonproductive cough

Contraindications: Opiate hypersensitivity; pregnancy category C

Adverse Effects: Dry mouth, constipation, nausea, vomiting; light-headedness, sedation, dizziness, drowsiness, euphoria, dysphoria; respiratory depression; urticaria, rash, pruritus

Interactions: Alcohol, CNS depressants, and herbal (St. John's wort) increases CNS depression
9. KETOCONAZOLE (NIZORAL)

Class: Antimicrobial – antibiotic; imidazole antifungal

Action: Broad-spectrum antifungal that interferes with synthesis of ergosterol and results in an increase in cell membrane permeability; fungistatic, but may be fungicidal in high concentrations

Dose: Topically, AAA qd-bid; 200–400 mg PO qd (monitor baseline LFTs, repeat at least monthly)

Indications: Oral form for systemic fungal infections including candidiasis, oral thrush, histoplasmosis, coccidioidomycosis, paracoccidioidomycosis, blastomycosis, and chromomycosis; topical form for tinea corporis and tinea cruris (*Epidermophyton floccosum, Trichophyton mentagrophytes, Trichophyton rubrum*) and and tinea versicolor (*Malassezia furfur*), seborrheic dermatitis

Contraindications: Ketoconazole hypersensitivity; alcoholism, fungal meningitis; onychomycosis; ocular administration; pregnancy category C

Adverse Effects: Rash, erythema, urticaria, pruritus, angioedema, anaphylaxis; nausea, vomiting, anorexia, epigastric or abdominal pain, constipation, diarrhea, fatal hepatic necrosis; gynecomastia; loss of libido, impotence, oligospermia, hair loss; acute hypoadrenalism, renal hypofunction

Interactions: Alcohol may cause sunburnlike reaction; antacids, anticholinergics, H2-receptor antagonists decrease absorption; isoniazid, rifampin increase metabolism and activity; levels of phenytoin and ketoconazole decreased; may increase cyclosporine and trazodone levels and toxicity; warfarin may potentiate hypoprothrombinemia; may increase levels of carbamazepine, cisapride, resulting in arrhythmias; may increase ergotamine toxicity; herbal echinacea may increase risk of hepatotoxicity

10. METHOCARBAMOL (ROBAXIN)

Class: Somatic nervous system agent – central-acting, skeletal muscle relaxant

Action: Exerts skeletal muscle relaxant action by depressing multisynaptic pathways in the spinal cord that control muscular spasm, and possibly by sedative effect; no direct action on skeletal muscles

Dose: 1.5 g PO qid x 2-3 d

Indications: For management of discomfort associated with acute musculoskeletal disorders as adjunct to physical therapy and other measures

Contraindications: Comatose; CNS depression; acidosis, kidney dysfunction; pregnancy category C

Adverse Effects: Fever, anaphylactic reaction, flushing, syncope, convulsions; urticaria, pruritus, rash, thrombophlebitis, pain, sloughing; conjunctivitis, blurred vision, nasal congestion; drowsiness, dizziness, light-headedness, headache; hypotension, bradycardia; nausea, metallic taste

Interactions: Alcohol and other CNS depressants enhance CNS depression
### 11. METHYLprednisolone (SOLU-MEDROL)

**Class:** Hormones and synthetic substitutes – adrenal corticosteroid, glucocorticoid, antiinflammatory

**Action:** Intermediate-acting synthetic steroid with less sodium and water retention effects than hydrocortisone; inhibits phagocytosis and release of allergic substances; modifies immune response to various stimuli; antiinflammatory and immunosuppressive

**Dose:** For inflammation, 2–60 mg/d PO; 4–80 mg/wk IM (Acetate) for 1–4 wk; 10–250 mg IV (Succinate) q6h; for acute spinal cord injury, 30 mg/kg IV over 15 min, followed in 45 min by 5.4 mg/kg/h x 23h

**Indications:** For management of acute and chronic inflammatory diseases, control of severe acute and chronic allergic processes, acute bronchial asthma, prevention of fat embolism in patient with long-bone fracture

**Contraindications:** Systemic fungal infections; pregnancy category C

**Adverse Effects:** Euphoria, headache, insomnia, confusion, psychosis; CHF, edema, nausea, vomiting, peptic ulcer; muscle weakness, delayed wound healing, muscle wasting, osteoporosis, aseptic necrosis of bone, spontaneous fractures; cushingoid features, growth suppression in children, carbohydrate intolerance, hyperglycemia; cataracts; leukocytosis; hypokalemia

**Interactions:** Amphotericin B, furosemide, thiazide diuretics increase potassium loss; may enhance virus replication or increase attenuated virus vaccine adverse effects; isoniazid, phenytoin, phenobarbital, rifampin increase metabolism and decrease effectiveness

### 12. Metronidazole (FLAGYL, METROGEL)

**Class:** Antimicrobial – antibiotic, antitrichomonal, amebicide

**Action:** Synthetic compound with direct trichomonacidal, amebicidal, and antibacterial activity (anaerobic bacteria and some gram-negative bacteria); effective against *Trichomonas vaginalis, Entamoeba histolytica, Giardia lamblia*, obligate anaerobic bacteria, gram-negative anaerobic bacilli, and *Clostridia*; microaerophilic *Streptococci* and most aerobic bacteria are resistant

**Dose:** For giardia 250 mg PO tid x 5-7 d; for amebiasis 500–750 mg PO tid; for pseudomembranous colitis, 250–500 mg PO tid-qid; for trichomoniasis, 2 g PO once; for rosacea, topically AAA bid

**Indications:** For giardiasis, trichomoniasis, amebiasis, and amebic liver abscess; topical for rosacea

**Contraindications:** Blood dyscrasias; active CNS disease; pregnancy category B

**Adverse Effects:** hypersensitivity (rash, urticaria, pruritus, flushing), fever, fleeting joint pains, *Candida* overgrowth; vertigo, headache, ataxia, confusion, irritability, depression, restlessness, weakness, fatigue, drowsiness, insomnia, paresthesias, sensory neuropathy; nausea, vomiting, anorexia, epigastric distress, abdominal cramps, diarrhea, constipation, dry mouth, metallic or bitter taste, proctitis; polyuria, dysuria, pyuria, incontinence, cystitis, decreased libido, nasal congestion; ECG changes (flattening of T wave)

**Interactions:** Oral anticoagulants potentiate hypoprothrombinemia; alcohol and solutions of citalopram, ritonavir, lopinavir, and IV formulations of sulfamethoxazole, trimethoprim, nitroglycerin may elicit disulfiram reaction due to the alcohol content; disulfiram causes acute psychosis; phenobarbital increases metabolism; may increase lithium levels; fluorouracil, azathioprine may cause transient neutropenia
13. MUPIROCIN (BACTROBAN)

**Class:** Antimicrobial – antibiotic; pseudomonic acid

**Action:** Topical antibacterial produced by fermentation of *Pseudomonas fluorescens*; inhibits protein synthesis by binding with bacterial transfer-RNA; effective against *Staphylococcus aureus* [including methicillin-resistant (MRSA) and beta-lactamase-producing strains], *Staphylococcus epidermidis, Staphylococcus saprophyticus,* and *Streptococcus pyogenes*

**Dose:** Topically AAA tid-qid x 1-2 wks

**Indications:** For impetigo or nasal carriage due to *Staphylococcus aureus*, beta-hemolytic Streptococci, and *Streptococcus pyogenes*; superficial skin infections

**Contraindications:** Hypersensitivity to any of its components; pregnancy category B

**Adverse Effects:** Burning, stinging, pain, pruritus, rash, erythema, dry skin, tenderness, swelling; intranasal, local stinging, soreness, dry skin, pruritus

**Interactions:** Incompatible with salicylic acid 2%; do not mix in hydrophilic vehicles or coal tar solutions; chloramphenicol may interfere with bactericidal action

14. NAPHAZOLINE (NAPHCON, VASOCON, CLEAR EYES)

**Class:** Autonomic nervous system agent – sympathomimetic, alpha-adrenergic agonist, vasoconstrictor, decongestant

**Action:** Direct-acting imidazoline derivative with marked alpha-adrenergic activity; systemic absorption may cause CNS depression rather than stimulation; produces rapid and prolonged vasoconstriction of arterioles, decreasing fluid exudation and mucosal engorgement

**Dose:** 1 drop in each eye qid prn for up to 4 days

**Indications:** For ocular vasoconstriction and decongestion

**Contraindications:** Narrow-angle glaucoma; MAOIs, TCAs; pregnancy category C

**Adverse Effects:** Hypersensitivity reactions, headache, nausea, weakness, sweating, drowsiness, hypothermia, coma; hypertension, bradycardia, shock-like hypotension; increased IOP, rebound congestion and chemical rhinitis with frequent and continued use

**Interactions:** TCAs and maprotiline may potentiate pressor effects
15. NAPROXEN (NAPROSYN)

Class: CNS agent – NSAID; anti-inflammatory, analgesic, antipyretic

Action: Propionic acid derivative with properties similar to ibuprofen; inhibits prostaglandin synthesis and platelet aggregation; prolongs bleeding time

Dose: 250–500 mg PO bid (max: 1000 mg/d)

Indications: For mild to moderate pain management and symptomatic treatment of acute and chronic arthritis

Contraindications: peptic ulcer; history of asthma, rhinitis, urticaria, bronchospasm, or shock precipitated by aspirin or other NSAIDs; pregnancy category B

Adverse Effects: Headache, drowsiness, dizziness, lightheadedness, depression; palpitation, dyspnea, peripheral edema, CHF, tachycardia; blurred vision, tinnitus, hearing loss; anorexia, heartburn, indigestion, nausea, vomiting, thirst, GI bleeding, elevated LFTs; thrombocytopenia, leukopenia, eosinophilia, pruritus, rash, ecchymosis; nephrotoxicity; pulmonary edema

Interactions: Herbals (feverfew, garlic, ginger, ginkgo) may increase bleeding

16. OMEPRAZOLE (PRILOSEC)

Class: GI agent – proton pump inhibitor (PPI)

Action: Antisecretory compound that is a gastric acid pump inhibitor; suppresses gastric acid secretion by inhibiting the H⁺, K⁺-ATPase enzyme system [the acid (proton H⁺) pump] in the parietal cells which relieves gastrointestinal distress and promotes ulcer healing

Dose: 20 mg PO qd x 4–8 wk

Indications: For treatment of duodenal and gastric ulcers, gastroesophageal reflux disease, and erosive esophagitis; used in combination with clarithromycin and metronidazole to treat duodenal ulcers associated with Helicobacter pylori

Contraindications: PPI hypersensitivity, GI bleeding, pregnancy category C

Adverse Effects: Headache, dizziness, fatigue; diarrhea, abdominal pain, nausea; hematuria, proteinuria; rash

Interactions: May increase diazepam, phenytoin, and warfarin levels
17. **OXYCODONE - CONTROLLED SUBSTANCE: SCHEDULE II**

**Class:** CNS agent – narcotic (opiate) agonist; analgesic

**Action:** Opium alkaloid semisynthetic derivative with action and potency similar to morphine; binds with stereo-specific receptors in various sites of CNS altering both pain perception and emotional response

**Dose:** 5–10 mg PO q6h prn

**Indications:** For moderate to moderately severe pain management; more effective in acute than chronic pain; used for bursitis, dislocations, simple fractures, other injuries, neuralgia, and postoperative pain

**Contraindications:** Oxycodone hypersensitivity; pregnancy category B (D for prolonged use or high dose use at term)

**Adverse Effects:** Euphoria, dysphoria, light-headedness, dizziness, sedation, anorexia, nausea, vomiting, constipation, jaundice; shortness of breath, respiratory depression; pruritus, rash; bradycardia; unusual bleeding or bruising; dysuria, urinary frequency and retention

**Interactions:** Alcohol, CNS depressants, and herbal (St. John's wort) add to CNS depressant activity

18. **RABEPRAZOLE (ACIPHEX)**

**Class:** GI agent – proton pump inhibitor (PPI)

**Action:** Gastric PPI that specifically suppresses gastric acid secretion by inhibiting the H⁺, K⁺-ATPase enzyme system (the acid [proton H⁺] pump) in the parietal cells of the stomach; does not exhibit H₂-histamine receptor antagonist properties

**Dose:** 20 mg PO qd

**Indications:** For healing and maintenance of erosive or ulcerative gastroesophageal reflux disease (GERD), duodenal ulcers, and hypersecretory conditions

**Contraindications:** PPI hypersensitivity; pregnancy category B

**Adverse Effects:** Headache; Stevens-Johnson syndrome, toxic epidermal necrolysis, erythema multiforme

**Interactions:** May decrease absorption of ketoconazole; may increase digoxin levels
19. **SCOPOLAMINE (TRANSDERM-SCOP)**

**Class:** Autonomic nervous system agent – parasympatholytic; anticholinergic, antimuscarinic, antispasmodic

**Action:** Alkaloid of belladonna with peripheral action resembling those of atropine, but in contrast, produces CNS depression with marked sedative and tranquilizing effects for use in anesthesia; potent mydriatic and cycloplegic action inhibiting secretions of salivary, bronchial, and sweat glands with less prominent effect on heart, intestines, and bronchial muscles

**Dose:** For motion sickness, 0.25–0.6 mg PO 1 h before travel or topical transdermal disc patch applied to dry surface behind ear q72h starting 12 h before travel; for ophthalmic refraction 1–2 drops in eye 1 h prior; for pre-anesthesia PO 0.5-1 mg PO or 0.3-0.6 mg IM/SC/IV

**Indications:** Prophylactic agent for motion sickness; used as mydriatic and cycloplegic in ophthalmology; preanesthetic agent to control bronchial, nasal, pharyngeal and salivary secretions; control of spasticity and drooling in paralytic and spastic states

**Contraindications:** Anticholinergic, belladonna, or barbiturate hypersensitivity; asthma; hepatitis; narrow angle glaucoma; GI or GU obstructive diseases; myasthenia gravis; pregnancy category C

**Adverse Effects:** Fatigue, dizziness, drowsiness, disorientation, restlessness, hallucinations, toxic psychosis; dry mouth and throat, constipation; urinary retention; decreased heart rate; dilated pupils, photophobia, blurred vision, follicular conjunctivitis; depressed respiration; local irritation, rash

**Interactions:** Amantadine, antihistamines, TCAs, quinidine, disopyramide, procainamide add to anticholinergic effects; decreases levodopa effects; methotrimeprazine may precipitate extrapyramidal effects; decreases absorption and antipsychotic effects of phenothiazines

---

20. **TERBINAFINE (LAMISIL)**

**Class:** Antimicrobial – antibiotic; antifungal

**Action:** Inhibits sterol biosynthesis in fungi; ergosterol, the principal sterol in the fungal cell membrane, becomes depleted and interferes with cell membrane function, thus producing antifungalidal effect

**Dose:** For tinea pedis, tinea cruris, and tinea corporis, topically AAA qd-bid x 1-7 wks; for onychomycosis, 250 mg PO qd x 6 wks for fingernails 12 wks for toenails (monitor baseline LFTs, repeat at least monthly)

**Indications:** For topical treatment of superficial mycoses such as interdigital tinea pedis, tinea cruris, and tinea corporis due to *Epidermophyton floccosum, Trichophyton mentagrophytes*, or *T. rubrum*; for oral treatment of onychomycosis due to tinea unguium

**Contraindications:** Terbinafine hypersensitivity; pregnancy category B

**Adverse Effects:** Pruritus, local burning, dryness, rash, vesiculation, redness, contact dermatitis at application site; headache; diarrhea, dyspepsia, abdominal pain, neutropenia; taste disturbances

**Interactions:** May increase theophylline levels; may decrease cyclosporine and rifampin levels
21. TINIDAZOLE (TINDAMAX)

**Class:** Antimicrobial – azole antibiotic; antiprotozoal amebicide

**Action:** Made from cell extracts of *Trichomonas*, the free radicals generated may be responsible for antiprotozoal activity; effective against *Trichomonas vaginalis*, *Giardia duodenalis*, *Entamoeba histolytica*

**Dose:** Giardiasis 2 g PO x 1 dose or Amebiasis/Amebic liver abscess 2 g PO qd x 3-5d, take with food

**Indications:** For treatment of protozoa infections (giardiasis, amebiasis, amebic liver abscess, trichomoniasis)

**Contraindications:** azole antibiotic hypersensitivity; pregnancy category D (1st trimester) and C (2nd/3rd)

**Adverse Effects:** Weakness, fatigue, malaise; dizziness, headache; metallic/bitter taste, nausea, anorexia, dyspepsia, cramps, epigastric discomfort, vomiting, constipation

**Interactions:** May increase INR with warfarin; alcohol may cause abdominal cramps, nausea, vomiting, headache, flushing; psychotic reactions with disulfiram; may increase half-life of phenytoin; may increase level and toxicity of lithium, fluorouracil, cyclosporine, tacrolimus; cholestyramine may reduce absorption

22. TRAMADOL (ULTRAM)

**Class:** CNS agent – narcotic (opiate) agonist; analgesic

**Action:** Centrally acting opiate receptor agonist that inhibits uptake of norepinephrine and serotonin, suggesting both opioid and nonopioid mechanisms of pain relief; may produce opioid-like effects, but causes less respiratory depression than morphine

**Dose:** 50–100mg PO q4–6h prn (max: 400 mg/d); may start with 25 mg/d if not well tolerated, and increase by 25 mg q3d up to 200 mg/d

**Indications:** For management of moderate to moderately severe pain

**Contraindications:** Opioid analgesic or tramadol hypersensitivity; MAOIs; acute alcohol intoxication, hypnotics, centrally acting analgesics, opioids, psychotropics; substance abuse; pregnancy category C

**Adverse Effects:** Drowsiness, dizziness, vertigo, fatigue, headache, somnolence, restlessness, euphoria, confusion, anxiety, coordination disturbance, sleep disturbance, seizures; palpitations, vasodilatation; nausea, vomiting, diarrhea, constipation, xerostoma, dyspepsia, abdominal pain, anorexia, flatulence; sweating, anaphylaxis, withdrawal syndrome with abrupt discontinuation; rash; visual disturbances; urinary retention/frequency

**Interactions:** Carbamazepine significantly decreases levels; may increase adverse effects of MAOIs, TCAs, cyclobenzaprine, phenothiazines, SSRIs; MAOIs may enhance seizure risk; may increase CNS effects when used with other CNS depressants; herbal St. John's wort may increase sedation
SECTION FOUR

RMED
MEDICAL OPERATIONS
& PLANNING
SENIOR MEDIC DUTIES AND RESPONSIBILITIES

The senior medic is customarily known as a company senior medic, and he traditionally functions in the capacity of a squad leader. However, in the context of the Ranger Medic Handbook the senior medic duty description will be used to define the responsibilities of the highest ranking and most experienced medic present at any given location and time. This medic is designated as the “senior medic” at that specific location and thus is responsible for the duties and responsibilities as listed below.

- Principal medical advisor to the commander and senior enlisted advisor
- Provide and supervise advanced trauma management within protocols and sick call within scope-of-practice
- Lead, supervise, and train junior medics
  - Individual training
  - Health and welfare
  - Development and counseling
  - Troop leading procedures and pre-combat inspections (PCIs)
- Plan, supervise, and conduct casualty response training for Rangers and Leaders
  - Ranger First Responder (RFR)
  - Casualty Response Training for Ranger Leaders (CRTRL)
  - Opportunity Training / Spot-Checking
- Maintain company level medical equipment and supplies
  - Accountability / Inventory
  - Maintenance / Serviceability
  - PCI of Individual Ranger Bleeding Control Kits
  - PCI of Squad Casualty Response Kits
  - Requisition and Receive Class VIII (Medical Supplies) from appropriate source
- Plan, coordinate, and execute medical planning for company level operations
  - On-Target casualty response plan
  - CASEVAC from target to next higher medical capability
  - Task organization of company medics
- Conduct after action reviews and report and archive medical lessons learned
- Monitor the status of health in the unit / element
  - Physically Limiting Profiles
  - Command Health Report
  - MEDPROS Data Entry and Information Review
MEDICAL & CASUALTY RESPONSE PLANNING
PART 1: Initial Planning / WARNORD

1-A. MEDICAL THREAT ASSESSMENT
- AFMIC CD – Find Country / Area of Operations
  - Host Country (ISB / FSB)
  - Target Country
- Determine known health threats & risks
  - Diseases / Illnesses
  - Environmental threats (Plants, Animals, Climate, Terrain)
- Current Unit SRP Status
- Preventive Medicine Guidelines (what is required before, during, and after)
- Enemy weapons, munitions, and tactics, to include NBC?
- How ready is the unit if it encounters diseases / illnesses?
- What preparation is needed by the unit?
- Do Rangers need special preventive medicine items issued?

1-B. HIGHER MEDICAL GUIDELINES & REQUIREMENTS
- Chemoprophylaxis
  - Anti-Malarial Drugs
  - Other preventive measures
- Special SRP requirements
- WHO Traveler Advisory
- USSOCOM / USASOC / Theater guidelines
- Regiment / Battalion guidelines
- Do we need to change anything in the way we normally do business?

1-C. REQUESTS FOR INFORMATION (RFI)
- Request updates to AFMIC information
- Maps / Imagery
- Host Nation (ISB) Medical Capabilities
  - Hospitals / medical facilities
  - Nationwide medical training / competency
- Any information not covered in AFMIC-CD or higher guidelines
- Submit through medical, intelligence (S2), and/or operations (S3) channels
- Ask for more information for what you need to know

1-D. DETERMINE MEDICAL ASSETS
- Organic, Attached, Air, Ground, Theater, JTF, Host Nation, ISB, FSB, etc...
- CASEVAC / MEDEVAC Support
  - How many and what type?
  - Capabilities and Limitations?
  - Hoist and high angle extraction?
  - Medical Personnel and Equipment on board? Level of Training?
75th Ranger Regiment Trauma Management Team (Tactical)
Ranger Medic Handbook

- Determine nearest surgical capability
  + Where are your casualties being evacuated to?
  + What are the capabilities / limitations?
  + What is their MASCAL or overload for their system?
- Determine Staging Base area medical support
  + Can they provide labs, x-rays, medications, preventive medicine, etc?

1-E. FAMILIARIZATION WITH MEDICAL ASSETS
- Published References (Look it up!)
  + What is a CSH?
  + What is a FST?
  + What is an ASMC?
- Can you see their layout / equipment?
- Can you conduct familiarization training as required?
- What are their capabilities and limitations?
- Can you talk to them and what can they know about you and your mission?

PART 2: Tactical Operation Development

2-A. CASUALTY ESTIMATION
- Look at the target and the templated enemy positions
- Look at the commander’s assault plan
- Utilize Medical Course of Action Tool (MCOAT)
- Plan to take casualties during every phase of the operation (infiltration, assault, clear/secure, consolidate, defend, exfiltration).
  + Where do you foresee taking casualties?
  + Where is it most critical for the medics to be located?
  + Do you need to task organize your medical team?
  + Where does the unit need to establish CCP’s?
  + What evacuation methods need to be considered?
  + Where is the closest HLZ or AXP?
  + Where do you emplace and preposition medical assets/augmentation?
- Review Preventive Medicine issues and anticipate DNBI
  + What are the health threats?
  + What actions will prevent or decrease disease and non-battle injuries?

2-B. DETERMINE KEY LOCATIONS
- Based on your casualty estimation and the tactical assault plan…
  + Where should the CCP be located?
  + Where should patient exchanges be located? (CEP, CCP, HLZ, AXP)
  + Where are the projected blocking positions, fighting positions, etc…?
  + Where is the CP / TOC?
  + Who is in charge of each key location?
  + Primary and Alternate Locations?
  + What are the ground movement routes?
2-C. DETERMINE CASUALTY FLOW
- Point-of-Injury to Fixed Facility
- Where are your casualties being evacuated to?
  - Are you evacuating by ground or air to JCCP?
  - Are you evacuating by ground or air to an AXP/HLZ?
  - What are the distances and time of travel?
  - Can your patients make it that far? What needs to be corrected?
  - Who is evacuating your casualties?

EXAMPLE:

2-D. AIR CASEVAC PLAN
- What is the type of Air CASEVAC mission?
  - Dedicated – an air asset whose purpose after infiltration is casualty evacuation. It is outfitted and manned for casualty management
  - Designated – an air asset that will be the aircraft instructed to evacuate casualties. May be equipped for casualties if requested.
  - On-Call – air assets that are held in reserve or must be launched to respond to casualty evacuation. May also apply to MEDEVAC covering the area.
- Aircraft type?
- Maximum casualty load?
- How are casualties to be loaded?
  - Packaging requirements: Litters, Skedcos, etc.?
  - Is the aircraft equipped with litter stanchions?
  - Loading procedures? Approach procedures?
- What medical capability is on the aircraft?
  - Flight medic or medical officer?
  - Casualty management equipment?
  - Medical resupply bundles?
- Request Procedures?
  - Procedures for requesting CASEVAC?
  - 9-Line MEDEVAC request versus modified format?
  - Communication requirements?
- Launch Authority?
  - Who is the launch authority for the aircraft?
  - What are the impacts on Ranger CASEVAC operations?
- Landing requirements?
  - Special H LZ considerations?
  - Special markings required?
  - Special equipment required?
2-E. GROUND CASEVAC PLAN---TWO PHASES:
1. Actions required on the target.
2. Actions required for evacuation away from the target.
   □ How should Rangers move casualties on the target to the CCP?
     † Aid & Litter Teams
     † Skedco, Litter, etc…
     † Ranger Ground Mobility (Quad, GMV, RSOV)
   □ What is the type of Ground CASEVAC mission?
     † Dedicated – a ground asset whose purpose after infiltration is casualty evacuation. It is outfitted and manned for casualty management
     † Designated – a ground asset that will be the vehicles instructed to evacuate casualties. May be equipped for casualties if requested.
     † On-Call – ground assets that are held in reserve or must be launched to respond to casualty evacuation. This may be vehicles of opportunity (tactical or captured).
   □ Vehicle type and maximum casualty load?
   □ How are casualties to be loaded?
     † Packaging requirements: Litters, Skedcos, etc.? 
     † Is the vehicle equipped with a carrying configuration?
     † Loading procedures?
   □ What medical capability is on the vehicle?
     † Medics? Medical Officers?
     † Casualty management equipment?
   □ Request Procedures?
     † Procedures for requesting ground CASEVAC?
     † 9-Line MEDEVAC request versus modified format?
     † Communication requirements?
   □ Launch Authority?
     † Who is the launch authority for the vehicles?
   □ Link-up Requirements
     † At your CCP or an AXP?
     † Marking / signaling procedures?

2-F. COMMUNICATIONS REQUIREMENTS
 □ Do all medics have radios?
 □ Can a medic contact a higher care provider for guidance?
 □ Types of radios / COMSEC?
 □ Medical Command & Control Delineation
 □ Callsigns / Frequencies / SOI
 □ Evacuation request frequencies?
 □ Evacuation asset frequencies?
 □ Casualty reporting/accountability?
 □ Re-Supply requests

2-G. CLASS VIII RE-SUPPLY REQUIREMENTS & METHODS
 □ How do you request re-supply?
 □ What are the re-supply methods?
PART 3: Coordination & Synchronization

3-A. PLANNING INTERACTION (WHO TO TALK & COORDINATE WITH)
- Commander & Operations Officer (Tactical Plan)
- Executive Officer (Support & Resources)
- First Sergeant (CCP Operations, Manifests, Aid & Litter Teams)
- Battalion Medical Planner (Medical Aspects)
- Platoon Sergeants (Squad Casualty Response & CCPs)
- Junior Medics (Understanding of the Plan)
- Battalion Staff Planners
  - S1 Personnel (Casualty Tracking and Accountability)
  - S2 Intel (Health Threat/Intelligence Information)
  - S3 Air (Air CASEVAC Operations)
  - S4 Logistics (Ground CASEVAC & Re-Supply)
  - S6 Commo (Radios, Freqs, Callsigns)

PART 4: Briefs, Rehearsals, and Inspections

4-A. MEDICAL & CASUALTY RESPONSE OPORD BRIEFING AGENDA
- Health Threat
- Casualty Response Concept of the Operation
- Casualty Flow
- Key Locations (CCPs, HLZs, AXPs, etc)
- Requesting Procedures (CASEVAC, MEDEVAC, Assistance, Re-Supply)
- Medic callsigns / frequencies
- Casualty Accountability

4-B. BACK-BRIEF WITH JUNIOR MEDICS
- Ensure junior medics understand tactical plan AND casualty response plan
- Understand packaging requirements
- Understand casualty marking procedures
- Understand communications methods

4-C. REHEARSALS
- RFR Drills
- Squad Casualty Response Drills (care under fire, CASEVAC request/loading)
- Aid & Litter Team Drills
- CCP Operations (Assembly, security & movement, casualty movement, CCP
markings, vehicle parking, link-up procedures, casualty tracking & recording, triage, treatment and management of casualties)

☐ Evacuation Request and Loading Procedures
☐ COMMEX
☐ Casualty Tracking / Accountability

4-D. PRE-COMBAT INSPECTIONS

☐ Individual Rangers
  ✦ Bleeding Control Kits (BCKs)
  ✦ Preventive Medicine (Iodine Tabs, Doxycycline, Diamox, etc…)

☐ Squad Casualty Response Kit
  ✦ Fire Team IV Kit
  ✦ RFR Bags
  ✦ Evacuation Equipment (Skedco, Litters, etc…)
  ✦ Vehicle mounted aidbags

☐ RMED Aidbags (Pack and/or reconfigure as required)
  ✦ Select appropriate aidbag system per mission requirements
  ✦ Ensure packing list IAW recommended DOS stockage

☐ Re-Supply Packages (Pack and/or reconfigure per mission requirements)
  ✦ Reconfigure per mission specifics (ground, air, etc…)
  ✦ Utilize speedballs, bundles, or pull-off configured as required
  ✦ Pre-position as required with aircraft and vehicles or at staging base with BLOC and logistics teams

☐ RMED Individual Equipment (weapon, NVG, radio, packing list, mission specific)

☐ Evacuation Assets (Quads, Vehicles, etc…)

PART 5: After Action Review in Training or Combat

☐ Was the mission executed as planned?
☐ What went right?
☐ What went wrong?
☐ What could have been done better?
☐ What could be fixed by planning / preparation?
☐ What could be fixed by training?
☐ What could be fixed by equipment modification?
☐ Identify and record Sustains & Improves by Phase of the Operation.
CASUALTY COLLECTION POINT (CCP) OPERATIONS

PART 1: Duties and Responsibilities

COMPANY MEDICS

- **Planning Phase**
  - Provide recommendations and advise to leadership on medical support
  - Medical Support Planning by phase of the operation
  - Casualty Response & Evacuation Plan by phase of the operation
  - Recommend to the Unit Leadership & Coordinate as required:
    - CCP Locations by phase
    - Medical Task Organization & Distribution
    - Ground (on the target) Evacuation Plan & Assets
    - Air/Ground (off the target) Evacuation Plan & Assets
    - CCP, HLZ, and Evacuation Asset Security
  - Pre-Combat Inspections of Junior Medics, Squad Casualty Response Kits, and Individual Ranger BCK/RFR Tasks

- **Execution Phase**
  - Triage, Treatment, Monitoring, and Packaging
  - Delegation of Treatment
  - Request Assistance from other medical or unit assets
  - Provide guidance and recommendations to leadership on casualty management & evacuation

BATTALION MEDICAL PERSONNEL & MEDICAL PLANNERS

- **Planning Phase**
  - Provide recommendations and advise to leadership on medical support
  - Recommend to the Unit Leadership & Coordinate as required:
    - CCP Locations of subordinate units by phase
    - Medical Task Organization & Distribution
    - Ground (on the target) Evacuation Plan & Assets for all targets
    - Air/Ground (off the target) Evacuation Plan & Assets for all targets
    - CCP, HLZ, and Evacuation Asset Security for all targets
  - Augmentation requirements of subordinate units
  - Link-in with tactical operations

- **Execution Phase**
  - Triage, Treatment, Monitoring, and Packaging
  - Delegation of Treatment
  - Request Assistance from other medical or platoon assets
  - Provide guidance and recommendations to leadership on casualty management
UNIT LEADERSHIP

Planning Phase

- Evacuation Plan by phase of the operation
- CCP locations, HLZ/AXP locations,
- Security of CCP, Security of HLZ/AXP
- Allocate Aid & Litter teams and carry evacuation equipment
- Accountability / Reporting Plan
- Distribution/Task Organization of Medical Personnel
- Pre-Combat Inspections of Junior Medics, Squad Casualty Response Kits, and Individual Ranger BCK/RFR Tasks
- Conduct Casualty Response Rehearsals

Execution Phase

- Establish and Secure CCP
- Provide assistance to medics with EMT augmentation and directing aid & litter teams
- Gather and Distribute casualty equipment and sensitive items
- Accountability and Reporting to Higher
- Request Evacuation and Establish CASEVAC link-up point
- Manage KIA remains

PART 2: Casualty Response Rehearsals

- Critical in pre-mission planning and overall unit rehearsals
- Each element should rehearse alerting aid & litter team and movement of a casualty
  - Alert and movement
  - Evacuation equipment prep
  - Clearing / securing weapons
- CCP members rehearse the following:
  - Clear and Secure CCP Location
  - Choke Point / Triage
  - Marking & Tagging
  - Accountability & Reporting
  - Equipment removal tagging/consolidation

PART 3: CCP Site Selection

- Reasonably close to the fight
- Near templated areas of expected high casualties
- Cover and Concealment
- In building or on hardstand (exclusive CCP building limits confusion)
- Access to evacuation routes (foot, vehicle, aircraft)
- Proximity to Lines of Drift on the objective
Adjacent to Objective Choke Points (breeches, HLZ’s, etc…)
Avoid natural or enemy choke points
Area allowing passive security (inside the perimeter)
Good Drainage
Trafficable to evacuation assets
Expandable if casualty load increases

PART 4: CCP Operational Guidelines

1SG / PSG is responsible for casualty flow and everything outside the CCP
- Provides for CCP structure and organization (color coded with chemlights)
- Maintains C2 and battlefield situational awareness
- Controls aid & litter teams, and provides security
- Strips, bags, tags, organizes, and maintains casualty equipment outside of treatment area as possible
- Accountable for tracking casualties and equipment into and out of CCP and provides reports to higher
- Casualties move through CCP entrance / exit choke point which should be marked with an IR Chemlight

Medical personnel are responsible for everything inside the CCP
- Triage officer sorts and organizes casualties at choke point into appropriate treatment categories
- Medical officers and medics organize medical equipment and supplies and render treatment to casualties
- EMTs, RFRs, A&L Teams assist with treatment and packaging of casualties

Minimal casualties should remain with original element or assist with CCP security if possible
KIA's should remain with original element or be transported to the BLOC

PART 5: CCP Building Guidelines

- Ensure building is cleared and secured
- Enter and assess the building prior to receiving casualties
  - Use largest rooms
  - Consider litter / skedco movement (can you do it in the area?)
  - Separate rooms for treatment categories?
  - Determine location of choke point / triage
  - Minimize congestion
- Remove / re-locate furniture or obstructions
- Color-code rooms to treatment categories (mark doors, etc…)
PART 6: Evacuation Guidelines

- Know the Evacuation Asset
  - Medical provider on board?
  - Monitoring equipment on board?
  - How many CAX can evacuate on asset?
- Packaging requirements for asset
  - Type litters?
  - Are there stirrups? Floor-Loading?
- Determine flow of casualties to the asset
  - Large Asset (Multiple CAX)
    - Routine on first
    - Priority on next
    - Critical (Urgent) on last, so they are first off at destination
  - Small Asset
    - Critical (Urgent) and Priority evacuated first

PART 7: CCP Layout Templates

- Use as a TEMPLATE
- Use as a Guideline
- Modify based on the objective and circumstances

CCP / CEP Template 1
(Adjacent to Breech)
75th Ranger Regiment Trauma Management Team (Tactical)
Ranger Medic Handbook
75th Ranger Regiment Trauma Management Team (Tactical)
Ranger Medic Handbook

CCP / CEP Template 4
(Building – Open/Hanger)

Target
KIA Morgue

Incoming CAX
Outgoing CAX

CCP / CEP Template 5
(Open Area / Field)

Target
KIA Morgue
HLZ
AXP

Incoming CAX
Outgoing CAX

Routines

1. URGENT/Immediate
2. PRIORITY/Delayed
3. ROUTINE/Minimal
4. ROUTINE/Expectant
PART 8: General Guidelines for CCP Personnel

- Maintain Security
- Maintain Command & Control
- Maintain Adequate Treatment
- Maintain Situational Awareness
- Maintain Organization
- Maintain Control of Equipment & Supplies
- Maintain Accountability

PART 9: Casualty Marking and Tagging

**COLOR CODING FOR TRIAGE & EVACUATION**
- Chemlights, colored engineer tape, or triage tags, will be used to color code as follows:
  - RED: Immediate / Critical (Urgent & Urgent-Surgical)
  - GREEN: Delayed / Priority
  - BLUE: Expectant / Routine
  - NONE: Minimal / Convenience

**CASUALTY TAGGING**
- The casualty card on the following page is the USSOCOM JTF Standard for casualty tagging:
75th Ranger Regiment Trauma Management Team (Tactical)
Ranger Medic Handbook

Cax Name ______________________
Medic’s Name ____________________
Incident: Day or Night

TIME
AVPU
Pulse
RESP
BP

DIRTY

A: NPA Cric King LT ET tube
B: ODressing NDecompression Chest Tube
C: Tourniquet Hemostatic Packed Pressure Dx
SalLock EJugular IV IO

FLUIDS: NS/RL 500 1000 1500
Hextend 500 1000

DRUGS:
PAIN
ABX
CWPP

Mech. of Injury- Treatments

Immediate Delayed Expectant Minimal
RED GREEN BLUE NO CHEM. LT
Critical(Urgent) <2 hours <4 hours <24 hours

TIME

AVPU
Pulse
RESP
BP

DIRTY

A: NPA Cric King LT ET tube
B: ODressing NDecompression Chest Tube
C: Tourniquet Hemostatic Packed Pressure Dx
SalLock EJugular IV IO

FLUIDS: NS/RL 500 1000 1500
Hextend 500 1000

DRUGS:
PAIN
ABX
CWPP

Mech. of Injury- Treatments

Immediate Delayed Expectant Minimal
RED GREEN BLUE NO CHEM. LT
Critical(Urgent) <2 hours <4 hours <24 hours
### PART 10: MEDEVAC Request Format

Use Lines 1-5 for pre-coordinated CASEVAC Requests using JTF Assets

<table>
<thead>
<tr>
<th>LINE</th>
<th>ITEM</th>
<th>Brevity Codes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Location / Grid</td>
<td>Grid (HLZ Name for JTF Assets)</td>
</tr>
<tr>
<td>2</td>
<td>Frequency &amp; Call-sign of requesting unit</td>
<td>FM Freq Callsign</td>
</tr>
</tbody>
</table>
| 3 | Number of Patients by Precedence | A – Urgent  
B – Urgent Surgical  
C – Priority  
D – Routine  
E – Convenience |
| 4 | Special Equipment Needed | A – None  
B – Hoist  
C – Extraction Equipment  
D – Ventilator |
| 5 | Number of Patients by Type (Litter & Ambulatory) | L – # of Litter Patients  
A – # of Ambulatory Patients |
| 6 | Security at Pick-Up Site (Wartime) | N – No enemy troops in area  
P – Possibly enemy troops in area  
E – Enemy troops in area (use caution)  
X – Enemy troops in area (armed escort required) |
| 6 | Number and type of wounded, injured or illness | Description of each |
| 7 | Method of Marking Pick-Up Site | A – Panels  
B – Pyrotechnic Signal  
C – Smoke Signal  
D – None  
E – Other (Specify) |
| 8 | Patient Nationality and Status | A – US Military  
B – US Civilian  
C – Non-US Military  
D – Non-US Civilian  
E – EPW |
| 9 | NBC Contamination (Wartime) | N – Nuclear  
B – Biological  
C – Chemical |
| 9 | Terrain Description (features in and around the landing site) | |

Time of Initial MEDEVAC Request: ____________________________

Time of MEDEVAC Launch: ___________________________________

Time of MEDEVAC Complete: _________________________________
PART 11: Hazardous Training Medical Coverage

DEFINITION
- Planning, coordination, and execution of backside medical coverage for high-risk or hazardous training events conducted by Ranger units

TYPICAL EVENTS REQUIRING MEDICAL COVERAGE
- Airborne operations
- Fast-rope operations (FRIES)
- Road Marches (12 miles and over)
- Maneuver Live Fires
- Demolitions/Explosives
- Other

MEDICAL COVERAGE DUTIES & RESPONSIBILITIES

1. Senior Coverage Medic
   - Plan & coordinate medical support requirements & considerations
   - Identify Hospitals and evacuation routes
     - Conduct Hospital Site Survey as required
     - Conduct face-to-face with hospital ER
     - Conduct route recon from target to hospital
   - Establish target medical coverage plan and casualty flow
   - Brief OIC/NCOIC medical support plan
     - Clarify OIC/NCOIC responsibilities and guidance
     - Clarify Medical responsibilities and guidance
   - EXECUTION Duties:
     - Patient Treatment & Monitoring on target and en route
     - Advise OIC/NCOIC as required
     - Update OIC/NCOIC/Higher HQ on condition of evacuated casualties
     - Inform unit medical officer of all casualties

2. OIC / NCOIC of Event
   - Overall responsible for administrative coverage (including medical)
   - Request / track external medical support requirements
   - Ensure appropriate type and number of vehicles with assigned drivers are dedicated to medical coverage
   - Ensure appropriate communications equipment is allocated to medical personnel
   - Link medical coverage plan with overall administrative coverage plan
   - EXECUTION duties
     - Collect casualty data and report to higher HQs
     - Request MEDEVAC
     - Identify and establish MEDEVAC HLZ
# DETERMINE COVERAGE REQUIREMENTS

- Determine medical support requirements based on type of training and appropriate SOP/Regulation.
  - RTC 350-2 Airborne SOP (ASOP)
  - RTC 350-6 FRIESSOP
  - RTC 350-1-2 (SOSOP)
  - Local Installation and Range Control Regulations / Guidelines
  - Training Area specific requirements
- Coordinate and request appropriate equipment, vehicles, personnel, and support assets

## DROP ZONE REQUIREMENTS

<table>
<thead>
<tr>
<th>Medical Officer</th>
<th>N/A</th>
<th>N/A</th>
<th>N/A</th>
<th>N/A</th>
<th>1</th>
<th>1</th>
<th>1</th>
<th>N/A</th>
</tr>
</thead>
<tbody>
<tr>
<td>Senior Medic</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Aidman</td>
<td>N/A</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td>3</td>
<td>3</td>
<td>4</td>
<td>1</td>
</tr>
<tr>
<td>Ambulance w/commo</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>4</td>
<td>4</td>
<td>4</td>
<td>1</td>
</tr>
<tr>
<td>Communications</td>
<td>1</td>
<td>2</td>
<td>3</td>
<td>3</td>
<td>5</td>
<td>5</td>
<td>6</td>
<td>2</td>
</tr>
<tr>
<td>5% Jump Injuries</td>
<td>3</td>
<td>6</td>
<td>12</td>
<td>18</td>
<td>24</td>
<td>30</td>
<td>36</td>
<td>N/A</td>
</tr>
</tbody>
</table>

## MAPS & ROUTE RECONS

- Request/Purchase/Acquire appropriate maps of training areas, adjacent military installations, and cities
  - Military Grid Reference System (MGRS)
  - Civilian Maps (Rand McNally, DeLorme, etc…)
  - Strip Maps / Site Published Maps
- Conduct map and ground recon of training areas (specifically key entrance & exit points).
- Note map problems/errors
- Identify hospitals/fire/EMS locations
IDENTIFY SPECIAL COVERAGE CONSIDERATIONS
- Weather
- Animals
- Plants
- Terrain hazards (high angle or high altitude)

IDENTIFY HOSPITALS
- Primary and Alternate evacuation hospital
- One should be a Level 1 Trauma Center
- Conduct hospital site survey and face-to-face
- Determine Hospital Communications:
  - ER Phone Line
  - ER Ambulance Line
  - Patient Admin Phone Line
  - Security Line Phone Line
- Determine Routes and Directions to hospitals
- Where are special injuries evacuated?
  - Neurosurgical
  - Burns
  - Trauma Centers
    - Level 1
    - Neurosurgeon on staff 24 hours
    - Level 2
    - Neurosurgeon on call, but not on site 24/7

VEHICLE REQUIREMENTS
- Driver: A dedicated driver – NOT the medic covering the event. Must be familiar with training area and evacuation routes.
- Ambulance: A covered vehicle capable of carrying at least 1 litter with spine-board attached. The vehicle must provide environmental control and adequate space for medical equipment. Mark vehicle as appropriate (ambulance symbols or lights).
  - Optimal Vehicles:
    - Van (15PAX only)
    - Large SUV (Expedition, Tahoe, etc…)
    - FLA (M996/M997)
  - Suboptimal Vehicles
    - Open HMMWV / GMV
    - MEDSOV (tactical operations only – not for admin coverage)
    - Small SUV (Explorer, Durango, Cherokee, etc…)
    - Small Van (7PAX)

EQUIPMENT REQUIREMENTS
- Standard Medical Equipment
  - Spinal Immobilization/Stabilization
  - Splint Sets (Quick Splints)
  - O2/Masks/BVM
Suction, Electric
KED/Oregon Spine Splints
Traction Splint
Vital Signs Monitor (Propaq, PIC, LifePak)
Litters (Raven/Skedco/Talon)
Blankets
MAST
Pain Control

- Special Equipment Considerations
  - Cold Weather
    - REPS (Rescue Wrap & Patient Heaters)
    - Thermal Angels
  - Hot Weather
    - Fans (battery operated)
    - Cold Packs
  - Burns

➢ COMMUNICATION REQUIREMENTS

- Equipment
  - FM & MX frequency capable radios
  - Cell Phone
- Radio Nets
  - Administrative Coverage (DZSO Net)
  - Exercise Target Control (O/C Net)
  - Tactical Nets
- En route Communications
  - Cell phone to notify receiving facilities

➢ MEDEVAC REQUEST PROCEDURES

- Military Installation
  - MEDEVAC unit and location
  - Request Procedures
    - Range Control?
    - MEDEVAC Freq?
    - Request format (other than 9-Line)
    - Aircraft / HLZ requirements/considerations
- Civilian Life Flight
  - Contact Numbers & Procedures
    - Direct Line and Alternate Contacts (State Police)
  - Special Aircraft Considerations
    - Aircraft Capabilities / Limitations
    - Aircraft / HLZ requirements/considerations
- HLZ Marking Requirements
ADMIN CASUALTY FLOW
- Point-of-Injury TO Home Station
- Casualty Flow on the Target / DZ to CCP or HLZ
  - Tactical to admin link-up and patient turnover
- From the target to hospital
- From hospital to home station
*General Rule:* All casualties go through tactical medical channels unless life, limb, or eyesight is threatened.

TACTICAL DROP ZONE COVERAGE FOR EXERCISES
- All casualties go through tactical evacuation channels unless life, limb or eyesight is threatened.
- No vehicles enter the drop zone without DZSO permission and tactical commanders notification
- Minimize white lights
- Minimize impact on tactical operations remaining off the DZ unless directed otherwise
- If possible, use tactical vehicles/assets to transport to admin CCP sites

PRE-COVERAGE INSPECTIONS
- ALWAYS CHECK YOURSELF AND INSPECT SUBORDINATES
  - Inspect / Inventory Medical equipment
    - Inventory against Hazardous Coverage Checklist
    - Function check mechanical devices & Monitors
    - Check Batteries
    - Aidbags
  - Check Vehicle(s)
    - PMCS
    - Fuel Level
    - Dispatch
    - Map/Routes
  - Support Equipment
    - Communications Equipment
    - Strobe lights / flashlights / head lamps
    - Night vision
    - GPS

REHEARSALS
- Drive routes to hospitals
  - During daytime and nighttime
  - Determine time from target to hospital
  - Consider civilian traffic interference
- Conduct target casualty flow to CCP
- Conduct CCP rehearsal
- Conduct COMMEX when all sites established
TREATMENT DURING EXERCISES

- On target
  - U.S. Standard of Care per unit protocols (there is no excuse)
  - Package casualties for evacuation
- En route
  - Patient Monitoring and re-evaluation of treatment and interventions
  - Notify receiving hospital
- Inform unit medical officer of casualties
- Keep OIC/NCOIC informed of patient status with routine updates

PART 12: Pre-Deployment and RRF-1 Assumption

EVENTS PRIOR TO DEPLOYMENT & RRF-1 ASSUMPTION

- 100% Equipment Inventory and Layout
  - Stockage and Accountability
  - Identify Critical Shortages
- SRP
  - Unit Medical Readiness (SRP by exception)
  - Individual SRP Packets for assigned medics
- N-Hour sequence activities review
- Alert Rosters
- Plan & POC’s for drawing of non-stocked Class VIII
  - NBC Class VIII

INVENTORY & LAYOUT

- Inspection by Senior Medics of 100% of inventory (equipment & supplies)
- Complete Layout
- Shortages Identified and Rectified
- Re-inspections as necessary
- Palletize / Load ISU / JI prep

*It is not a waste of time!!! You are not above inspections or PCIs!!!
RMED Equipment Layout Diagram (Example)

MEDICAL READINESS & SRP
- Current Snapshot of Unit in MEDPROS
  - Identify Med SRP Shortcomings
  - Advise the Commander on solutions
  - Plan for the fix
  - Execute the fix
  - Update Records
  - Review / Submit Command Health Report
  - Review / Submit profile / non-deployable roster
- Ensure subordinate medics SRP packets are complete

REVIEW ALERT PROCEDURES
- Alert Rosters
- N-Hour Sequence review
  - Who is responsible for what?
  - Do we have potential short-comings?
  - Confirm POC’s for actions.

MEDICAL LOGISTICS ISSUES
- Confirm plan for installation support requirements:
  - How to draw Class VIII shortages
  - How to draw NBC Medical Items
PART 13: Post-Deployment and Recovery

AGGRESSIVE LEADERSHIP & MANAGEMENT
- The senior medic must take charge and be responsible for his element’s post-deployment recovery
- The senior medic must direct subordinates and enforce standards
- The senior medic must maintain an air of professionalism
- Ensure deployment packages are in a high state of readiness

ACCOUNTABILITY OF EQUIPMENT
- Hand Receipt items
- Serial Number items

PMCS / CLEAN / REPAIR EQUIPMENT
- Proper Inspection and PMCS on equipment and functions.
- All equipment cleaned of bodily fluids, environment soiling, and debris.
- Repair or turn-in broken or malfunctioning equipment.

IDENTIFY & REPLACE SHORTAGES
- 100% Inventory of stockages against packing lists
- Early identification of shortages and expended items
- Document expenditure trends
- Submission of request for re-supply
- Receive supplies
- Replace stockages
- 100% Inventory of stockages
- Maintain shortage list for future stockage

PHASE 1 (Prior to Re-Deployment)
- Accountability of sensitive, hand receipt, and serial number items
- Missing items reported to command immediately.
- Damaged items reported to command immediately
- Remove batteries from equipment.
- Pack sensibly into ISU-90 or onto pallets.

PHASE 2 (Days 1 to 2 of Recovery)
- Complete unit individual requirements-weapons, NVG’s, P-mask, commo
- Disseminate Recovery Plan and Schedule
- Disseminate Post-Deployment SRP Plan
75th Ranger Regiment Trauma Management Team (Tactical)
Ranger Medic Handbook

- Anti-Malarial Prophylaxis
- Lab Testing required (HIV, etc...)
- Post-Deployment Health Surveillance Forms

- Conduct Individual Inventories
  - RMED Aid Bags
  - Individual Ranger BCKs
  - Squad RFR Bags
  - Utilize PSG & SL to get platoon/squad inspections & requirements

- Turn In Narcotics and Prescriptions/FMC’s
- Submit individual shortages

**PHASE 3 (Days 3 to 4 of Recovery)**
- Receive and re-stock individual items
  - RMED aid bags
  - Ranger BCKs
  - Squad RFR Bags
  - Replace/Recharge all batteries

- Clean/Inspect/PMCS Medical Equipment
  - Hazardous Coverage Kits
    - All items cleaned, function checked, and component inventory
  - Inventory MABR Sets
    - Remove all items
    - Clean Pelicans
    - Re-Pack available components fixing immediate shortages as available
    - Re-Assess Shortages
  - Inventory PM and Contingency Boxes (same protocol)

- Submit Shortages for MABR, Hazardous Coverage Kits, PM & Contingency boxes

**PHASE 4 (Days 5 to 7 of Recovery)**
- Receive requested shortages
- Restock Individual Items, MABR, Hazardous Coverage Kits, PM & Contingency boxes
- Reassess shortages and ensure long-term order is initiated.

**PHASE 5 (NLT Day 9 of Recovery)**
- All Post-Deployment SRP Requirements completed.
  - Post-Deployment Health Surveillance Surveys turned into higher.
  - All labs and prophylaxis requirements completed or scheduled

- Inspection from Next-Higher Med Supervisor
  - 100% layout, inventory, and inspection of medical equipment and supplies
  - Re-sign/Re-assess hand receipts. Initiate report of surveys as required.

- Schedule AAR and Counseling periods
PHASE 6 (NLT Day 15 of Recovery)
- Conduct AAR/Lessons Learned
  - All medical personnel in unit
  - Every man comes to the table with:
    - 3 X Sustains
    - 3 X Improves
    - 1 X Lesson Learned
  - Document AAR Findings, archive findings, and submit to higher.
- Counseling
  - Focus on performance during the period of the deployment.
  - Offer guidance & recommendations
  - Provide every individual with at least:
    - 2 X Areas to Sustain
    - 2 X Areas to Improve
    - 1 X Learning Assignment
SECTION FIVE

RMED PACKING LISTS & REFERENCE
The packing lists below are intended to be minimum stockage lists for the typical Ranger combat mission. Medics are authorized the flexibility to ADD components to their equipment as based on the mission requirements. Medics are not authorized to deviate from the minimum packing list unless approved by the unit medical director. Individual line item deviations are authorized for items that are unavailable through Class VIII channels as long as replacement items are merely a deviation from a specific brand name or manufacturer.

### RMED RBA / RLCS Minimum Stockage

The RMED RBA/RLCS packing list are items that the medic carries on his body without opening an aid-bag or rucksack. All items are to be carried in a manner that provides ease of access. The intent of this packing list is to provide all immediate initial care for a trauma casualty without opening external bags and equipment.

<table>
<thead>
<tr>
<th>NSN</th>
<th>COMMON NAME</th>
<th>QTY</th>
</tr>
</thead>
<tbody>
<tr>
<td>RMED Kit, Ranger Load Carriage System (RLCS)</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td><strong>AIRWAY</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6515-01-540-7568</td>
<td>Cricothyroidotomy Kit</td>
<td>1</td>
</tr>
<tr>
<td>6515-01-529-1187</td>
<td>Nasopharyngeal Airway, 28fr w/Lubricant</td>
<td>1</td>
</tr>
<tr>
<td><strong>BREATHING</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6515-01-541-0635</td>
<td>14G / 3.5&quot; Needle</td>
<td>1</td>
</tr>
<tr>
<td>6515-01-532-8019</td>
<td>Chest Seal (Hyfin) 6&quot;</td>
<td>2</td>
</tr>
<tr>
<td>6510-01-408-1920</td>
<td>Chest Seal (Asherman)</td>
<td>2</td>
</tr>
<tr>
<td><strong>CIRCULATION / BLEEDING</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6515-01-521-7976</td>
<td>Combat Applications Tourniquet (CAT)</td>
<td>2</td>
</tr>
<tr>
<td>6510-01-492-2275</td>
<td>Emergency Trauma Dressing, 6&quot;</td>
<td>2</td>
</tr>
<tr>
<td>6510-01-541-2896</td>
<td>Hemostatic Dressing (Chitosan)</td>
<td>2</td>
</tr>
<tr>
<td>6510-01-541-2896</td>
<td>Hemostatic Bandage (Chitoflex)</td>
<td>2</td>
</tr>
<tr>
<td>6510-01-529-1213</td>
<td>Kerlex, Vacuum Sealed</td>
<td>4</td>
</tr>
<tr>
<td><strong>DISABILITY / IMMOBILIZATION</strong></td>
<td></td>
<td>0</td>
</tr>
<tr>
<td><strong>FLUIDS / IV ACCESS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6515-01-537-4094</td>
<td>Saline Lock Kit</td>
<td>2</td>
</tr>
<tr>
<td>Local Purchase</td>
<td>Sharps Container</td>
<td>1</td>
</tr>
<tr>
<td><strong>MONITORING &amp; DIAGNOSTIC</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Local Purchase</td>
<td>Pulsoximeter, Finger</td>
<td>1</td>
</tr>
<tr>
<td><strong>MISCELLANEOUS</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6515-01-540-7284</td>
<td>Exam Light (Tactical Green)</td>
<td>1</td>
</tr>
<tr>
<td>Local Purchase</td>
<td>Headlamp</td>
<td>1</td>
</tr>
<tr>
<td>NSN by size</td>
<td>Gloves, Exam (Black Talon)</td>
<td>6</td>
</tr>
<tr>
<td>6515-01-538-9276</td>
<td>Trauma Shears, 7.25&quot;</td>
<td>1</td>
</tr>
<tr>
<td>6515-01-540-7226</td>
<td>Scissor Leash or Gear-Keeper</td>
<td>1</td>
</tr>
<tr>
<td>NSN</td>
<td>COMMON NAME</td>
<td>QTY</td>
</tr>
<tr>
<td>----------------</td>
<td>--------------------------------------------------</td>
<td>-----</td>
</tr>
<tr>
<td>6545-01-539-6444</td>
<td>AidBag, M-9 (TSS-M-9-RG)</td>
<td>1</td>
</tr>
<tr>
<td>6515-01-529-1187</td>
<td>Nasopharyngeal Airway, 28fr w/Lubricant</td>
<td>1</td>
</tr>
<tr>
<td>6515-01-540-7568</td>
<td>Cricothyroidotomy Kit</td>
<td>1</td>
</tr>
<tr>
<td>6515-01-515-0151</td>
<td>King LT-D Supralaryngeal Airway size 4</td>
<td>1</td>
</tr>
<tr>
<td>6515-01-540-7206</td>
<td>Suction, Hand-held (Suction Easy or Squid)</td>
<td>1</td>
</tr>
<tr>
<td>6515-01-541-0635</td>
<td>14G / 3.5&quot; Needle</td>
<td>1</td>
</tr>
<tr>
<td>6515-01-532-8019</td>
<td>Chest Seal (Hyfin) 6&quot;</td>
<td>2</td>
</tr>
<tr>
<td>6510-01-408-1920</td>
<td>Chest Seal (Asherman)</td>
<td>2</td>
</tr>
<tr>
<td>6515-01-519-4476</td>
<td>Bag-Valve-Mask</td>
<td>1</td>
</tr>
<tr>
<td>6515-01-521-7976</td>
<td>Combat Applications Tourniquet (CAT)</td>
<td>2</td>
</tr>
<tr>
<td>6510-01-492-2275</td>
<td>Emergency Trauma Dressing, 6&quot;</td>
<td>3</td>
</tr>
<tr>
<td>6510-01-541-8121</td>
<td>Emergency Trauma Dressing, Abdominal</td>
<td>1</td>
</tr>
<tr>
<td>6510-01-502-6938</td>
<td>Hemostatic Dressing (Chitosan)</td>
<td>2</td>
</tr>
<tr>
<td>6510-01-541-2896</td>
<td>Hemostatic Bandage (Chitoflex)</td>
<td>2</td>
</tr>
<tr>
<td>6510-01-529-1213</td>
<td>Kerlex, Vacuum Sealed</td>
<td>3</td>
</tr>
<tr>
<td>Pending</td>
<td>Tactical Compression Wrap</td>
<td>1</td>
</tr>
<tr>
<td>6510-00-201-1755</td>
<td>Cravat Bandage, Muslin (or ACE Wrap)</td>
<td>2</td>
</tr>
<tr>
<td>6515-01-346-9186</td>
<td>Traction Splint (KTD or TTS)</td>
<td>1</td>
</tr>
<tr>
<td>6515-01-494-1951</td>
<td>SAM Splint II</td>
<td>2</td>
</tr>
<tr>
<td>6515-01-537-4094</td>
<td>Saline Lock Kit</td>
<td>2</td>
</tr>
<tr>
<td>6505-01-498-8636</td>
<td>Hextend IV 500cc</td>
<td>2</td>
</tr>
<tr>
<td>NSN</td>
<td>Sodium Chloride Flush, 50cc</td>
<td>1</td>
</tr>
<tr>
<td>Component List</td>
<td>IV Kit</td>
<td>3</td>
</tr>
<tr>
<td>6515-01-530-6147</td>
<td>FAST-1 Sternal Intraosseous</td>
<td>1</td>
</tr>
<tr>
<td>6515-01-537-2611</td>
<td>BOA Constricting Band</td>
<td>1</td>
</tr>
<tr>
<td>6515-01-523-3317</td>
<td>Raptor IV Securing Device</td>
<td>3</td>
</tr>
<tr>
<td>Local Purchase</td>
<td>Sharps Shuttle Container w/Locking Mechanism</td>
<td>1</td>
</tr>
<tr>
<td>Local Purchase</td>
<td>Stethoscope (mission dependent)</td>
<td>1</td>
</tr>
<tr>
<td>Local Purchase</td>
<td>Pulsoximeter, Finger</td>
<td>1</td>
</tr>
<tr>
<td>Component List</td>
<td>RMED Medications Kit</td>
<td>1</td>
</tr>
<tr>
<td>6515-01-532-8056</td>
<td>Hypothermia Kit (mission and aidbag dependent)</td>
<td>1</td>
</tr>
<tr>
<td>6515-01-540-7284</td>
<td>Exam Light (Tactical Green)</td>
<td>1</td>
</tr>
<tr>
<td>NSN for size</td>
<td>Gloves, Exam (Black Talon)</td>
<td>6</td>
</tr>
<tr>
<td>6510-01-532-4283</td>
<td>Tape, 2&quot;</td>
<td>2</td>
</tr>
<tr>
<td>6515-01-538-9276</td>
<td>Trauma Shears, 7.25&quot;</td>
<td>1</td>
</tr>
<tr>
<td>6515-01-540-7226</td>
<td>Scissor Leash or Gear-Keeper</td>
<td>1</td>
</tr>
</tbody>
</table>
## Mission Dependent Aidbag Items

<table>
<thead>
<tr>
<th>Component List</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chest Tube Kit (Mission Dependent)</td>
<td></td>
</tr>
<tr>
<td>6515-01-509-6866 SAM Pelvic Sling</td>
<td></td>
</tr>
<tr>
<td>6515-01-541-8147 ACE Cervical Collar</td>
<td></td>
</tr>
<tr>
<td>6515-01-148-6178 Field Otoscope/Ophthalmoscope Set</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Component List</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Minor Wound Care Kit</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Local Purchase</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glucometer</td>
<td></td>
</tr>
<tr>
<td>6515-00-149-1406 Thermometer, Oral</td>
<td></td>
</tr>
<tr>
<td>6515-00-149-1407 Thermometer, Rectal</td>
<td></td>
</tr>
</tbody>
</table>

## RMED Medications Kit Minimum Stockage

<table>
<thead>
<tr>
<th>RMED Medications Kit (Proficient and Always Carried)</th>
<th>1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Local Purchase</td>
<td></td>
</tr>
<tr>
<td>Drug Case (Otter or Armadillo)</td>
<td></td>
</tr>
<tr>
<td>Component List</td>
<td></td>
</tr>
<tr>
<td>Combat Wound Pill Pack (CWPP)</td>
<td></td>
</tr>
<tr>
<td>6505-01-091-7538 Diphenhydramine HCL Inj 50mg (Benadryl)</td>
<td></td>
</tr>
<tr>
<td>6505-01-492-6420 Dexamethasone Inj, 4mg/ml (5ml) (Decadron)</td>
<td></td>
</tr>
<tr>
<td>6505-01-238-5634 Epi-Pen Anaphylaxis Auto-Injector</td>
<td></td>
</tr>
<tr>
<td>NDC 63459-0508-30 Fentanyl Transmucosal Lozenge, 800mcg</td>
<td></td>
</tr>
<tr>
<td>6505-01-503-5374 Ertapenem Inj, 1gm (Invanz)</td>
<td></td>
</tr>
<tr>
<td>6505-00-149-0113 Morphine Sulfate Inj, 5mg</td>
<td></td>
</tr>
<tr>
<td>6505-01-435-9958 Nalaxone Inj, 0.4mg (Narcan)</td>
<td></td>
</tr>
<tr>
<td>6505-00-680-7352 Promethazine Inj, 25mg (Phenergan)</td>
<td></td>
</tr>
<tr>
<td>NDC 0074-3795-01 Ketorolac Inj, 30mg (Toradol)</td>
<td></td>
</tr>
<tr>
<td>6505-01-199-3137 Acetaminophen Tabs, 500mg (Tylenol)</td>
<td></td>
</tr>
<tr>
<td>6505-00-137-5891 Diazepam Inj, 5mg (Valium)</td>
<td></td>
</tr>
<tr>
<td>6515-01-344-8487 Tubex Injector, Cartridge Unit</td>
<td></td>
</tr>
<tr>
<td>6515-01-356-8511 Syringe, 10cc Luer-Lok Tip</td>
<td></td>
</tr>
<tr>
<td>NSN</td>
<td></td>
</tr>
<tr>
<td>Needle, Hypo 18G/1.5&quot;</td>
<td></td>
</tr>
</tbody>
</table>

## Combat Wound Pill Pack (CWPP) Carried by every Ranger

<table>
<thead>
<tr>
<th>NDC/Stock #</th>
<th>Description</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>6505-01-199-3137</td>
<td>Acetaminophen Tabs, 500mg (Tylenol)</td>
<td>2</td>
</tr>
<tr>
<td>6085-1733-01</td>
<td>Moxifloxacin HCL Tab, 400mg (Avelox)</td>
<td>1</td>
</tr>
<tr>
<td>6505-01-541-3243</td>
<td>Meloxicam, 15mg Tab (Mobic)</td>
<td>1</td>
</tr>
</tbody>
</table>
## 75th Ranger Regiment Trauma Management Team (Tactical)
### Ranger Medic Handbook

#### SALINE LOCK KIT (6515-01-537-4094)
<table>
<thead>
<tr>
<th>NSN</th>
<th>Item Description</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>6510-00-786-3736</td>
<td>18G X 1.5&quot; Catheter/Needle</td>
<td>2</td>
</tr>
<tr>
<td>6515-01-519-6764</td>
<td>Alcohol Pad</td>
<td>2</td>
</tr>
<tr>
<td>6510-00-058-4421</td>
<td>Constricting Band, Penrose</td>
<td>1</td>
</tr>
<tr>
<td>6515-01-321-3336</td>
<td>2X2 Sponge, Sterile</td>
<td>1</td>
</tr>
<tr>
<td>6515-01-356-8511</td>
<td>Saline Plug, Locking</td>
<td>1</td>
</tr>
<tr>
<td>NSN</td>
<td>18G X 1.5&quot; Needle, Hypoderm</td>
<td>1</td>
</tr>
<tr>
<td>6515-01-523-3317</td>
<td>Raptor IV Securing Band</td>
<td>1</td>
</tr>
<tr>
<td>6510-01-135-4267</td>
<td>Tega-derm</td>
<td>1</td>
</tr>
<tr>
<td>8105-01-099-0355</td>
<td>Pill Bag</td>
<td>1</td>
</tr>
</tbody>
</table>

#### CHEST TUBE KIT
<table>
<thead>
<tr>
<th>NSN</th>
<th>Item Description</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>6515-00-334-9500</td>
<td>Forceps, 9&quot; Pean</td>
<td>1</td>
</tr>
<tr>
<td>6515-01-149-8097</td>
<td>Scalpel, #10</td>
<td>1</td>
</tr>
<tr>
<td>6515-00-763-7366</td>
<td>36fr Chest Tube</td>
<td>1</td>
</tr>
<tr>
<td>6515-00-926-9150</td>
<td>Heimlich Valve</td>
<td>1</td>
</tr>
<tr>
<td>6510-00-721-9808</td>
<td>Sponge, Sterile 4X4</td>
<td>4</td>
</tr>
<tr>
<td>6510-01-408-1920</td>
<td>Asherman Chest Seal</td>
<td>0</td>
</tr>
<tr>
<td>NSN</td>
<td>Chux</td>
<td>1</td>
</tr>
<tr>
<td>6505-00-598-6116</td>
<td>Lidocaine Inj, 1%</td>
<td>1</td>
</tr>
<tr>
<td>6515-01-356-8511</td>
<td>Syringe, 10cc Luer-Lok Tip</td>
<td>1</td>
</tr>
<tr>
<td>6510-01-532-4283</td>
<td>Tape, 2&quot;</td>
<td>1</td>
</tr>
<tr>
<td>NSN</td>
<td>Sterile Gloves</td>
<td>2</td>
</tr>
<tr>
<td>NSN</td>
<td>1-O Armed Suture</td>
<td>2</td>
</tr>
<tr>
<td>6510-00-202-0800</td>
<td>Petrolatum Gauze</td>
<td>2</td>
</tr>
<tr>
<td>6505-00-914-3593</td>
<td>Betadine Solution .5 oz</td>
<td>0</td>
</tr>
</tbody>
</table>

#### CRICOTHYROIDOTOMY KIT (6515-01-540-7568)
<table>
<thead>
<tr>
<th>NSN by size</th>
<th>Item Description</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>6515-01-149-8097</td>
<td>Scalpel, #10</td>
<td>1</td>
</tr>
<tr>
<td>NSN by size</td>
<td>Gloves, Exam (Black Talon)</td>
<td>2</td>
</tr>
<tr>
<td>6515-01-356-8511</td>
<td>Syringe, 10cc Luer-Lok Tip</td>
<td>1</td>
</tr>
<tr>
<td>Pending</td>
<td>Tracheal Hook (NARP)</td>
<td>1</td>
</tr>
<tr>
<td>6510-00-786-3736</td>
<td>Alcohol Prep Pad</td>
<td>1</td>
</tr>
<tr>
<td>6510-01-010-0307</td>
<td>Povidone-Iodine Pad</td>
<td>1</td>
</tr>
<tr>
<td>Pending</td>
<td>Tube, 6mm Bore-cuffed Cricothyroidotomy</td>
<td>1</td>
</tr>
</tbody>
</table>

#### IV KIT
<table>
<thead>
<tr>
<th>NSN</th>
<th>Item Description</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>6515-00-115-0032</td>
<td>IV Solution Set, 10 drops/ml</td>
<td>1</td>
</tr>
<tr>
<td>6515-01-537-4094</td>
<td>Saline Lock Kit</td>
<td>1</td>
</tr>
<tr>
<td>6510-01-135-4267</td>
<td>Tegaderm 4.75&quot;X4&quot;</td>
<td>1</td>
</tr>
<tr>
<td>MINOR WOUND CARE KIT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>----------------------------------------------------------</td>
<td>-----</td>
<td></td>
</tr>
<tr>
<td>6510-00-111-0708 Pad, Non-Adherent (Telfa)</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>6505-00-914-3593 Betadine 0.5oz</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>6510-01-456-2000 Moleskin, 12&quot;</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>6510-00-597-7469 Band-Aids 3&quot;x75&quot;</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>6510-00-054-7255 Steri-Strips</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>6510-00-721-9808 Sponge, 4X4 Sterile</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>6515-01-149-8097 Scalpel, #10</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>6510-01-010-0307 Pad, Povidine</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>6510-00-786-3736 Pad, Alcohol</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>Local Purchase</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Compeed Dressing</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>6505-01-414-1821 Tincture of Benzoin Ampule 0.6ml</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>6510-01-008-7917 Applicator, Povidine-Iodine</td>
<td>2</td>
<td></td>
</tr>
</tbody>
</table>
# ABBREVIATION LIST

<p>| AAS  | acute abdominal series                      | C/O  | complaining of |
| ABD  | abdomen                                     | CLS  | combat lifesaver |
| ABG  | arterial blood gas                          | CMD  | command         |
| AC   | before eating (ante cibium)                | CMO  | civil-military operations |
| ACL  | anterior cruciate ligament                 | CNS  | central nervous system |
| ACLS | Advanced Cardiac Life Support              | CO   | commanding officer |
| A&amp;O X-| alert and oriented times orientation       | CO2  | carbon dioxide   |
| AF   | afebrile                                    | COTCCC | committee on tactical combat casualty care |
| AFSOC| US Air Force Special Operations Command    | CPAP | continuous positive airway pressure |
| AKA  | above-the-knee amputation                  | CPR  | cardiopulmonary resuscitation |
| ALS  | advanced life support                      | CR   | casualty response |
| AP   | anteroposterior                             | CRTRL| casualty response training for ranger leaders |
| AMEDD| army medical department                    | CSF  | cerebral spinal fluid |
| AMS  | acute mountain sickness; altered mental status | CTA  | clear to auscultation |
| ARDS | acute respiratory distress syndrome         | CXP  | casualty exchange point |
| ASA  | acetylsalicylic acid (aspirin)              | CXR  | chest x-ray      |
| ASAP | as soon as possible                         | D/C  | discontinue or discharge |
| AT/NC| atraumatic, normocephalic                   | DDx  | differential diagnosis |
| ATLS | advanced trauma life support               | DEA  | drug enforcement agency |
| ATM  | advanced trauma manager                    | DMO  | diving medical officer |
| ATP  | advanced tactical practitioner              | DOA  | dead on arrival  |
| AXP  | ambulance exchange point                    | DOB  | date of birth    |
| BAS  | battalion aid station                      | DOE  | dyspnea on exertion |
| bid  | twice a day                                 | DNBI | disease/non-battle injury |
| BCK  | bleeder control kit                         | DNR  | do not resuscitate |
| BKA  | below-the-knee amputation                   | DO  | doctor of osteopathy |
| BLS  | basic life support                         | DOB  | date of birth    |
| BM   | bowel movement                              | DPL  | diagnostic peritoneal lavage |
| BN   | battalion                                   | DPN  | drops per minute |
| BP   | blood pressure                              | DPT  | diphtheria, pertussis, tetanus |
| BPM  | beats per minute                            | DTR  | deep tendon reflex |
| BRBBPR| bright red blood per rectum                | DVT  | deep venous thrombosis |
| BS   | bowel sounds                                | Dx   | diagnosis        |
| BSI  | body substance isolation                    | DZ   | drop zone        |
| BVM  | bag-valve-mask                              | EBL  | estimated blood loss |
| BW   | biological warfare                          | ECG  | electrocardiogram |
| Bx   | biopsy                                      | EDC  | estimated date of confinement |
| c    | with (cum)                                  | EKG  | electrocardiogram |
| C    | celsius or centigrade                       | EMG  | electromyelogram |
| C2   | command &amp; control                           | EMS  | emergency medical system or service |
| CA   | civil affairs                               | EMT  | emergency medical technician |
| CAD  | coronary artery disease                     | EMT-B| emergency medical technician-basic |
| CAM  | chemical agent monitor                      | EMT-I| emergency medical technician-intermediate |
| CAMS | civil affairs medical sergeant              | EMT-P| emergency medical technician-paramedic |
| CANA | convulsant antidote for nerve agents        | EOM  | extraocular muscles |
| CAT  | computed axial tomography                   | EOMI | extraocular muscles intact |
| CAT  | combat application tourniquet               | EPW  | enemy prisoner of war |
| CAX  | casualties                                  | ET   | endotracheal (tube) |
| CBC  | complete blood count                        | ETOH | ethanol alcohol |
| cc   | cubic centimeter                            | F    | farenheit        |
| CC   | chief complaint                             | FB   | foreign body     |
| CCP  | casualty collection point                   | F&amp;D  | fixed and dilated |
| CDC  | centers for disease control                 | FamHx| family history   |
| CDR  | commander                                   | F/C  | fevers, chills   |
| CEP  | casualty evacuation point                   | FDA  | food and drug administration |
| CHI  | closed head injury                          | FITT | frequency, intensity, time, type |
| c    | with (cum)                                  | FMED | flight medic     |</p>
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>PERRLA</td>
<td>pupils equal, round, reactive to light and accomadation</td>
</tr>
<tr>
<td>PFT</td>
<td>pulmonary function test</td>
</tr>
<tr>
<td>PHTLS</td>
<td>pre-hospital trauma life support</td>
</tr>
<tr>
<td>PJ</td>
<td>USAF pararescuemen</td>
</tr>
<tr>
<td>PM</td>
<td>preventive medicine</td>
</tr>
<tr>
<td>PMHx</td>
<td>past medical history</td>
</tr>
<tr>
<td>PMI</td>
<td>point of maximal impulse</td>
</tr>
<tr>
<td>PO</td>
<td>by mouth (per os)</td>
</tr>
<tr>
<td>POW</td>
<td>prisoner of war</td>
</tr>
<tr>
<td>PPD</td>
<td>purified protein derivative</td>
</tr>
<tr>
<td>ppm</td>
<td>parts per million</td>
</tr>
<tr>
<td>PPV</td>
<td>positive pressure ventilation</td>
</tr>
<tr>
<td>PR</td>
<td>per rectum</td>
</tr>
<tr>
<td>PRN</td>
<td>as often as needed (pro re nata)</td>
</tr>
<tr>
<td>PSHx</td>
<td>past surgical history</td>
</tr>
<tr>
<td>PSI</td>
<td>pounds per square inch</td>
</tr>
<tr>
<td>Pt</td>
<td>patient</td>
</tr>
<tr>
<td>PT</td>
<td>physical therapist</td>
</tr>
<tr>
<td>PUD</td>
<td>peptic ulcer disease</td>
</tr>
<tr>
<td>PULHES</td>
<td>physical profile factors: P-physical capacity or stamina, U-upper extremities, L-lower extremities, H-hearing and ears, E-eyes, S-psychiatric</td>
</tr>
<tr>
<td>q</td>
<td>every (quaque)</td>
</tr>
<tr>
<td>QC</td>
<td>quality control</td>
</tr>
<tr>
<td>qd</td>
<td>every day</td>
</tr>
<tr>
<td>qh</td>
<td>every hour</td>
</tr>
<tr>
<td>q_h</td>
<td>every _ hours</td>
</tr>
<tr>
<td>qid</td>
<td>four times a day (quater in die)</td>
</tr>
<tr>
<td>qod</td>
<td>every other day</td>
</tr>
<tr>
<td>qt</td>
<td>quart</td>
</tr>
<tr>
<td>qty</td>
<td>quantity</td>
</tr>
<tr>
<td>R</td>
<td>right</td>
</tr>
<tr>
<td>RBC</td>
<td>red blood cell</td>
</tr>
<tr>
<td>RDA</td>
<td>recommended dietary allowance</td>
</tr>
<tr>
<td>REM</td>
<td>rapid eye movement</td>
</tr>
<tr>
<td>RFR</td>
<td>ranger first responder</td>
</tr>
<tr>
<td>Rh</td>
<td>Rhesus blood factor</td>
</tr>
<tr>
<td>RHQ</td>
<td>regimental headquarters</td>
</tr>
<tr>
<td>RGR</td>
<td>ranger</td>
</tr>
<tr>
<td>RIH</td>
<td>right inguinal hernia</td>
</tr>
<tr>
<td>RLL</td>
<td>right lower lobe</td>
</tr>
<tr>
<td>RLQ</td>
<td>right lower quadrant</td>
</tr>
<tr>
<td>RMED</td>
<td>ranger medic</td>
</tr>
<tr>
<td>RMED</td>
<td>regimental medical section</td>
</tr>
<tr>
<td>RML</td>
<td>right middle lobe</td>
</tr>
<tr>
<td>R/O</td>
<td>rule out</td>
</tr>
<tr>
<td>ROM</td>
<td>range of motion</td>
</tr>
<tr>
<td>ROS</td>
<td>review of systems</td>
</tr>
<tr>
<td>RSTB</td>
<td>regimental special troops battalion</td>
</tr>
<tr>
<td>RUL</td>
<td>right upper lobe</td>
</tr>
<tr>
<td>RUQ</td>
<td>right upper quadrant</td>
</tr>
<tr>
<td>RR</td>
<td>respiratory rate</td>
</tr>
<tr>
<td>RRF-1</td>
<td>ranger ready force one</td>
</tr>
<tr>
<td>RRF-2</td>
<td>ranger ready force two</td>
</tr>
<tr>
<td>RRF-3</td>
<td>ranger ready force three</td>
</tr>
<tr>
<td>RRR</td>
<td>regular rate and rhythm</td>
</tr>
<tr>
<td>RSRMED</td>
<td>regimental senior medic</td>
</tr>
<tr>
<td>RSURG</td>
<td>regimental surgeon</td>
</tr>
<tr>
<td>RTC</td>
<td>return to clinic</td>
</tr>
<tr>
<td>Rx</td>
<td>prescription, treatment</td>
</tr>
<tr>
<td>s</td>
<td>without (sine)</td>
</tr>
<tr>
<td>S1</td>
<td>personnel and administration</td>
</tr>
<tr>
<td>S2</td>
<td>intelligence and security</td>
</tr>
<tr>
<td>S3</td>
<td>operations and training</td>
</tr>
<tr>
<td>S4</td>
<td>logistics and supply</td>
</tr>
<tr>
<td>S5</td>
<td>civil affairs and information operations</td>
</tr>
<tr>
<td>S6</td>
<td>signal and communications</td>
</tr>
<tr>
<td>S8</td>
<td>force modernization, plan, R&amp;D</td>
</tr>
<tr>
<td>SCUBA</td>
<td>self-contained underwater breathing apparatus</td>
</tr>
<tr>
<td>SEM</td>
<td>systemic ejection murmur</td>
</tr>
<tr>
<td>SF</td>
<td>special forces</td>
</tr>
<tr>
<td>SFMS</td>
<td>special forces medical sergeant</td>
</tr>
<tr>
<td>SL</td>
<td>sublingual</td>
</tr>
<tr>
<td>SRMED</td>
<td>senior ranger medic</td>
</tr>
<tr>
<td>Sn</td>
<td>signs</td>
</tr>
<tr>
<td>Sochx</td>
<td>social history</td>
</tr>
<tr>
<td>SOAR</td>
<td>special operations aviation regiment</td>
</tr>
<tr>
<td>SOB</td>
<td>shortness of breath</td>
</tr>
<tr>
<td>SOCM</td>
<td>special operations combat medic</td>
</tr>
<tr>
<td>SOF</td>
<td>special operations forces</td>
</tr>
<tr>
<td>SQ</td>
<td>subcutaneous</td>
</tr>
<tr>
<td>STD</td>
<td>sexually transmitted disease</td>
</tr>
<tr>
<td>Surg</td>
<td>Surgeon (Battalion, Regimental, or command)</td>
</tr>
<tr>
<td>Sx</td>
<td>symptoms</td>
</tr>
<tr>
<td>Tab</td>
<td>tablet</td>
</tr>
<tr>
<td>TBD</td>
<td>to be determined</td>
</tr>
<tr>
<td>TBSA</td>
<td>total body surface area</td>
</tr>
<tr>
<td>TCCC</td>
<td>tactical combat casualty care</td>
</tr>
<tr>
<td>TC3</td>
<td>tactical combat casualty care</td>
</tr>
<tr>
<td>Td</td>
<td>tetanus-diphtheria toxoid</td>
</tr>
<tr>
<td>tid</td>
<td>three times a day (ter in die)</td>
</tr>
<tr>
<td>TKO</td>
<td>to keep open</td>
</tr>
<tr>
<td>TM</td>
<td>tympanic membrane</td>
</tr>
<tr>
<td>TMT</td>
<td>trauma management team</td>
</tr>
<tr>
<td>TN</td>
<td>trauma management team</td>
</tr>
<tr>
<td>TNTC</td>
<td>to numerous to count</td>
</tr>
<tr>
<td>tsp</td>
<td>teaspoon</td>
</tr>
<tr>
<td>TTP</td>
<td>tenderness to palpation</td>
</tr>
<tr>
<td>Tx</td>
<td>treatment</td>
</tr>
<tr>
<td>ud</td>
<td>as directed (ut dictum)</td>
</tr>
<tr>
<td>UE</td>
<td>upper extremities</td>
</tr>
<tr>
<td>URI</td>
<td>upper respiratory tract infection</td>
</tr>
<tr>
<td>USASOC</td>
<td>united states army special operations command</td>
</tr>
<tr>
<td>USSOCOM</td>
<td>united states special operations command</td>
</tr>
<tr>
<td>UTI</td>
<td>urinary tract infection</td>
</tr>
<tr>
<td>VA</td>
<td>visual acuity</td>
</tr>
<tr>
<td>VE</td>
<td>venereal disease</td>
</tr>
<tr>
<td>VSS</td>
<td>vital signs stable</td>
</tr>
<tr>
<td>WARNORD</td>
<td>warning order</td>
</tr>
<tr>
<td>WBC</td>
<td>white blood cell</td>
</tr>
<tr>
<td>WHO</td>
<td>world health organization</td>
</tr>
<tr>
<td>WD</td>
<td>well developed</td>
</tr>
<tr>
<td>WIA</td>
<td>wounded in action</td>
</tr>
<tr>
<td>WMD</td>
<td>weapons of mass destruction</td>
</tr>
<tr>
<td>WN</td>
<td>well nourished</td>
</tr>
<tr>
<td>WNL</td>
<td>within normal limits</td>
</tr>
<tr>
<td>WP</td>
<td>white phosphorus</td>
</tr>
<tr>
<td>XO</td>
<td>executive officer</td>
</tr>
<tr>
<td>Y/O</td>
<td>years old</td>
</tr>
<tr>
<td>1SG</td>
<td>first sergeant</td>
</tr>
<tr>
<td>91W</td>
<td>army military occupational specialty - health care specialist</td>
</tr>
</tbody>
</table>
68W army military occupational specialty -
health care specialist as of 01 Oct 06
>,<,= greater than, less than, equal
### Conversion Charts

#### Length Conversions

<table>
<thead>
<tr>
<th>Conversion</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 inch = 2.54 cm</td>
<td></td>
</tr>
<tr>
<td>1 foot = 30.5 cm = 0.305 m</td>
<td></td>
</tr>
<tr>
<td>1 yard = 0.91 m</td>
<td></td>
</tr>
<tr>
<td>1 mile = 1.6 km</td>
<td></td>
</tr>
<tr>
<td>1 mm = 0.1 cm = 0.039 in</td>
<td></td>
</tr>
<tr>
<td>1 cm = 10 mm = 0.39 in</td>
<td></td>
</tr>
<tr>
<td>1 m = 100 cm = 39 in</td>
<td></td>
</tr>
<tr>
<td>1 km = 100 m = 1093 yd</td>
<td></td>
</tr>
</tbody>
</table>

#### Weight Conversions

<table>
<thead>
<tr>
<th>Conversion</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 oz = 30 g</td>
<td></td>
</tr>
<tr>
<td>1 lb = 16 oz = 0.45 kg</td>
<td></td>
</tr>
<tr>
<td>1 ton = 2000 lbs = 907 kg</td>
<td></td>
</tr>
<tr>
<td>1 grain = 65 mg</td>
<td></td>
</tr>
<tr>
<td>1 g = 001 kg = 0.36 oz</td>
<td></td>
</tr>
<tr>
<td>1 kg = 1000 g = 2.2 lbs</td>
<td></td>
</tr>
<tr>
<td>1 ton (metric) = 1000 kg = 2200 lbs</td>
<td></td>
</tr>
</tbody>
</table>

#### Body Weight Conversions (Pounds to Kilogram)

<table>
<thead>
<tr>
<th>Pounds (lb)</th>
<th>Kilograms (kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>110</td>
<td>49.89</td>
</tr>
<tr>
<td>120</td>
<td>54.43</td>
</tr>
<tr>
<td>130</td>
<td>58.96</td>
</tr>
<tr>
<td>140</td>
<td>63.50</td>
</tr>
<tr>
<td>150</td>
<td>68.04</td>
</tr>
<tr>
<td>160</td>
<td>72.57</td>
</tr>
<tr>
<td>170</td>
<td>77.11</td>
</tr>
<tr>
<td>180</td>
<td>81.64</td>
</tr>
<tr>
<td>190</td>
<td>86.18</td>
</tr>
<tr>
<td>200</td>
<td>90.72</td>
</tr>
</tbody>
</table>

#### Volume Conversions

<table>
<thead>
<tr>
<th>Conversion</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 fl oz = 30 ml = 30 cc</td>
<td></td>
</tr>
<tr>
<td>1 US Gal = 128 fl oz = 3785 ml</td>
<td></td>
</tr>
<tr>
<td>1 cc = 0.001 liter</td>
<td></td>
</tr>
<tr>
<td>1 ml = 1 cc = 0.34 fl oz</td>
<td></td>
</tr>
<tr>
<td>1 liter = 1000 ml = 340 fl oz</td>
<td></td>
</tr>
</tbody>
</table>

#### Temperature Conversions

\[
F = (1.8) \times C + 32 \\
C = (F – 32) / (1.8)
\]
75th Ranger Regiment Trauma Management Team (Tactical)
Ranger Medic Handbook

The Ranger Medic Code

1. I will always remember that these are the finest Infantry on this earth, and that as such they
deserve the finest health care.

2. No Ranger or Ranger dependent who comes to me for health care will ever be turned away
without their needs being addressed, even if their paperwork/administrative requirements are not
in order.

3. I will never let slip my mind the fact that in chaos of battle, I am all that stands between that
bleeding, wounded Ranger and the finality of death. I will perform my job with such skill that the
grim reaper will walk away empty-handed.

4. I will always remember that I must not only treat wounded Rangers, I must also carry them
sometimes. I will maintain the physical conditioning necessary to accomplish this.

5. I will always remember that uniforms, weapons and supplies can all be DX’d but that each
Ranger only comes with one body. I will never jeopardize the safety and/or recovery of that body
by performing medical tasks beyond my skill and training.

6. I will always be cognizant of the fact that people do not suddenly get well after 1700 hours and on
weekends, and that as such, I will willingly provide or coordinate for health care 24 hours a day, 7
days a week.

7. I will never do anything stupid because “they” or “regulations” require it to be so. I will find a way
to accomplish my mission and serve the Rangers of this Regiment.

8. I will always remember that everything I use is paid for by US citizens. I will remember those tax
dollars are collected from the American people and given to the Rangers because those people
believe that in exchange for that money they will be kept safe from the tyrants of the world.

9. I will never forget that this is an Infantry unit supported by a medical team; not a medical team
supported by a plethora of Infantry.

10. I will never forget that when the tyrants of the earth look towards the USA and plot mischief, they
see a wall of cold steel backed up by determined men wearing Tan Berets; and then they plot
their mischief somewhere else. The extent to which I support that wall is the extent to which I
have a right to consume oxygen.

“It is not the strongest of the species that survive, but the one most responsive to change”
-Charles Darwin

“Greater love has no one than this, that he lay down his life for his friends.”
-John 15:13 (NIV)

“The quality of a person's life is in direct proportion to their commitment to excellence, regardless
of their chosen endeavor”
-Vince Lombardi

“To know what you know and to know what you don’t know, that is knowledge”
-Confucius
The Ranger Creed

Recognizing that I volunteered as Ranger, fully knowing the hazards of my chosen profession, I will always endeavor to uphold the prestige, honor, and high esprit de corps of my Ranger Regiment.

Acknowledging the fact that a Ranger is a more elite soldier who arrives at the cutting edge of battle by land, sea, or air, I accept the fact that as a Ranger, my country expects me to move further, faster and fight harder than any other soldier.

Never shall I fail my comrades. I will always keep myself mentally alert, physically strong, and morally straight and I will shoulder more than my share of the task whatever it may be, one hundred percent and then some.

Gallantly will I show the world that I am a specially selected and well trained soldier. My courtesy to superior officers, neatness of dress, and care of equipment shall set the example for others to follow.

Energetically will I meet the enemies of my country. I shall defeat them on the field of battle for I am better trained and will fight with all my might. Surrender is not a Ranger word. I will never leave a fallen comrade to fall into the hands of the enemy, and under no circumstances will I ever embarrass my country.

Readily will I display the intestinal fortitude required to fight on to the Ranger objective and complete the mission, though I be the lone survivor.

Rangers Lead the Way